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This thesis deals with the diagnostic evaluation of subjects with MCI. We would like to start 
with two case histories to exemplify the common diagnostic issues with these subjects. 
Case A
A 66-year old man, Mr. A, was referred by his GP to the memory clinic for the evaluation of his 
increasing forgetfulness and concentration problems. Mr. A presented with slowly progressive 
forgetfulness and problems with concentration over approximately the past two years. He 
forgot names, could not remember details of his last holiday and forgot what someone had 
told him. He feared to become demented, like his mother. Mr. A asked the clinician some 
questions: Are the symptoms suggestive of early dementia or could there be another cause for 
the complaints? Would the symptoms increase in the future? 
 Mr. A was a friendly man who appeared a little bit nervous. He retired three years 
ago, but remained active through his hobbies, doing volunteer work, and taking care 
of his grandchildren. Somatic, neurologic, psychiatric, and laboratory assessments were 
unremarkable. General cognitive functioning was normal (MMSE = 28), with a very mild decline 
in functioning (Global Deterioration Scale, GDS = 2), very mild impairments in daily functioning 
(Blessed Dementia Rating Scale, BDS = 0.5), and very mild symptoms of depression (Hamilton 
Depression Rating Scale, HDRS = 1). Additional diagnostics were applied. The MRI-scan showed 
some atrophy of the medial temporal lobe (score is 1). The neuropsychological assessment 
showed a high level of intelligence, corresponding with his high level of education. Memory 
scores were below average (-1.3 SD), but did not fulﬁl the criteria of a formal impairment. Mr. 
A showed an ineﬃcient use of memory strategies in the learning phase. In addition, he had 
increased distractibility in the inhibition of an automatic respons. Other cognitive domains, 
including speed, visuoconstruction, language, and working memory performances were 
within normal ranges. Based on the neuropsychiatric, neuropsychological, and laboratory 
assessments and on the MRI-ﬁndings, the conclusion was that Mr. A was not demented, but 
because of some decreased test performances in memory and executive functioning, and the 
very mild medial temporal lobe atrophy, a decrease in functioning compared to his previous 
level could not be excluded. For monitoring his cognitive functioning, Mr. A participated in the 
Maastricht follow-up study, which has follow-up assessments after 2, 5 and 10 years. As part 
of this study the APOE genotype was determined, and showed that Mr. A carried one APOE e4 
allele.
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2-years follow-up
Mr. A reported an increase of memory and concentration problems. He forgot names and 
appointments. He often did not know what he was doing and had problems with doing two 
things simultaneously. His wife conﬁrmed these problems. He tried to cope with the complaints 
by using an agenda and making lists of things to do. His interest in things, which are more 
eﬀortful at the moment, decreased. He sometimes felt a bit sad. There were no changes in 
hobbies or housekeeping activities. General cognitive functioning was mildly impaired (MMSE 
= 25, GDS = 3). Daily functioning was not impaired as demonstrated with a BDS of 0. There 
was evidence of mild depressive symptoms (HDRS = 8). The neuropsychological assessment 
showed low scores on concept shifting, delayed recall of a word learning test and the immediate 
recall and delayed recall of a story, but not severe enough to fulﬁl the criteria of an impaired 
test score. Compared to the baseline assessment there was a decline in memory functioning, 
cognitive speed, and IQ. The diagnostic team decided that the symptoms were not of suﬃcient 
severity for a diagnosis of dementia, but were too prominent for normal aging. The course 
of the symptoms raised the suspicion that the symptoms could be early signs of preclinical 
dementia. 
5-years follow-up
Mr. A reported increasing forgetfulness. He often forgot to use his agenda, had to read things 
again, forgot the contents of books he had read last week and had increasing problems with 
ﬁnding the way in unfamiliar places. General cognitive functioning remained stable, and 
depressive symptoms were only very mild. Test performances showed impairment in the 
delayed recall of unstructured information and impairments in concept shifting. Functioning 
in daily life was mildly impaired as demonstrated with a BDS of 1.5. His spouse reported mild 
changes in behaviour such as irritability, and taking less initiative. The diagnosis made was 
cognitive disorder not otherwise speciﬁed.
10-years follow-up
After nine years, Mr. A’s wife contacted the memory clinic for a new appointment, because she 
noted severe progression of the problems in cognitive functioning and daily functioning of her 
husband. Mr. A had severe forgetfulness, such as problems with remembering conversations, 
news from the television or newspaper, and names, also of family members. In addition, he 
said things over and over again. In daily functioning, he experienced problems with driving, 
problems with his orientation, and problems with the ﬁnancial administration. He was less 
interested in his hobbies or in visiting friends. At home, he only did things when he was 
stimulated by his spouse. He had no problems with mood or sleeping, but he had lost some 
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weight in the past year. General cognitive functioning was impaired (MMSE = 22), and there was 
signiﬁcant impairment in daily functioning (BDS = 4). On the neuropsychological assessment 
there were multiple cognitive deﬁcits in the domains of memory, speed, executive functioning, 
verbal ﬂuency and visuoconstruction. The diagnosis of Alzheimer type dementia was made. 
The wife of Mr. A asked whether there were other tests to conﬁrm this diagnosis. The clinician 
adviced to repeat the MRI scan and to measure beta amyloid and tau protein in cerebrospinal 
ﬂuid. 
Case B
Mrs. B was referred to the memory clinic by her GP, because she was worried about her memory 
problems. She reported that she had to write down everything, and forgot appointments she 
had made the day before. Mrs. B was a 66-year old, friendly and communicative woman, with 
a moderate level of education. She stopped working one year previously and noted memory 
complaints since that time point. Her husband did not report any changes in daily functions, he 
only reported signs of irritability and nervousness. Mrs B worried a lot about her forgetfulness, 
also at night when she could not sleep. She wanted to know whether she was becoming 
demented or not. And, if so how long this process would take. 
 General cognitive and daily functions were very mildly impaired. There were mild 
depressive symptoms (HDRS score of 11). There were no abnormalities on neurologic, somatic 
or laboratory examinations. The MRI-scan showed no abnormalities. The neuropsychological 
assessment showed below average memory performances on the immediate recall and 
delayed recall of a word list, but a normal performance on the recognition part of the test. 
Other performances were within normal limits. The neuropsychologist remarked that Mrs. 
B was very nervous, mainly about the memory tests. Mrs. B also participated in the follow-
up study. Her performances after 2, 5 and 10 years varied over time. Memory performances 
improved to normal levels at the two and ﬁve years follow-up, whereas executive functioning 
declined at the ﬁve-years follow-up, but remained stable between the 5 and 10-years follow-
up. At the 10-years follow-up cognition was within normal limits and it was concluded that her 
memory problems were probably related to depressive symptomatology and normal aging.
Both cases fulﬁlled the criteria of MCI at baseline, but showed a diﬀerent course with a diﬀerent 
outcome over the follow-up period of 10 years. Some of the questions that arise from these 
case reports are: 
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- Which factors at baseline could have predicted the diﬀerence in course and outcome of the 
cognitive problems in case A and B?
- Could the GP have foreseen this course, and was the referral to the memory clinic correct?
 
These questions that are common in clinical practice formed the basis for the research 
described in this thesis.

1 Introduction
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1.1 Cognitive impairments in non-demented subjects
Problems in cognitive functioning, as reported by Mr A and Mrs B in Chapter 0, are very 
common in middle-aged and elderly subjects. The most frequently reported problem is 
forgetfulness. The prevalence of forgetfulness in non-demented subjects varies from 41% in 
subjects between 55 and 65 years old to 52% in subjects over 70 years (Ponds et al., 1997). 
These cognitive problems can be part of the normal aging process, but they can also be very 
early symptoms of dementia. The phase between normal cognitive functioning and dementia 
is often called Mild Cognitive Impairment (MCI). In this phase, subjects experience cognitive 
problems and a decline in functioning compared to a previous level of functioning that is greater 
than would be expected based on age and educational level. Still, the cognitive and functional 
impairments of subjects with MCI are not severe enough to meet the criteria for dementia. 
Subjects with MCI mainly experience problems with memory functioning, but may also have 
impairments in other cognitive domains such as attention, executive functioning or language 
(Dickerson et al., 2007). The prevalence of MCI in older adults ranges from approximately 11 to 
17% in community studies depending on cohort source and deﬁnition (Ganguli, 2006; Mariani 
et al., 2007).
 In the last 20 years, there has been a lot of interest in subjects with MCI, as these 
subjects are at increased risk for developing dementia, especially Alzheimer’s disease (AD). 
Longitudinal and prospective studies have reported conversion rates from MCI to AD from 6-
25% per year, compared to a conversion rate to AD of 1-2% in the general population (Feldman 
& Jacova, 2005; Geslani et al., 2005; Panza et al., 2008; Petersen et al., 1999; Visser et al., 2006). 
However, not all subjects with MCI will develop AD, and the cognitive impairment can remain 
stable or even improve over time (Visser et al., 2002). Cognitive impairment that remains stable 
or improves over time is unlikely to be caused by AD and may result from several psychological, 
somatic or social aspects (Jorm et al., 2004; Ponds et al., 1997; Zimprich et al., 2003). This shows 
that the natural course of MCI is heterogeneous and uncertain. Thus, generally subjects with 
AD have experienced a phase of MCI prior to the diagnosis of AD, but not all subjects with MCI 
have prodromal AD (Figure 1.1).
�
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Figure 1.1
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1.2   Research challenges in MCI
Because of the aging population, the prevalence of MCI will increase in future. Also the number 
of subjects with dementia in The Netherlands is estimated to increase from about 200.000 in 
2000 to more than 400.000 subjects in 2050 (Health Counsil of the Netherlands, 2002). This 
implies that the impact of MCI and AD on the health care system will increase rapidly in the 
following years. With no current pharmacological therapy available, which can intervene with 
the degenerative process and stop the disease progression, it is still important to investigate 
subjects with MCI for several scientiﬁc and clinical reasons. From a scientiﬁc point of view it 
is important to identify subjects with MCI who will develop AD. The characteristics of these 
preclinical subjects and the course of their complaints will give more insight into the underlying 
mechanisms of pathological aging and can be useful for the identiﬁcation of factors that 
predict AD. When pharmacological treatment, with drugs with disease modifying properties, 
becomes available this will be most eﬀective in the earliest stages of the disease. Therefore, the 
identiﬁcation of subjects at risk is very important for screening purposes. 
 From a clinical point of view, it is important to diﬀerentiate between probable 
progressive and non-progressive MCI, as in both groups the cause of the cognitive complaints 
will be diﬀerent and both groups of subjects will beneﬁt from other sorts of advice and 
treatment. In addition, a reliable prognosis may give subjects the opportunity to anticipate on 
their future. 
1.3  Role of health care settings in the evaluation of subjects with 
cognitive impairments
In the Dutch health care system, the general practitioner (GP) is normally the ﬁrst person who 
is contacted by subjects with cognitive complaints or their relatives. GP’s often know their 
patient for a longer time and are therefore in an excellent position to detect gradual changes in 
cognitive and behavioural functioning. For these reasons the GP could have an important role 
in the identiﬁcation of subjects at risk for dementia (Artero & Ritchie, 2003; Barrett et al., 1996; 
Wilkinson et al., 2004) and subjects who could beneﬁt from additional diagnostics and referrals 
to specialized facilities such as memory clinics. However, the symptoms that are suspected for 
future cognitive decline or dementia in a general practice setting remain largely unknown.
 Secondary health care facilities for the evaluation of cognitive complaints are 
outpatient clinics for neurological, psychiatric and geriatric patients. As cognitive impairments 
can have multiple causes, it has been recognized that the evaluation of cognitive impairments 
should follow a multidisciplinary approach. For this reason specialized services, often referred 
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to as Memory Clinics (MCs), have been set up. Memory clinics are relatively new facilities in 
the health care system. In The Netherlands, the ﬁrst MCs developed in 1986 in Maastricht 
and Tilburg (Verhey et al., 1987). These settings have a multidisciplinary way of working and 
are involved in the early diagnosis and treatment of people with dementia (Lindesay et al., 
2002; Wright & Lindesay, 1995). An overview about the organization and working methods of 
memory clinics in The Netherlands was published in 1998 (Verhey et al., 1999). The ﬁndings of 
the 12 MCs that were operational at that time showed that MCs were mainly associated with 
university hospitals, and were mainly involved in the diagnostic process of dementia. However, 
the role of memory clinics in subjects with milder cognitive problems, such as subjects with 
MCI or no cognitive disorder, is largely unclear. In addition, it is unclear which people seek help 
at a memory clinic for their cognitive problems and which people do not.
1.4  Predictors for outcome in MCI
The heterogeneity in cause and prognosis of cognitive complaints increases the need for 
sensitive predictors, which can determine whether subjects with cognitive impairments will 
progress to AD or not. In the last 20 years, several predictors have been identiﬁed which 
increase the predictive accuracy of MCI for AD. These predictors include increased age (Reiman 
& Caselli, 1999; Visser et al., 2002), female gender (Gao et al., 1998), low level of education 
(Reiman & Caselli, 1999; Schmand et al., 1997), cognitive measures (Dickerson et al., 2007; 
Saxton et al., 2004; Twamley et al., 2006), medial temporal lobe atrophy (DeCarli et al., 2007; 
Twamley et al., 2006), and cerebrospinal ﬂuid levels of beta-amyloid and tau (Mariani et al., 
2007). However, none of these predictors can predict AD with suﬃciently high accuracy. In this 
thesis we will focus on a number of predictors.
1.4.1.  Memory impairment
One of the strongest predictors of AD is impairment in memory functioning, mainly in episodic 
memory (Sarazin et al., 2007; Saxton et al., 2004; Twamley et al., 2006; Visser et al., 2002) which is 
often measured with total scores on immediate or delayed recall tests. However, not all subjects 
with memory impairment develop AD. Memory performances can be enhanced by the use of 
strategies during the learning of new information (Saan & Deelman, 1986; Sternberg & Tulving, 
1977). It is known that the eﬀective use of these strategies is impaired in subjects with AD 
(Delis et al., 1991). However, the predictive value of these strategies for the development of 
AD in subjects with MCI is not clear and should be established further, as this could give more 
insight into the underlying mechanisms of memory performances and memory impairments 
in subjects with MCI and may help in the identiﬁcation of subjects with prodromal AD. 
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1.4.2  APOE genotype
The apolipoprotein E (APOE) e4 allele is a major genetic risk factor for Alzheimer’s disease (AD) 
(Petersen et al., 1995), and is a predictor for AD in subjects with MCI. In addition, it is associated 
with memory impairment both in subjects with AD and non-demented subjects (Small et al., 
2004; van der Vlies et al., 2007). The relation between the APOE e4 genotype and memory 
dysfunctioning in subjects with MCI is less clear. In addition, it is unclear whether the eﬀect 
of the APOE genotype on memory functioning is caused by underlying AD pathology or is an 
independent eﬀect. The eﬀect of the APOE e4 allele on several aspects of memory is important, 
because it could increase the understanding of the underlying pathology of MCI. 
1.4.3  Non-cognitive symptoms
Besides impairments in cognitive functioning, behavioural problems are also common in 
subjects with AD and MCI (Aalten et al., 2005; Apostolova & Cummings, 2007; Lopez et al., 2005; 
Lyketsos et al., 2002). Most commonly reported are symptoms of depression, anxiety, apathy 
and irritability. Some studies found that the presence of these symptoms was associated with 
an increased risk for the development of dementia (Modrego & Ferrandez, 2004; Palmer et al., 
2007; Robert et al., 2006). However, there is no consensus in the literature about the predictive 
value of these aﬀective symptoms for AD as other studies found a negative or no association 
between aﬀective symptoms and AD (Copeland et al., 2003; Feldman et al., 2007; Korf et al., 
2004; Liu et al., 2007; Palmer et al., 2007; Panza et al., 2008; Robert et al., 2006; Rozzini et al., 
2005; Teng et al., 2007; Tierney et al., 1999; Visser et al., 2000; Visser et al., 2000; Wang et al., 
2006). Conﬂicting results may be explained by diﬀerences in selection of the subjects (setting 
and used MCI-criteria), measurement of the aﬀective symptoms, age at baseline or length of 
follow-up. However, the conﬂicting ﬁndings from previous studies are remarkable and should 
be established further.
1.5  Aim of the thesis
The main aim of this thesis was to investigate the course of cognitive complaints in subjects 
with MCI and to identify early predictors of dementia, especially AD. In this thesis we wanted 
to investigate the following objectives: 
(a) Which learning strategies are predictive for the development of AD in subjects with 
MCI? 
(b) What is the eﬀect of the APOE genotype on memory function in middle-aged and 
older subjects with MCI?
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(c) Which non-cognitive symptoms are predictive for AD in subjects with MCI?
(d) Which symptoms can predict dementia in a general practice setting?
(e) What are the determinants of subjects who seek help for their subjective memory 
complaints at a memory clinic? 
(f ) How did memory clinics in The Netherlands develop, and which role do they play for 
subjects with MCI?
1.6  Outline of this thesis
This thesis is organized as follows. The chapters can be divided into two parts. In part I, we 
focused on the predictive value of several risk factors for AD in subjects with MCI. There are 
several deﬁnitions present in the literature for describing the phase between normal cognitive 
functioning and dementia. In the present thesis, MCI is used to refer to subjects, who had 
subjective memory complaints in the absence of dementia, and had a Global Deterioration 
Scale (Reisberg et al., 1982) score of 2 or 3, and no signiﬁcant impairment in general cognitive 
functioning or daily functioning. Also other studies have used these criteria (Feldman & Jacova, 
2005; Tabert et al., 2006; Tierney, Szalai, Snow, Fisher, Tsuda et al., 1996).
 In Chapter 2, we investigated the predictive accuracy of an active learning strategy 
(subjective organization), and a more passive rehearsal based strategy (serial clustering) for 
AD. We performed a prospective longitudinal study with follow-up assessments after 2, 5 and 
10 years among subjects with MCI form the Maastricht Memory Clinic. 
 In Chapter 3, we investigated the relation between the APOE e4 genotype and several 
aspects of verbal memory in subjects with MCI from the Maastricht Memory Clinic. In addition, 
we investigated whether the eﬀect of the APOE e4 allele on memory functioning is diﬀerent in 
middle-aged and old subjects. 
 In Chapter 4, the predictive accuracy of several aﬀective symptoms for the 
development of AD was investigated using a prospective longitudinal study with a follow-up 
period up to 10 years. We investigated the predictive accuracy of depression, anxiety, apathy, 
sleeping problems and somatic symptoms. We also investigated whether the eﬀect of aﬀective 
symptoms on AD was dependent on age, the presence of amnestic MCI, and length of follow-
up up to 10 years.
 In Chapter 5, we investigated the predictive value of cognitive impairment, aﬀective 
symptoms, behavioural problems, vascular problems, gait disturbances, and changes in 
appetite and weight for future dementia in general practice settings. For this study, we used 
data from the Registration Network of Family Practices (RNH). We performed a case-control 
design, matched for age, sex and general practice setting.
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 In part II, we focused on the memory clinic settings. Subjects with cognitive problems 
or their family often feel uncomfortable with their complaints and often worry about their 
impairments. These subjects are often referred to Memory Clinics for the evaluation of their 
complaints.
 In Chapter 6, we investigated which factors are determinants of seeking help at a 
memory clinic for subjective memory complaints in subjects without objectiﬁed memory 
impairment. In this study, we compared cases from the Maastricht Memory Clinic to control 
subjects from the Maastricht aging study who did not seek help for their subjective memory 
complaints. We investigated the following symptoms: depression, anxiety, memory self-
eﬃcacy, quality of life, changes in memory and daily functioning, and worries caused by a 
family history of dementia. 
 The development of memory clinics in The Netherlands in the past 10 years is described 
in Chapter 7. We sent an inventory to all MCs that were operational in The Netherlands at that 
time. In addition, this chapter investigated the role of this facility for non-demented subjects 
such as subjects with MCI or subjects with subjective cognitive complaints. 
 Lastly, in Chapter 8, we summarized the main ﬁndings of this thesis, and we discussed 
the usefulness of the present study for further research and clinical practice. 

Part 1

2 The predictive value of memory strategies for Alzheimer’s disease in subjects with Mild Cognitive Impairment
Submitted
Ramakers, IHGB., Visser, PJ., Aalten, P., Maes, HL.,  
Lansdaal, HGM., Meijs, CJC., Jolles, J. & Verhey, FRJ. 
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Abstract 
Background. Subjects with Alzheimer’s disease (AD) show impaired learning strategies. 
Whether impaired learning strategies are already present in subjects with prodromal AD 
remains unknown. The aim of the present study was to investigate the predictive accuracy of 
learning strategies for AD in subjects with Mild Cognitive Impairment (MCI).
Methods. Subjects with MCI (n = 284) were selected from the Maastricht Memory Clinic. 
Subjects were and reassessed over a period of 10 years. Sixty of the 284 subjects convert to AD. 
Learning strategies investigated were subjective organization and serial clustering.
Results. Lower scores of subjective organization were associated with a higher risk for AD 
at follow-up (OR = 1.74, 95% CI = 1.16–2.66, p = 0.008). Serial clustering did not predict AD. 
Findings were similar in subjects aged 40-59 years and subjects aged 60-85 years.
Conclusion. Prodromal AD is characterized by impaired learning strategies. This ﬁnding may 
have implications for the early detection of AD in subjects with MCI and for the development 
of cognitive training programs.
Key words: Mild cognitive impairment, Alzheimer’s disease, learning strategies, predictors
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Introduction 
Mild Cognitive Impairment (MCI) is common among the elderly. It is a relevant health care 
problem because it reduces the quality of daily living, and because a subgroup of subjects 
with MCI show a progressive course and will develop Alzheimer’s disease (AD) in the future 
(Visser et al., 2006). It remains diﬃcult to identify AD among subjects with MCI. This would 
be important because drugs that have the potential to modify the disease progression are 
supposed to be most eﬀective in the early stage of the disease. 
 The main feature of AD are impairments in encoding and retrieval of new information. 
Encoding is facilitated by the use of learning strategies (Saan & Deelman, 1986; Sternberg 
& Tulving, 1977), and there is evidence that subjects with AD do not use learning strategies 
eﬃciently (Delis et al., 1991). Previous studies reported that, when compared to healthy 
controls, subjects with AD showed signiﬁcantly lower average levels of semantic clustering 
(Carlesimo et al., 1998; Perri et al., 2005), and did not beneﬁt from the semantic relatedness of 
the presented stimuli (Carlesimo et al., 1998). Also subjects with MCI less often used semantic 
clustering as a learning strategy compared to control subjects (Perri et al., 2005; Ribeiro et al., 
2007). Therefore, impaired learning strategies could be a predictor for AD in subjects with MCI, 
but this has not yet been investigated.
 The main aim of this study is to investigate the predictive accuracy of learning 
strategies for AD in subjects with MCI. Learning strategies that will be investigated are 
subjective organization and serial clustering. Subjective organization refers to constancies 
in the order of responses, that develop over a series of free recalls. Subjective organization 
requires an active reorganization of the presented words (Bousﬁeld & Bousﬁeld, 1966; Saan & 
Deelman, 1986; Sternberg & Tulving, 1977). In contrast, serial clustering is an automatic, more 
passive strategy in which the words are recalled in the same order as they were oﬀered (Delis 
et al., 1987). Because subjective organization requires more eﬀort and is less automatic than 
serial clustering, we hypothesised that subjective organization would be impaired in early AD 
and would be predictive for AD at follow-up, while serial clustering would be not. 
Methods 
Subjects
Subjects were selected from an ongoing, prospective, longitudinal study of non-demented 
subjects referred to the Maastricht Memory Clinic. The memory clinic is an outpatient clinic 
at the Maastricht University Hospital in the Netherlands (Verhey et al., 1993). Subjects were 
referred to the memory clinic for evaluation of their cognitive complaints. The design of this 
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study has been described in detail elsewhere (Verhey et al., 1993; Visser et al., 2006; Visser & 
Verhey, 2007; Visser et al., 2000). Consecutive patients were included at the time of the ﬁrst 
visit to the memory clinic. Inclusion criteria were age 40 years or older and having MCI, deﬁned 
as a score of 2 or 3 on the Global Deterioration Scale (GDS) (Reisberg et al., 1982). This broad 
deﬁnition of MCI is consistent with that of other studies (Feldman & Jacova, 2005; Tabert et 
al., 2006; Tierney et al., 1996). It was used because subjects with AD in the predementia stage 
do often not meet more strict criteria of MCI, such as criteria for amnestic MCI (Geslani et al., 
2005; Storandt et al., 2006; Visser & Verhey, 2008). Exclusion criteria were dementia at baseline 
and an apparent cause for their cognitive impairment, such as cerebrovascular disorders, brain 
trauma, endocrine disorders or psychiatric disorders other than mild aﬀective disorders at 
baseline (Visser et al., 2000). For the present study, we selected subjects with the same version 
of the 15-item Auditory Verbal Learning Task (AVLT, see below) (Brand & Jolles, 1985; Van der 
Elst et al., 2005) and who had been eligible for the ﬁrst follow-up visit (see below). The baseline 
characteristics of the study sample (n = 284) are shown in Table 1. The study was approved by 
the medical ethical Committee at Maastricht University Hospital. After the study was explained 
to the subjects, all subjects gave their written informed consent.
Clinical assessment and diagnosis at baseline 
At baseline, all subjects underwent a standardised assessment, which included a detailed 
history of the subject, a psychiatric, neurological, and physical examination, the Mini Mental 
State Examination (MMSE) (Folstein et al., 1975), assessment using clinical rating scales (i.e. 
GDS (Reisberg et al., 1982), Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960) and 
the Blessed Dementia Rating Scale (BDRS) (Blessed et al., 1968)), appropriate laboratory tests 
(i.e. tests for hematology, glucose, biochemical analyses, vitamin B12, and thyroid stimulating 
hormone), a neuropsychological assessment including tests covering the domains of memory, 
attention, executive functioning, language, praxis, and intelligence (Verhey et al., 1993), and 
CT or MRI as described elsewhere (Verhey et al., 1993). The diagnosis of dementia and AD was 
made according to the DSM-IV and NINCDS-ADRDA criteria (APA, 1994; McKhann et al., 1984).
Clinical assessment and diagnosis at follow-up
Two, ﬁve, and ten years after baseline, subjects were invited to participate in a follow-up 
assessment. Because enrolment was continuous, not all subjects had completed all follow-
up assessments. The number of subjects eligible for the 2-year follow-up was 348, for the 5-
year follow-up 382, and for the 10-year follow-up 217. The follow-up assessment included a 
standardized questionnaire about medical history and cognitive complaints, the MMSE, GDS, 
BDS, HDRS, and an extensive neuropsychological assessment comparable to baseline. Subjects 
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who refused to come for the follow-up assessment were assessed via a telephone interview, 
which included a standardized questionnaire about medical history and cognitive complaints, 
and the Telephone Interview for Cognitive Status (Brandt et al., 1988). The diagnosis of 
dementia was based on the DSM IV criteria (APA, 1994) and was made independently by both 
a neuropsychiatrist and a neuropsychologist. Both professionals were blinded to the baseline 
results. If disagreement on the diagnosis occured, a consensus meeting was held. Subjects 
who were diagnosed as being demented at the ﬁrst follow-up (two years after baseline), were 
not invited for the next follow-up (ﬁve years after baseline). The outcome after two, ﬁve, and 
ten years was deﬁned as the subject had developed AD or had no dementia. 
Memory strategies
Memory strategies were tested using the Dutch version of the AVLT at baseline (Van der Elst 
et al., 2005). Fifteen unrelated monosyllabic words were presented ﬁve times and after each 
presentation the subject was asked to recall as many words as possible. After 20 minutes, 
during which non-verbal tests were performed, delayed recall was tested. The strategies of 
subjective organization and serial clustering were investigated using the ﬁve learning trials of 
the AVLT.
Subjective organization 
Subjective organization refers to the consistencies in response order, that develop over a series 
of free recalls (Bousﬁeld & Bousﬁeld, 1966; Tulving, 1962). Based on the output order in which 
the words from two successive trials are listed by the subject, combinations (clusters) of words 
that are recalled together in these two successive trials are identiﬁed. These combinations are 
based on the organization schema developed by the individual subject, and are not dependent 
on prespeciﬁed categorization based on semantic relationships, which is used in several word 
learning tests such as the California Verbal Learning Test (Delis et al., 1987).  
 A bidirectional inter-trial repetition (ITR) measure was used (Sternberg & Tulving, 
1977). This measure is a variant of the unidirectional ITR measure, ﬁrst proposed by Bousﬁeld 
& Bousﬁeld (1966). In the bidirectional ITR, comparisons were made between the forward 
and backward sequence of recalled words in two successive trials. Each time a combination 
of two words is recalled consecutively in one trial and also in the following trial (= Inter-Trial 
Repetition) the subjects gets one point. The bidirectional ITR corrects for clusters that occur 
by chance with the following formula (Sternberg & Tulving, 1977): Subjective organization = 
Observed (ITR) – Expected (ITR), where expected ITR = 2c(c - 1) / h * k. Observed ITR is the 
number of pairs of items recalled on trial t and t + 1 in adjacend output positions in either of the 
two possible orders. Expected ITR is the expected number of pairs of items, c was the number 
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of common items recalled in both trials t and t + 1, h was the number of items recalled in trial t, 
and k was the number of items recalled in trial t + 1. An outcome of 0 indicated that the number 
of observed ITRs is equal to the number of expected ITRs. A score higher than 0 indicates more 
use of subjective organization than expected by chance.
Serial clustering 
Serial clustering refers to the number of word pairs that are reproduced in the same order as 
they were presented (Delis et al., 1988; Kramer et al., 1997). This form of clustering is a more 
passive approach to recall. To measure serial clustering, we used an adapted form of the formula 
devised by Mulder et al. (1996). In this formula, the total number of observed serial clusters is 
divided by the number of clusters that are expected based to occur on change (Bouma et 
al., 1996; Mulder et al., 1996; Saan & Deelman, 1986). The expected number that would be 
generated by chance is calculated by dividing the number of all possible clusters by the total 
number of words recalled in that trial. A positive score indicates that the subjects reported 
more clusters than would be expected generated by chance. 
 The diﬀerence between subjective organization and serial clustering is that in serial 
clustering the subject reproduce the items in the same order as they were presented, whereas 
in subjective organization the subjects has to reorganize the presented items into clusters that 
are logical to the subjects by keeping the other items in mind.
Statistical analyses
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) 
for Macintosh, version 11. To analyse diﬀerences between converters and non-converters, 
independent t-tests were conducted for continuous variables, and chi-square tests for level 
of education and dichotomous variables. Level of education was classiﬁed as low (at most 
primary education), middle (junior vocational education), or high (senior vocational education 
or academic training) (UNESCO, 1976). The predictive accuracy was analyzed using a discrete-
time survival analysis model and implemented using logistic regression and an appropriately 
adjusted dataset (Hosmer & Lemeshow, 1999). The outcome group included all subjects with 
AD at follow-up. The reference group included subjects without dementia at follow-up. Subjects 
with a non-AD type dementia at follow-up were excluded from the analyses. Analyses were 
done with and without adjustment for age, sex, and education. The average level of subjective 
organization was deﬁned as the sum of the four trial-pairs divided by four. The average level of 
serial clustering was deﬁned as the sum of each of the trial-scores divided by ﬁve. Because the 
risk for AD is dependent on age (Visser et al., 2006; Visser et al., 2000), we also repeated analyses 
in two subgroups (40-59 years and 60-85 years). Two-factor repeated measures ANOVAs were 
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performed, with group as a between factor, trial as a within factor, and age, education, and 
sex as covariates, to analyze the course of learning strategies across the 5 learning trials of the 
AVLT at baseline. In order to investigate the relation between the use of learning strategies and 
delayed recall performance, we performed correlation analyses. All tests were two-tailed, and 
the signiﬁcance level was set at 0.05.
Results
The diagnosis at the latest follow-up for which the subject was eligible was available for 284 
of the 348 subjects (82%). The outcome was unavailable for 64 of the subjects because: (a) the 
subjects did not want to participate in the follow up (n = 15), (b) the subject was untraceable 
(n = 24), (c) the subject had passed away (n = 17), (d) the subjects suﬀered severe illness (n = 1), 
or other reasons (n = 7). Subjects with completed follow-up were about 3 years younger and 
had lower GDS and BDS scores than subjects who did not complete the follow-up. Both groups 
were comparable with respect to education, sex distribution and scores on the MMSE, HDRS, 
and z-score on the delayed recall test of the AVLT. Of these 284 subjects 60 (21%) subjects had 
developed AD within the follow-up period up to 10 years, 31 after 2 years, 19 after 5 years, and 
10 after 10 years. Table 1 shows the baseline characteristics of the subjects who developed AD 
Table 1. Characteristics of subjects who developed AD and who did not.
Not demented
(n = 224)
AD
(n = 60)
p-value
Age, M ± SD 55.6 ± 9.3 67.8 ± 8.0 < 0.001
Sex, % man 59 48 0.141
Education, % low/moderate/high 17/47/36 27/45/28 0.200
MMSE, M ± SD 28.6 ± 1.5 26.6 ± 2.2 < 0.001
HDRS, M ± SD 10.0 ± 6.5 8.0 ± 5.6 0.032
BDS, M ± SD 1.1 ± 1.3 1.9 ± 1.7 0.003
GDS, M ± SD 2.3 ± 0.5 2.6 ± 0.5 < 0.001
Delayed recall, z-score, M ± SD -0.50 ± 1.2 -2.3 ± 1.0 < 0.001
Learning, z-score, M ± SD -0.58 ± 1.2 -1.9 ± 1.0 < 0.001
Subjective organization*, M ± SD 1.2 ± 1.0 0.7 ± 0.8 < 0.001
Serial clustering*, M ± SD 3.0 ± 1.5 2.7 ± 1.7 0.138
M = mean, SD = standard deviation, MMSE = Mini Mental State Examination, HDRS = Hamilton Depression 
Rating Scale, GDS = Global Deterioration Scale, BDS = Blessed Dementia Rating Scale 
* = Mean over the learning trials
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and those who did not. Subjects with AD at follow-up had a signiﬁcantly lower baseline MMSE 
score, a higher GDS and BDS score, a lower HDRS score, a lower z-score on the delayed recall 
test of the AVLT, and were older than those without AD at follow-up. Sex distribution, and level 
of education were comparable in both groups. 
 The average score of the strategies used in the ﬁve learning trials of the two groups are 
presented in Table 1. Converters had signiﬁcantly lower mean levels of subjective organization. 
Serial clustering was comparable in both groups.
 Two factor GLM repeated measures ANOVA analyses, with age, sex and educational 
level as covariates showed a signiﬁcant main eﬀect of group on subjective organization (F 
= 5.7; df = 1; p = .017), indicating that converters had signiﬁcant lower scores of subjective 
organization across the learning trials than non-converters (Figure 1a). The main eﬀect for trial 
and the interaction eﬀect between group and trial did not reach statistical signiﬁcance. For 
serial clustering, the main eﬀects for group and trial, and the interaction eﬀect between group 
and trial were not statistically signiﬁcant (Figure 1b). 
 Survival analyses corrected for baseline age, education, and sex showed that lower 
levels of subjective organization were associated with an increased risk for AD (OR = 1.7, 95% 
CI = 1.16 – 2.66, p = 0.008). Serial clustering was not predictive for AD at follow-up (p = 0.438).
 In the age subgroups similar ﬁndings were obtained. Decreased use of subjective 
organization was associated with an increased risk for AD in both age subgroups (subjects 40-
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Figure 1: Average levels of learning strategies in converters and non-converters to AD. A: 
Subjective organization, B: Serial clustering. The black line represents the converters, the grey 
line the non-converters.
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59 years old: OR = 3.1, 95% CI = 0.97 – 9.9, p = 0.055; subjects 60-85 years old: OR = 1.6, 95% CI 
= 1.01 – 2.5, p = 0.046). Serial clustering was not predictive for AD in either age group.
 In order to investigate whether subjective organization was associated with 
progression to AD at the short term or long term, we performed separate analyses for subjects 
who were diagnosed with AD after 2, 5, and 10 years. The OR for AD after 2 years (31 subjects 
with AD) was 1.96, for AD after 5 years (19 subjects with AD) 1.03, and for AD after 10 years (10 
subjects with AD) 4.5.
 In order to investigate the relation between the use of learning strategies and delayed 
recall performance, we performed correlation analyses. There was a signiﬁcant relation between 
subjective organization and delayed recall performance (r = 0.49, p < 0.001), but not with serial 
clustering. 
Discussion
Less use of subjective organization was associated with an increased risk for AD. Use of serial 
clustering was not predictive for AD. 
 Serial clustering is a passive, low-level approach to recall, which does not involve 
any new transformation or organization of the presented information (Glosser et al., 2002). 
Subjective organization, on the other hand, requires more eﬀort and an active reorganization 
of the presented information by keeping the other items accessible in the mind. This eﬀortful 
strategy consumes a greater portion of a person’s limited mental resources (Bjorklund & 
Douglas, 1997), and seems to be problematic for subjects with MCI who later convert to AD. 
Our ﬁndings correspond with the ﬁndings of a cross-sectional study of Carlesimo et al. (1998), 
which suggested that memory aspects that require more processing resources can be use 
to diﬀerentiate normal from pathological aging. This is consistent with the idea that more 
passive on rehearsal based strategies develop earlier in childhood and deteriorate later in life, 
while more complex organization strategies develop later in childhood (Schneider & Sodian, 
1997) and degenerate earlier in the elderly. Lower scores of subjective organization were 
associated with an increased risk for AD both at the short term and at the long term, indicating 
that impairments in subjective organization is a very early symptom of AD. Why subjective 
organization was not predictive for AD after 5 years is not clear and may be a chance ﬁnding.
 Subjective organization depends on active reorganization of the incoming 
information, and may therefore be related to prefrontal lobe functioning and executive 
functioning (Fletcher et al., 1998; Fletcher et al., 1998; Kramer et al., 2005; Savage et al., 
2001). In order to investigate whether the eﬀect of subjective organization on AD was 
mediated by an impairment in executive function, we post-hoc repeated the analyses with 
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correction for Stroop card III score, TMT B score, and ﬂuency (Reitan, 1958; Stroop, 1935; 
Van der Elst et al., 2006a, 2006b). In these analyses, subjective organization remained a 
signiﬁcant predictor for AD, which suggests that subjective organization problems can not be 
explained by impairments in executive functioning, as measured with the tests we used in the 
present study. 
 We found that subjective organization was associated with the delayed recall 
performance at baseline. This suggests that subjective organization improves learning and 
subsequent retrieval from long-term memory. 
Implications
The ﬁnding that subjective organization was already impaired in prodromal AD gives new 
insights in the cognitive mechanisms that underlie memory dysfunction in subjects with 
prodromal AD. In clinical practice, subjective organization scores may help to predict AD in 
subjects with MCI. The observed correlation between subjective organization and delayed 
recall performance supports the use of cognitive training in subjects with MCI (Belleville, 2008) 
and may help the development of new cognitive training programmes which take learning 
strategies into account. Because of the role of learning strategies in prodromal AD, the type of 
word list used to assess memory function may be important for the ability to detect of subjects 
with AD. Word lists that include semantic related words might be less useful to identify subjects 
with prodromal AD, because active reorganization of the presented material is less needed. 
Word list learning tests in which the order of the words are presented varies over the learning 
trials, such as the word learning test of the Consortium to Establish a Registry for Alzheimer’s 
disease (Welsh et al., 1994) or the cognitive part of the Alzheimer’s Disease Assessment Scale 
(Rosen et al., 1984), might make it more diﬃcult for subjects to apply subjective organization 
or serial clustering strategies and might be sensitive for early AD. 
 To our knowledge, this study was the ﬁrst longitudinal study investigating the use of 
memory strategies in subjects with MCI and their predictive accuracy for AD in a large clinical 
sample with a follow-up up to 10 years. The post-hoc calculation indicated that based on 
the means of subjective organization the power of the total study was .97 at a signiﬁcance 
level of .05. Nonetheless, this study does have some points of attention. One issue worth 
mentioning is that the possibility to use strategies is related to the number of recalled words 
after each learning trial. However, we corrected the cluster scores for the total number words 
remembered in each learning trial. Additionally, the course of memory strategies over time 
was not investigated in this study. We did exclude subjects with a non-AD type dementia at 
follow-up. However, when we repeated the analyses with including non-AD type dementia in 
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the no AD group, results were comparable.  The results of this study can be applied to subjects 
from a memory clinic, but may not be generalisable to other settings. 
 In summary, we found that the ineﬀective use of eﬀortful strategies was associated 
with an increased risk for AD. This ﬁnding may help to identify subjects with prodromal AD in 
subjects with MCI and may help to develop cognitive training programs.
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Abstract
Background: Memory problems are a main feature of Mild Cognitive Impairment (MCI) and 
may be related to the Apolipoprotein E (APOE) e4 allele. We investigated whether the eﬀect of 
the APOE genotype on memory in subjects with MCI was dependent on age and underlying 
Alzheimer disease (AD) pathology. 
Methods: Subjects with MCI older than 40 years (n=181) were selected from a memory clinic 
setting. Subjects with at least one APOE e4 allele (n=84) were compared to non-carriers on 
learning, delayed recall, intrusions, retention rate, subjective organization, serial clustering, 
primacy and recency eﬀect with a multi-trial verbal learning test. Subjects were reassessed 5 
to 10 years later in order to identify those who developed AD. Analyses were performed in the 
total sample and in a middle-aged (age 40-59) and elderly subgroup (age 60-85).
Results: In the total sample, the APOE e4 allele was most strongly related to impaired learning. 
In the middle-aged subgroup, the APOE e4 allele was most strongly related to decreased 
subjective organization and in the old subgroup to a decreased delayed recall. After excluding 
subjects with incipient AD (n = 34), results remained similar in the middle-aged subgroup, but 
in the old subgroup the APOE genotype was no longer associated with memory dysfunction.
Conclusion: The presence of the APOE e4 allele is associated with impaired memory functioning 
in both middle-aged and old subjects with MCI, although the memory function aﬀected varies 
with age. Its eﬀect on memory function may be dependent on underlying AD pathology in 
elderly subjects, but not in middle-aged subjects.
Key words: APOE, MCI, Alzheimer’s disease, memory strategies.
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Introduction
The apolipoprotein E (APOE) e4 allele is a major risk factor for Alzheimer’s disease (AD) (Petersen 
et al., 1995) and is associated with memory impairment both in subjects with AD and non-
demented subjects (Small et al., 2004; van der Vlies et al., 2007; Wilson et al., 2002). The APOE 
e4 allele may also aﬀect on memory function in subjects with mild cognitive impairment (MCI) 
(Albert et al., 2007; Farlow et al., 2004; Smith et al., 1998). MCI refers to cognitive impairment in 
subjects without dementia, and is associated with an increased risk for AD (Visser et al., 2006). 
The relation between the APOE e4 allele and memory function in MCI is still poorly understood. 
It is not clear whether the eﬀect of APOE on memory function is mediated by underlying AD 
pathology (Bennett et al., 2005), or is an independent eﬀect of the APOE genotype (Martins 
et al., 2006). In addition, in order to better understand the relation between APOE genotype 
and memory function it would be important to know whether the eﬀect of APOE genotype is 
dependent on age, because underlying pathology in MCI may vary with age (Nilsson et al., 2006; 
Small et al., 2004). In addition, it would be important to know which aspect of memory is most 
severely aﬀected, because this may given an indication of which brain regions are involved. 
Previous studies in subjects with MCI however, were conducted in elderly subjects only (Albert 
et al., 2007; Farlow et al., 2004), and mainly investigated learning and delayed recall. 
 The aims of the present study were to investigate the eﬀect of the APOE e4 allele on 
memory function in middle-aged (40 - 59 years) and elderly (60 - 85 years) subjects with MCI 
from a memory clinic setting and to investigate whether the eﬀect of APOE e4 allele on memory 
function was dependent on underlying AD pathology. To that end we followed subjects for 
5 to 10 years and repeated analyses after exclusion of subjects who developed AD during 
this period. Besides learning and delayed recall, we also investigated memory measures that 
have not been investigated before such as primacy, recency, retention, intrusions, subjective 
organization, and serial clustering. Subjective organization and serial clustering are learning 
strategies that are used by a subject to learn new information. These strategies are impaired in 
early AD (Carlesimo et al., 1998; Delis et al., 1991; Perri et al., 2005). 
Methods
Subjects
Subjects were selected from an ongoing longitudinal study of non-demented subjects referred 
to the Maastricht memory clinic. The memory clinic is an outpatient clinic of the university 
hospital Maastricht (Verhey et al., 1993). The design of the study has been described in detail 
elsewhere (Verhey et al., 1993; Visser et al., 2006). Consecutive patients were included at the time 
CHAPTER 3
38
of the ﬁrst visit to the memory clinic. Inclusion criteria were age 40 years or older, and had MCI, 
deﬁned as a score of 2 or 3 on the Global Deterioration Scale (GDS) (Reisberg et al., 1982). This 
broad deﬁnition of MCI is consistent with that of other studies (Feldman & Jacova, 2005; Tabert 
et al., 2006; Tierney et al., 1996). It was used because subjects with AD in the predementia stage 
do often not meet more strict criteria of MCI, such as criteria for amnestic MCI (Geslani et al., 
2005; Storandt et al., 2006; Visser & Verhey, 2007). Exclusion criteria were dementia at baseline 
and an apparent cause for their cognitive impairment, such as cerebrovascular disorders, brain 
trauma, endocrine disorders or psychiatric disorders other than mild aﬀective disorders at 
baseline (Visser et al., 2000). Subjects included in this study were referred to the memory clinic 
by general practitioners (76%), neurologists (6%), psychiatrists (12%) or others (6%). 
 For the present study we selected those subjects eligible for the ﬁve or ten year 
follow-up (n = 454). During this period ﬁve versions of the Auditory Verbal Learning Test 
(AVLT) (Brand & Jolles, 1985) were used at baseline. In order to avoid a version eﬀect of the 
AVLT, we only included subjects with the version that was most commonly used (n = 368). 
Subjects with this version had similar age, sex, level of education, MMSE score, GDS score and 
BDS score, as subjects with other versions of the AVLT. Next we excluded subjects on whom 
APOE genotyping had not been performed (n = 187). The ﬁnal study sample consisted of 181 
subjects. Data on APOE genotype was mainly unavailable because blood for genotyping was 
collected at follow-up during a speciﬁc time period. In addition, a few subjects refused APOE 
genotyping. Subjects whose APOE status was not available were signiﬁcantly older (60.7 vs. 
57.0 years, p = .001) compared to subjects whose APOE status was known. Both groups were 
comparable with respect to educational level, sex distribution, MMSE score, HDRS score and 
total delayed recall at baseline, as well as percentage of subjects with AD at follow-up. 
Clinical assessment at baseline and follow-up
At baseline, all subjects underwent a standardised assessment, which included a detailed 
history of the subject, a psychiatric, neurological, and physical examination, the Mini Mental 
State Examination (MMSE) (Folstein et al., 1975), GDS (Reisberg et al., 1982), Hamilton Depression 
Rating Scale (HDRS) (Hamilton, 1960) and the Blessed Dementia Rating Scale (BDS) (Blessed et 
al., 1968), appropriate laboratory tests, a neuropsychological assessment, and a CT or MRI as 
described elsewhere  (Verhey et al., 1993). For describing purposes we subdivided subjects at 
baseline in 4 MCI groups based on the neuropsychological test performances in the domains 
of memory, attention, executive functioning, language, and visuoconstruction, as described 
elsewhere (Visser et al., 2006). Performance in a cognitive domain was considered impaired in 
the score on at least one test from that domain was below -1.5 standard deviation (SD) of age, 
sex and education corrected means of healthy control subjects (Van der Elst et al., 2005; Van 
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der Elst et al., 2006b) except for the measure of visuoconstruction in which impairment was 
based on a qualitative rating (Visser et al., 2006). Subjects without impairment in any domain 
were classiﬁed as subjective complaints (n = 53); subjects with only impairments in one or 
more non-memory domain as non-amnestic MCI (naMCI) (n = 66), subjects with impairment in 
only the memory domain as amnestic MCI single domain (aMCI-SD) (n = 13), and subjects with 
both impairments in memory and non-memory domains as amnestic MCI multiple domain 
(aMCI-MD) (n = 48). One subject could not be classiﬁed, because non-memory tests had not 
be done. The criteria for naMCI and aMCI also require intact activities of daily living (Petersen, 
2004). This was operationalized as the absence of dementia and a score below 4 on the GDS, 
which was part of the inclusion criteria of the study, in agreement with previous studies 
(Geslani et al., 2005).
 Two, ﬁve and ten years after baseline, the subjects were invited for a follow-up 
assessment. This assessment included a standardized questionnaire about medical history 
and cognitive complaints, the MMSE, GDS, BDS, HDRS, and an extensive neuropsychological 
assessment comparable to the baseline assessment. Subjects who refused to come for the 
follow-up were assessed via a telephone interview, which included a standardized questionnaire 
about medical history and cognitive complaints, and the Telephone Interview for Cognitive 
Status (Brandt et al., 1988). The diagnosis of dementia and AD was made independently by 
both a neuropsychiatrist and a neuropsychologist according to the DSM-IV and NINCDS-
ADRDA criteria (APA, 1994; McKhann et al., 1984). Both were blinded to the baseline results. If 
disagreement on the diagnosis occurred, a consensus meeting was held. Subjects, who were 
diagnosed as being demented at follow-up, were not invited for the next follow-up. 
Outcome at follow-up
The average follow-up duration was 8.7 years. Because blood for genotyping was collected 
at follow-up, all subjects had at least one follow-up. Of the 181 subjects included at baseline, 
140 subjects had been in the study long enough to be contacted for the 10-year follow-up 
and cognitive outcome was available for 120 (86%) of them, the other subjects (n = 41) only 
had a ﬁve year follow-up. Reason for no outcome at the 10-year follow-up was because the 
subjects refused (n = 6), had died (n = 7), or were untraceable (n = 7). Subjects with and without 
cognitive outcome had comparable age, sex distribution, level of education and MMSE score. 
During the total follow-up period 34 subjects (19%) had developed AD. After 5 years 26 subjects 
had developed AD, and after 10 years 8. Of those with AD at follow-up, 6 were younger than 60 
years and 28 were older than 60 years.
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Measures of memory impairment
In the Dutch version of the AVLT (Brand & Jolles, 1985; Van der Elst et al., 2005) ﬁfteen unrelated 
monosyllabic words are presented ﬁve times in the same order and after each presentation the 
subject is asked to recall as many words as possible. After 20 minutes, in which non-verbal tests 
were performed, delayed recall was tested. The AVLT can be used to investigate the following 
aspects of verbal memory functioning:
Learning: total of correctly remembered words from the 5 immediate recall trials.
Delayed recall: total number of correctly remembered words after 20 minutes.
Retention: total delayed recall score divided through the highest score at the 5 immediate recall 
trials, multiplied by 100.
Intrusion: number of recalled words in the 5 immediate recall trials that were not part of the 
AVLT.
Subjective organization: Subjective organization refers to the constancies in response ordering, 
that develop in a series of free recalls (Bousﬁeld & Bousﬁeld, 1966; Tulving, 1962). Based on 
the output order in which the words from two successive trials are listed by the subjects, 
combinations (clusters) of words that are recalled together in these two successive trials 
are identiﬁed. These combinations are based on the organization schema developed by the 
individual subject, and are not dependent on prespeciﬁed categorization based on semantic 
relationships, which is used in several word learning tests such as the California Verbal Learning 
Test (Delis et al., 1987). A bidirectional inter-trial repetition (ITR) measure was used (Saan & 
Deelman, 1986; Sternberg & Tulving, 1977). Each time a combination of words is recalled 
consecutively in one trial and also in the next trial (= inter-trial repetition) the subject gets one 
point. The bidirectional ITR corrects for clusters that occur by chance with the following formula: 
Subjective organization = observed (ITR) – expected (ITR), where expected ITR = 2c(c -1) / h * k 
(Saan & Deelman, 1986; Sternberg & Tulving, 1977). Observed ITR is the number of pairs of 
items recalled on trial t and t + 1 in adjacent output positions in either of the two possible 
orders. Expected ITR is the expected number of pairs of items, c is the number of common 
items recalled on both trials t and t + 1, h is the number of items recalled on trial t, and k is the 
number of items recalled on trial t + 1. An outcome of 0 indicates that the number of observed 
ITRs is equal to the number of expected ITRs. A score higher than 0 indicates more use of 
subjective organization than expected by chance.
Serial clustering: Serial clustering is a measure for the reproduction of words in the same order 
as that they were presented. This form of clustering indicates a more passive approach to recall. 
Serial clustering was calculated with correction for the number of clusters that can be expected 
to occur by chance (Mulder et al., 1996; Saan & Deelman, 1986).
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Primacy eﬀect: ratio of the number of words remembered from the ﬁrst 3 words of the list 
divided by 3.
Recency eﬀect: ratio of the number of words remembered from the last 3 words of the list 
divided by 3.
Apolipoprotein E genotyping
APOE genotype was determined on genomic DNA extracted form EDTA anticoagulated blood 
using the polymerase chain reaction (PCR) technique (Bekers et al., 2002; Slooter et al., 1998; 
Wenham et al., 1991). Genotyping was done blinded for all clinical data. Eighty-four subjects 
(46%) had one or two e4 alleles (APOE+), viz. e4e4 (n = 9, 5%), e3e4 (n = 69, 38%), and e2e4 
(n = 6, 3%). Ninety-seven subjects (54%) had no e4 allele (APOE-), viz. e3e3 (n = 76, 42%), e2e3 
(n = 20, 11%), and e2e2 (n = 1, 0.5%). 
Statistics
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS) for 
the Macintosh, version 11. To analyse baseline diﬀerences between carriers and non-carriers of 
the APOE e4 allele independent t-tests were used for continues variables, and Chi-square tests 
for categorical variables. Level of education was classiﬁed into low (at most primary education), 
middle (junior vocational education), or high (senior vocational education or academic 
training) (UNESCO, 1976). Univariate variance analyses (ANOVA) adjusted for age, education 
and sex were used to test group diﬀerences in memory performance between carriers and 
non-carriers of the APOE e4 allele. Stepwise binairy logistic regression analysis with correction 
for age, sex and education was used to identify the memory variable to which the APOE e4 
allele was strongest related. All analyses were repeated without subjects who had developed 
AD within the study period of 10 years and were performed in the total group and in subjects 
aged 40 to 59 years (middle-aged subgroup) and 60 to 85 years (older subgroup). To adjust for 
multiple comparisons we used an α-level of 0.01.
Results
Baseline characteristics
Baseline characteristics of carriers and non-carriers of the APOE e4 allele are presented in 
Table 1. In the total group, APOE e4 carriers were about 4 years older, had a signiﬁcantly lower 
MMSE and delayed recall score, a slightly higher GDS score, a lower HDRS score, and more often 
aMCI (46 vs 24%, p =  0.003) compared to non-carriers. Educational level and sex distribution 
were comparable. In the middle-aged subgroup, baseline characteristics and distribution of 
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MCI-subtypes was comparable between subjects with and without the APOE e4 allele. In the 
elderly subgroup, APOE e4 carriers had a lower score on the delayed recall test and were more 
often aMCI-MD (42 vs. 19%, p = 0.045) than subjects without the APOE e4 allele. The APOE 
e4 allele was more common in subjects older than 60 years (58%) than in the middle-aged 
subgroup (40%) (p = .015). 
Eﬀect of APOE on memory function
Memory performances of carriers and non-carriers of the APOE e4 allele are presented in 
Table 2. In the total sample, carriers of the e4 allele had lower scores on learning, delayed recall, 
subjective organization and primacy. In subjects younger than 60 years, APOE e4 carriers had 
lower scores on learning and subjective organisation, while in the elderly subgroup APOE e4 
carriers had lower scores on learning and delayed recall (Table 2). 
 Binary logistic regression analyses, adjusted for age, sex and education showed that 
in the total sample the APOE e4 allele was most strongly related to the learning performance 
(p = .003). In middle-aged subjects, the APOE e4 allele was most strongly related to subjective 
organization (p = .011), while in the elderly subjects the APOE e4 allele was most strongly 
related to the delayed recall performance (p = .02).
Eﬀect of underlying AD pathology
When the subjects with AD at follow-up were excluded from the analyses (6 in the 60- group, and 
28 subjects in the 60+ group), the APOE e4 allele was associated with lower scores on learning 
in the total group (p = 0.025). In middle-aged subjects, the APOE e4 allele was still associated 
with lower scores on subjective organization (p = 0.028), but no longer with learning. In the 
60+ group, the APOE genotype was no longer associated with any of the memory measures.
Discussion
In the present study, we found an eﬀect of the APOE e4 allele on various aspects of memory 
in subjects with MCI, which depends on age and underlying AD pathology. In elderly subjects, 
the APOE e4 allele was most strongly related to delayed recall performance, compared to 
subjective organization in the middle-aged subgroup. The eﬀect of APOE on memory function 
may have been related to underlying AD pathology in subjects over 60 years, but not in middle-
aged subjects. 
 The eﬀect of the APOE e4 genotype on delayed recall, and learning in elderly subjects 
with MCI is in line with previous studies (Albert et al., 2007; Smith et al., 1998). It suggests 
involvement of the medial temporal lobe as this region plays an important role in these 
APOE AND MEMORY IN MCI
43
 
A
ll 
su
bj
ec
ts
 
 
Su
bj
ec
ts
 4
0 
- 6
0 
ye
ar
s
 
 
Su
bj
ec
ts
 6
0 
- 8
5 
ye
ar
s
 
 
A
PO
E 
e4
-             
A
PO
E 
e4
+
p
A
PO
E 
e4
-       
      
A
PO
E 
e4
+
p
A
PO
E 
e4
-             
A
PO
E 
e4
+
p
n 
=
 9
7
n 
=
 8
4
n 
=
 7
0
n 
=
 4
6
n 
=
 2
7
n 
=
 3
8
A
ge
, M
 ±
 S
D
55
.2
 ±
9.
2
59
.0
 ±
 9
.9
0.
00
7
50
.4
 ±
 4
.8
51
.5
 ±
 5
.6
0.
27
67
.6
 ±
 5
.5
68
.2
 ±
 5
.2
0.
7
Ed
uc
at
io
n,
 %
 lo
w
12
24
0.
12
9
20
0.
23
22
29
0.
76
Se
x,
 %
 m
al
e
57
55
0.
79
60
59
0.
89
48
50
0.
88
M
M
SE
, M
 ±
 S
D
28
.7
 ±
 
1.
4
28
.0
 ±
 2
.0
0.
01
28
.9
 ±
 1
.3
28
.7
 ±
 1
.4
0.
51
28
.0
 ±
 1
.6
27
.0
 ±
 2
.3
0.
06
D
el
ay
ed
 re
ca
ll 
(Z
-s
co
re
), 
M
 ±
 S
D
-0
.5
 ±
 1
.3
-1
.2
 ±
 1
.2
<
0.
00
1
-0
.5
 ±
 1
.2
-0
.8
 ±
 1
.2
0.
10
-0
.7
 ±
 1
.5
-1
.6
 ±
 1
.2
0.
00
6
M
C
I-s
ub
gr
ou
ps
  -
 a
M
C
I-S
D
, %
5
11
0.
26
4
3
9
0.
17
1
11
11
0.
94
0
  -
 a
M
C
I-M
D
, %
19
35
0.
01
0
19
30
0.
15
1
19
42
0.
04
5
  -
 N
on
-a
m
ne
st
ic
 M
C
I, 
%
45
27
0.
01
6
43
28
0.
09
8
48
26
0.
07
0
  -
 S
ub
je
ct
iv
e 
co
m
pl
ai
nt
s,
 %
31
27
0.
57
0
35
33
0.
80
9
22
21
0.
91
0
G
D
S,
 M
 ±
 S
D
2.
3 
±
 0
.5
2.
5 
±
 0
.6
0.
01
2.
3 
±
 0
.4
2.
4 
±
 0
.5
0.
14
2.
4 
±
 0
.5
2.
7 
±
 0
.6
0.
17
BD
S,
 M
 ±
 S
D
1.
3 
±
 1
.2
1.
6 
±
 1
.7
0.
18
1.
2 
±
 1
.3
1.
4 
±
 1
.6
0.
62
1.
5 
±
 1
.1
1.
9 
±
 1
.7
0.
3
H
D
RS
, M
 ±
 S
D
 
10
.7
 ±
 
5.
5
8.
8 
±
 6
.1
0.
02
5
 
10
.9
 ±
 5
.7
8.
9 
±
 6
.4
0.
10
 
10
.4
 ±
 5
.2
8.
6 
±
 5
.8
0.
2
M
 =
 m
ea
n,
 S
D
 =
 st
an
da
rd
 d
ev
ia
tio
n,
 M
M
SE
 =
 M
in
i M
en
ta
l S
ta
te
 E
xa
m
in
at
io
n,
 a
M
C
I-S
D
 =
 a
m
ne
st
ic
 M
C
I s
in
gl
e 
do
m
ai
n,
 a
M
C
I-M
D
 =
 a
m
ne
st
ic
 M
C
I m
ul
tip
le
 
do
m
ai
n,
 G
D
S 
=
 G
lo
ba
l D
et
er
io
ra
tio
n 
Sc
al
e,
 H
D
RS
 =
 H
am
ilt
on
 D
ep
re
ss
io
n 
Ra
tin
g 
Sc
al
e,
 B
D
S 
=
 B
le
ss
ed
 D
em
en
tia
 R
at
in
g 
Sc
al
e,
 A
PO
E 
e4
- =
 n
on
-c
ar
rie
rs
 o
f 
th
e 
A
PO
E 
e4
 a
lle
le
, A
PO
E 
e4
+
 =
 h
om
oz
yg
ot
e 
or
 h
et
er
oz
yg
ot
e 
ca
rr
ie
rs
 o
f t
he
 A
PO
E 
e4
 a
lle
le
.
Ta
b
le
 1
: B
as
el
in
e 
ch
ar
ac
te
ris
tic
s 
ac
co
rd
in
g 
to
 A
PO
E 
st
at
us
.
CHAPTER 3
44
Ta
b
le
 2
: E
ﬀe
ct
 o
f t
he
 A
PO
E 
e4
 a
lle
le
 o
n 
m
em
or
y 
fu
nc
tio
n.
 
A
ll 
su
bj
ec
ts
 
 
Su
bj
ec
ts
 4
0 
- 6
0 
ye
ar
s
 
 
Su
bj
ec
ts
 6
0 
– 
85
 y
ea
rs
 
A
PO
E 
e4
-    
       
  
A
PO
E 
e4
+
p
 
A
PO
E 
e4
-     
        
A
PO
E 
e4
+
p
 
A
PO
E 
e4
-    
        
 
A
PO
E 
e4
+
p
 
n 
=
 9
7
n 
=
 8
4
 
n 
=
 7
0
n 
=
 4
6
 
n 
=
 2
7
n 
=
 3
8
 
Le
ar
ni
ng
41
.9
 ±
 1
0.
9
35
.3
 ±
 1
0.
3
0.
00
2
43
.7
 ±
 9
.8
38
.9
 ±
 1
0.
1
0.
04
37
.6
 ±
 1
2.
4
30
.7
 ±
 8
.9
0.
02
D
el
ay
ed
 re
ca
ll
8.
53
 ±
 3
.4
6.
39
 ±
 3
.5
0.
00
3
9.
1 
±
 3
.0
8.
0 
±
 3
.0
0.
09
7.
0 
±
 4
.0
4.
4 
±
 3
.1
0.
01
Su
bj
ec
tiv
e 
or
ga
ni
za
tio
n
1.
4 
±
 1
.1
0.
9 
±
 0
.8
0.
00
3
1.
6 
±
 1
.1
1.
0 
±
 0
.8
0.
00
9
1.
2 
±
 0
.9
0.
8 
±
 0
.8
0.
12
Se
ria
l c
lu
st
er
in
g
3.
1 
±
 1
.5
2.
7 
±
 1
.6
0.
16
3.
3 
±
 1
.5
2.
8 
±
 1
.4
0.
09
2.
8 
±
 1
.5
2.
6 
±
 1
.7
0.
81
Pr
im
ac
y
0.
73
 ±
 0
.2
0.
64
 ±
 0
.2
0.
04
0.
8 
±
 0
.2
0.
7 
±
 0
.2
0.
08
0.
7 
±
 0
.2
0.
6 
±
 0
.2
0.
23
Re
ce
nc
y
0.
63
 ±
 0
.2
0.
55
 ±
 0
.2
0.
10
0.
7 
±
 0
.2
0.
6 
±
 0
.2
0.
14
0.
6 
±
 0
.2
0.
5 
±
 0
.2
0.
46
In
tr
us
io
ns
1.
9 
±
 2
.4
2.
4 
±
 3
.1
0.
33
2.
1 
±
 2
.6
2.
2 
±
 3
.0
0.
88
1.
5 
±
 1
.9
2.
6 
±
 3
.2
0.
15
Re
te
nt
io
n 
(%
)
75
.5
 ±
 2
2.
3
65
.0
 ±
 2
6.
3
0.
06
 
79
.6
 ±
 1
7.
5
76
.9
 ±
 1
7.
8
0.
37
 
65
.0
 ±
 2
9.
4
50
.6
 ±
 2
7.
9
0.
08
D
at
a 
ar
e 
m
ea
n 
±
 s
ta
nd
ar
d 
de
vi
at
io
n.
A
PO
E 
e4
-: 
no
n-
ca
rr
ie
rs
 o
f t
he
 A
PO
E 
e4
 a
lle
le
, A
PO
E 
e4
+
: h
om
oz
yg
ot
e 
or
 h
et
er
oz
yg
ot
e 
ca
rr
ie
rs
 o
f t
he
 A
PO
E 
e4
 a
lle
le
.
APOE AND MEMORY IN MCI
45
memory functions. Indeed, there is evidence that elderly subjects with MCI with an APOE allele 
have more atrophy in these region compared to subjects without an APOE allele (Fleisher et 
al., 2005). The eﬀect of the APOE e4 allele on memory functioning may have been modulated 
by underlying AD pathology, since after exclusion of subjects who developed AD, the APOE 
genotype was no longer associated with memory performance. This ﬁnding is consistent 
with a population-based study in elderly subjects which showed that the APOE is no longer 
associated with cognition after correction for amyloid load in the brain (Bennett et al., 2005). 
However, the lack of an eﬀect of APOE genotype on memory after exclusion of incipient AD 
cases might also have resulted from a lack of statistical power, because after the exclusion of 
AD subjects only 10 subjects older than 60 years carried the APOE e4 allele. 
 In subjects younger than 60 years, the e4 allele was most strongly associated with 
subjective organization, and to a lesser extent with learning. Subjective organization is an 
eﬀortful learning strategy requiring an active reorganization of the incoming information 
to enhance the quality of encoding, and is thought to be mediated by the prefrontal lobe 
(Fletcher, Shallice, & Dolan, 1998; Fletcher et al., 1998; Kramer et al., 2005; Savage et al., 2001). 
In order to investigate whether this eﬀect was mediated by impairment in executive function, 
we post hoc repeated the analyses with correction for Stroop card III score and TMT B score 
(Reitan, 1958; Stroop, 1935). In these analyses, subjective organization remains signiﬁcantly 
related to APOE genotype, which suggests that subjective organization problems in APOE e4 
carriers can not be explained by impairments in executive functioning. No other studies have 
investigated the eﬀect of APOE on memory in middle-aged subjects with MCI, but in healthy 
young and middle-aged subjects the APOE e4 allele did not have an eﬀect on memory function 
(Jorm et al., 2007). The lack of eﬀect in young and middle-aged healthy APOE e4 carriers could 
be explained by test selection, because only measures of learning or delayed recall were tested 
which was not severely aﬀected by the APOE e4 allele in our study. Alternatively, the eﬀect of 
the APOE e4 allele on cognitive function in younger subjects may become apparent only if 
impairment is severe enough to meet criteria of MCI and leads to referral to a memory clinic.
 The eﬀect of the APOE e4 allele on memory functioning in the middle-aged subgroup 
seemed not to be modulated by incipient AD, because after exclusion of subjects who 
converted to AD subjective organization remained associated with the e4 allele. This could 
mean that the APOE e4 allele directly aﬀects memory functioning independently of AD related 
pathology, for example by its eﬀect on lipid or glucose metabolism (Martins et al., 2006). 
Another explanation is that the memory problems were related to AD pathology, but that in 
these middle-aged subjects the follow-up interval was not long enough to identify everyone 
who would progress to clinical AD. In that case, subjective organization could be a very early 
marker of AD (Carlesimo et al., 1998; Delis et al., 1991; Perri et al., 2005). 
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 There is ample evidence that the APOE e4 allele aﬀects brain functioning in parietal, 
temporal and prefrontal regions in young to middle-aged subjects who are cognitively intact 
(Reiman et al., 2004; Scarmeas et al., 2003; Trivedi et al., 2006). The interpretation of these 
studies is still controversial. Some studies suggest that these brain abnormalities reﬂect early 
AD as AD pathology is found in the same regions and may be present decades before the onset 
of dementia (Mondadori et al., 2006; Reiman et al., 2004). Others consider this unlikely and 
suggest that these abnormalities are a direct eﬀect of the APOE genotype on lipid or glucose 
metabolism that may facilitate the onset of AD at a later age (Scarmeas et al., 2005). The eﬀect 
of APOE on frontal lobe functioning in young to middle-aged subjects may explain the eﬀect 
of APOE on subjective organization in the present study (Bartzokis et al., 2006; Bookheimer et 
al., 2000; Filbey et al., 2006; Reiman et al., 2004; Wishart et al., 2006). Although neuroimaging 
studies in this age range showed also impairments in the medial temporal lobe, learning 
and delayed recall were not severely aﬀected in the middle-aged subgroup in our study 
(Bookheimer et al., 2000; Scarmeas et al., 2005; Wishart et al., 2006). One explanation is that 
these memory functions could still be compensated for. 
  Serial clustering, primacy, recency, intrusions and retention were not related to APOE 
genotype. Serial clustering, primacy, recency do not require active organization of the incoming 
information and are more related to working memory and short term memory processes. In 
general, these aspects of memory functioning are relatively less sensitive to neurodegeneration 
(Perri et al., 2005). The lack of an eﬀect of the number of intrusions might be explained by the 
low prevalence of intrusions in the total sample. Retention was lower in APOE e4 carriers, but 
did not reach statistical signiﬁcance. 
 The APOE allele distribution in our sample is comparable with that reported in other 
studies with MCI (Farlow et al., 2004; Petersen et al., 1995). The prevalence of the APOE e4 allele 
in our middle-aged subgroup (40%) and in the elderly subgroup (58%) was higher than the 
prevalence of the APOE e4 allele in subjects from the general population aged 40-60 (32%) and 
60–85 years (24%) from the Maastricht Aging Study (MAAS) (Jolles et al., 1995). This suggests 
that carriers of the APOE e4 allele more often have memory problems leading to a referral to a 
memory clinic than non-carriers, even at a relative young age. 
 Strengths of the present study include the large sample size, the broad age range, the 
variety of memory measures tested, and the long follow-up period to identify subjects with 
incident AD. The study also had some limitations. Firstly, after exclusion of those who developed 
AD the sample size in the older subgroup was small, resulting in only 10 subjects older than 60 
years who carried an e4 allele. Secondly, because subjects were selected from a memory clinic 
results may not be generalizable to other settings and subjects with MCI according to other 
deﬁnitions. Thirdly, the follow-up period may be too short to identify all subjects who convert 
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to AD. Another point is that blood samples for APOE genotyping were collected at follow-up 
only. However, the baseline characteristics of the subjects with data on APOE genotype and 
those without data on APOE genotype were comparable, except regarding age, which was 
3 years lower in those with genotyping. This suggests that genotyping at follow-up may not 
have introduced a strong bias.
 In conclusion, the ﬁndings of this study, that investigated several aspects of verbal 
memory across a broad age range in clinical subjects with MCI showed that APOE genotype 
has an eﬀect on memory that is dependent on age. In subjects of 60 years and older, memory 
functions associated with the medial temporal lobe were predominantly aﬀected, while 
in middle-aged subjects memory functioning related to the frontal lobe was most strongly 
aﬀected. Together with the observation that memory functioning was dependent on AD 
pathology in elderly subjects, but not in middle-aged subjects, this suggests that diﬀerent 
mechanisms underlie the APOE-related memory dysfunction in diﬀerent age groups. Whether 
the eﬀect of APOE genotype on subjective organization in middle-aged subjects is indeed an 
AD independent process needs to be investigated in future imaging studies and longitudinal 
studies with a longer follow-up. 

4 Aﬀective symptoms as predictors for Alzheimer’s disease in subjects with Mild Cognitive Impairment: a 10-year follow-
up study
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Abstract
Context: Aﬀective symptoms are common in subjects with mild cognitive impairment (MCI). 
Previous studies yielded conﬂicting results regarding the question whether these symptoms 
are predictive for future Alzheimer’s disease (AD).
Objectives: To investigate the predictive accuracy of aﬀective symptoms for AD during a 10-
year follow-up in subject with MCI, and to investigate whether the predictive accuracy was 
modiﬁed by age, the presence of amnestic MCI and length of follow-up. 
Design: Prospective cohort study with follow-up assessments after 2, 5 and 10 years.
Setting: Memory clinic
Participants: 263 consecutive newly referred subjects with MCI older than 55 years and without 
obvious causes of cognitive impairment. 
Assessment: Ratings for depression, anxiety, apathy, and sleeping problems from the Hamilton 
Depression Rating Scale.
Main Outcome Measure: Conversion to AD at follow-up. 
Results: Aﬀective symptoms were present in 50-70% of the subjects. The average follow-up 
period was 5.4 years and 79 subjects (29%) developed AD. All aﬀective symptoms were associated 
with a decreased risk for AD, which was statistically signiﬁcant for sleeping problems (sleeping 
problems OR = 0.35 (95% CI = 0.20-0.62, P<0.001), depression OR = 0.61 (95% CI = 0.36-1.01, P 
= 0.059), anxiety OR = 0.58 (95% CI = 0.34-1.0, P = 0.051), apathy OR  = 0.67 (95% CI = 0.4-1.1, 
P = 0.14)). Depression was associated with a decreased risk for AD only in subjects without 
amnestic MCI (OR = 0.34, 95% CI = 0.13–0.93, P = 0.036), but not in subjects with amnestic 
MCI (OR = 1.1, 95% CI = 0.50–2.3, P = 0.85). The risk of anxiety for AD was diﬀerent (P = 0.046) 
between subjects diagnosed with AD at the 5-year follow-up (OR = 0.23, 95% CI = 0.0-0.66, 
P = 0.077) and subjects diagnosed with AD at the 10-year follow-up (OR = 1.7, 95% CI = 0.32-
9.01, P = 0.539).
 
Conclusions: Aﬀective symptoms are generally associated with a decreased risk for AD. The risk 
may be dependent on MCI subtype or length of follow-up, but it does not depend on age.
Key words: Aﬀective symptoms, Mild Cognitive Impairment, Alzheimer’s disease, and predictive 
accuracy.
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Introduction
Mild Cognitive Impairment (MCI) is a condition that refers to cognitive impairment in subjects 
without dementia. It has many causes, including Alzheimer’s disease (AD) (Visser et al., 2006). 
It is important to identify MCI subjects with prodromal AD, because if disease modifying drugs 
for AD become available, these are likely be most eﬀective in the early stage of the disease. 
A possible predictor for AD are aﬀective symptoms, such as depression, anxiety and apathy 
(Ownby et al., 2006). These symptoms are common in subjects with MCI (Apostolova & 
Cummings, 2007), but it is uncertain whether they can predict AD in this population (Steﬀens 
et al., 2006). Depressive symptoms were associated with an increased risk for AD in some 
studies (Gabryelewicz et al., 2007; Modrego & Ferrandez, 2004), and with a decreased risk in 
others (Liu et al., 2007; Rozzini et al., 2005), while most studies did not ﬁnd a relation between 
depression and AD at all (Table 1) (Copeland et al., 2003; Feldman et al., 2007; Korf et al., 2004; 
Palmer et al., 2007; Panza et al., 2008; Robert et al., 2006; Teng et al., 2007; Tierney et al., 1999; 
Visser et al., 2000; Visser et al., 2000; Wang et al., 2006). Similarly, discrepant results have been 
reported regarding the predictive accuracy of apathy and anxiety for AD (Feldman et al., 2007; 
Liu et al., 2007; Palmer et al., 2007; Robert et al., 2006; Teng et al., 2007).
 The contradictory ﬁndings suggest that the relation between aﬀective symptoms and 
AD is modiﬁed by other factors, which varied between studies, but these factors have not yet 
been identiﬁed. Statistically non-signiﬁcant ﬁndings may be explained by a small sample size 
or a brief follow-up period. Aim of the present study was to investigate the predictive accuracy 
of aﬀective symptoms for AD in a large clinical cohort of subjects with MCI over a 10-year 
period. In addition, we investigated whether age, the presence of amnestic MCI, and length of 
follow-up modiﬁed the relation between aﬀective symptoms and AD. We hypothesized that the 
association between aﬀective symptoms and AD would be strongest in elderly subjects or in 
subjects with amnestic MCI, as these subjects are more likely to develop AD (Visser et al., 2006). 
We investigated length of follow-up as possible eﬀect modiﬁcator, because previous studies 
suggested that the risk of depression for dementia may increase or decrease with length of 
follow-up (Green et al., 2003; Ownby et al., 2006). Besides depression, anxiety, and apathy, we 
also investigated sleeping problems as a predictor for AD. Sleeping problems are common 
in aﬀective disorders and previous studies found that these problems may be predictive for 
cognitive decline or dementia (Jelicic et al., 2002). 
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Table 1: Studies on the predictive value of depressive symptoms for AD or dementia in subjects 
with MCI. 
Study Setting N MCI-deﬁnition Age MMSE Depression 
scale
Depression diagnosis
Tierney et al., 1999 Community 143 GDS 2 or 3 72.0 27.8* GDS-30 GDS-30 >10
Visser et al., 2000 Clinical 74 aMCI 61.1 27.3 HDRS DSM IV minor and major depression, 
and HDRS > 13
Visser et al., 2000 Clinical 111 GDS 2 or 3 66.0 27.9 HDRS DSM IV minor and major depression
Visser et al., 2002 Community 45 Minimal 
dementia
79.4 22.8 na CAMDEX-criteria
Copeland et al., 
2003 
Community 123 CDR = 0.5 72.0 29.2 na at least 1 symptom DSM-III-R depression 
criteria
Estévez-González et 
al., 2003
Clinical 70 GDS 2 or 3 68.1 27.5 GDS-30 na
Tian et al., 2003 Clinical 129 Test impairment 70.0 24.6 Cornell na
Korf et al., 2004 Clinical 75 Test impairment 62.8 26.9 MADRS MADRS > 6
Modrego & 
Ferrandez, 2004 
Clinical 114 aMCI 72.8 27.8 GDS-30 GDS-30 > 9 and DSM-IV depression 
or depressed mood  without guild/
worthlessness
Rozzini et al., 2005 Clinical 46 aMCI 70.5 26.8 GDS-15 DSM-IV major depression
Robert et al., 2006 Clinical 216 Complaints and 
test impairment
71.9 27.5 MADRS MADRS > 10
Wang et al., 2006 Clinical 58 aMCI 76.3 25.9 GDS-15 na
Yaﬀe et al., 2006 Clinical 327 Test impairment 72.9 25.7 na At least 2 symptoms DSM-III-R 
depression criteria
Feldman et al., 2007 Clinical 510 CDR 0.5 and 
aMCI
70.6 26.9 HDRS na
Gabrylewicz et al., 
2007 
Clinical 105 CDR 0.5 and test 
impairment
69.3 27.2 MADRS na
Liu et al., 2007 Clinical 124 CDR 0.5 74.7 25.2 HDRS na
Palmer et al., 2007 Community 47 Complaints and 
test impairment
84.0 na CPRS mood CPRS mood>1
Teng et al., 2007 Clinical 51 Complaints and 
test impairment 
72.8 27.6 NPI-
depression 
NPI-depression score > 0
Panza et al., 2008 Community 139 Test impairment 80.6 21.4 GDS-30 GDS-30 > 9
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Table 1 continued: Studies on the predictive value of depressive symptoms for AD or dementia 
in subjects with MCI. 
Study Exclusion criteria 
depression
Prevalence 
depression 
Depression 
scale score
Years follow
up
Outcome Prediction
Relation with 
outcome#
ES^ (95% CI) OR^^ (95% CI)
Tierney et al., 1999 None 22% 4.9 2 AD 0 -0.04 (0.47-0.39) 0.99 (0.35–2.8)
Visser et al., 2000 None 35% 11.1 3.7 AD 0 -0.33 (-0.87-0.21) 0.57 (0.17–1.9)
Visser et al., 2000 None 56% 10.1 2.6 Dementia 0 -0.14 (-0.59-0.32) 1.38 (0.55–3.5)
Visser et al., 2002 None 13% na 2.3 Dementia 0 na 1.2 (0.24–6.0)
Copeland et al., 
2003 
None 38% na 3 AD 0 0.10 (-0.37-0.56) 1.09 (0.43–2.8)
Estévez-González et 
al., 2003
None na 11.2 2.3 AD na -0.56 (-1.1-0.07) na
Tian et al., 2003 None na 4.3 2 Dementia 0 -0.03 (-0.41-0.36) na
Korf et al., 2004 None 42% na 2.8 Dementia 0 na 0.48 (0.2–1.2)
Modrego & 
Ferrandez, 2004 
None 36% 9.6 3 AD + 1.25 (0.84-1.65) 11.9 (4.4-32.2)
Rozzini et al., 2005 None 48% na 2 AD - na 0.24 (0.07–0.81)
Robert et al., 2006 MADRS > 20 20%
 
6.9 1 AD 0 0.28 (-0.16-0.72) 2.1 (0.8–5.4)
Wang et al., 2006 None na 4.0 1.8 AD 0 -0.46 (-1.0-0.09) na
Yaﬀe et al., 2006 na 38% na 3.1 Dementia 0 na 1.23 (0.75-2.0)
Feldman et al., 2007 HDRS > 12 and 
HDRS item 1 > 0
na 2.7 4 AD 0 0.04 (-0.17-0.25) na
Gabrylewicz et al., 
2007 
MADRS > 28 na 9.7 3 Dementia + 0.32 (-0.15-0.78) na
Liu et al., 2007 None na 8.2 1.7 AD - -0.49 (-0.88-0.09) na
Palmer et al., 2007 None 36% na 3 AD 0 na 1.3 (0.4-5.1)
Teng et al., 2007 None 39% 1.2 2 AD + na 4.5 (1.1-17.9)
Panza et al., 2008 None 61% na 3.5 Dementia 0 na 1.6 (0.8-3.1) 
legend on page 54
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Legend Table 1
na = not available, MCI: Mild Cognitive Impairment, aMCI: amnestic Mild Cognitive Impairment, CIND: 
Cognitive Impairment No Dementia, AD: Alzheimer disease, HDRS: Hamilton Depression Rating Scale, 
GDS-15: Geriatric Depression Scale 15 items, GDS-30: Geriatric Depression Scale 30 items, GDS: Global 
Deterioration Scale, NPI: Neuropsychiatric Inventory, CPRS: Comprehensive Psychopathological Rating 
Scale, GMSS: Geriatric Mental State Schedule, CESDS: Center for Epidemiologic Studies Depression Scale, 
mCESDS: modiﬁed Center for Epidemiological Studies Depression Scale, CDR: Clinical Dementia Rating, 
Cornell: Cornell Scale for Depression in Dementia.
# This column summarizes statistically signiﬁcant ﬁndings as reported in each study. 0 = depression is 
not associated with outcome; + = depression is associated with an increased risk for AD or dementia; - = 
depression is associated with a decreased risk for AD or dementia.
^ES = Eﬀect Size based on diﬀerences in depression scores between subjects with and without AD or 
dementia at follow-up and presented as Cohen’s delta. A negative score means that subjects with AD or 
dementia at follow-up have a lower score on the depression scale than subjects without AD or dementia 
at follow-up.
^^OR = Odds ratio. Odds ratio was based on dichotomous data presented in the publication and 
uncorrected for any confounders. An OR below 1 indicates that depression is associated with a lower risk 
for AD or dementia at follow-up.
* MMSE based on data from another study, which included a similar sample (Tierney et al., 1996).
Methods
Subjects
Subjects were selected from an ongoing longitudinal study of non-demented subjects referred 
to the Maastricht Memory Clinic. The memory clinic is an outpatient clinic of the Maastricht 
University hospital (Verhey et al., 1993). The design of this study has been described in detail 
elsewhere (Verhey et al., 1993; Visser et al., 2006). Consecutive patients were included at the time 
of the ﬁrst visit to the memory clinic. Subjects included had to be 40 years or older and to have 
MCI, which was deﬁned as a score of 2 or 3 on the Global Deterioration Scale (GDS) (Reisberg 
et al., 1982). This broad deﬁnition of MCI is consistent with that of other studies (Feldman & 
Jacova, 2005; Tabert et al., 2006; Tierney et al., 1996). This deﬁnition was used because subjects 
with AD in the predementia stage often do not meet the more strict criteria of MCI, such as the 
criteria for aMCI (Dickerson et al., 2007; Geslani et al., 2005; Storandt et al., 2006; Visser & Verhey, 
2007). Exclusion criteria were the existence of dementia at baseline and an apparent cause for 
cognitive impairment, such as cerebrovascular disorders, brain trauma, endocrine disorders or 
psychiatric disorders other than mild aﬀective disorders at baseline (Visser et al., 2000). 
 For the present study we selected subjects older than 55 years who had been eligible 
for at least one follow-up assessment (n = 263). Subjects included in this study were referred 
to the memory clinic by general practitioners (72%), neurologists (4%), psychiatrists (13%) or 
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others (11%). The study was approved by the medical ethical Committee at the Maastricht 
University hospital. After the study was explained to the subjects, all subjects gave their written 
informed consent.
Clinical assessment at baseline and follow-up
At baseline, all subjects underwent a standardised assessment, which included a detailed 
history of the subject, a psychiatric, neurological, and physical examination, the Mini Mental 
State Examination (MMSE) (Folstein et al., 1975), the GDS (Reisberg et al., 1982), the 17-item 
version of the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960), the Blessed Dementia 
Rating Scale (BDS) (Blessed et al., 1968), and appropriate laboratory tests, a neuropsychological 
assessment including tests for measuring learning and memory, working memory, ﬂuency, 
intelligence, speed of information processing and executive functioning, and a CT or MRI as 
described elsewhere (Verhey et al., 1993). 
 Two, ﬁve and ten years after baseline, subjects were invited to participate in a 
follow-up assessment. Because subjects were continuously enrolled, not all subjects were 
long enough in the study to have a follow-up assessment after 5 or 10- years. At the time of 
analyses, 263 subjects had been eligible for the two-year follow-up, 232 for the ﬁve-year follow-
up and 133 for the ten-year follow-up. The follow-up assessment included a standardized 
questionnaire about medical history and cognitive complaints, the MMSE, GDS, BDS, HDRS, 
and a neuropsychological assessment comparable to the baseline assessment. Subjects who 
refused to come for the follow-up assessment were contacted via a telephone interview, which 
included a standardized questionnaire about medical history and cognitive complaints, and 
the Telephone Interview for Cognitive Status (Brandt et al., 1988). 
 Amnestic MCI was deﬁned as a score 1.5 standard deviation (SD) below the mean of a 
reference population, after correction for age, sex and education on the delayed recall measure 
of the Auditory Verbal Learning Test (AVLT) (Petersen et al., 1999) (Van der Elst et al., 2005). The 
amnestic MCI criteria also require also intact activities of daily living. This was operationalized 
as the absence of dementia and a score below 4 on the GDS, which was part of the inclusion 
criteria of the study, in accordance with previous studies (Geslani et al., 2005). 
 The diagnosis of dementia and AD was made according to the DSM-IV and NINCDS-
ADRDA criteria (APA, 1994; McKhann et al., 1984). The diagnosis of frontotemporal dementia 
was made according to the Neary criteria (Neary et al., 1998). Vascular dementia was diagnosed 
according to the NINDS-AIREN criteria (Roman et al., 1993). Diagnoses of dementia and AD 
were made independently by both a neuropsychiatrist and a neuropsychologist. Both were 
blinded to the baseline results. If disagreement on the diagnosis occured, a consensus meeting 
was held. If no consensus could be reached, the subject was considered not demented.
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Aﬀective symptoms
From the HDRS (Hamilton, 1960) we used the subscales for anxiety (item 9, 10, 11, 15, and 17), 
depression (item 1, 2, 3, 7, and 8), insomnia (item 4, 5, and 6) (Shafer, 2006), and apathy (item 
7, 8, and 13) (Li et al., 2001). 
Statistical analyses
Statistical analyses were performed using the Statistical Package for Social Sciences (SPSS), 
version 11 for Mac OS X. We dichotomized all aﬀective symptom scores. Symptoms were 
considered to be clinically present if at least one item included in a subscale was either one or 
Table 2: Baseline comparisons of the converters and non-converters.
Total group
(n = 263)
Outcome at follow-up P Value not 
demented 
vs. AD
Not 
demented 
(n = 125)
AD
(n = 79)
Other 
dementia
(n = 11)
Age (M ± SD) 66.9 ± 7.7 64.2 ± 7.4 69.8 ± 6.8 65.8 ± 5.1 .000
Older than 70 years (%) 36 25 46 18 .003
Sex (% female) 44 39 54 27 .024
Education (% low-middle-high) 23/46/31 19/50/31 23/45/32 18/46/36 .747
MMSE (M ± SD) 27.6 ± 2.1 28.3 ± 1.6 26.3 ± 2.3 27.7 ± 1.6 .000
AVLT-delayed recall (M ± SD) 6.0 ± 3.8 7.7 ± 3.2 2.8 ± 2.5 7.6 ± 2.1 .000
Amnestic MCI (%) 42 22 77 18 .000
HDRS-total score (M ± SD) 9.0 ± 6.2 9.1 ± 6.4 7.7 ± 5.7 10.6 ± 6.0 .110
Major depression (%) 21 22 13 18 .124
BDS-total score (M ± SD) 1.8 ± 1.8 1.3 ± 1.4 1.9 ± 1.6 3.3 ± 4.0 .004
GDS-total score (M ± SD) 2.5 ± 0.5 2.3 ± 0.5 2.7 ± 0.5 2.6 ± 0.5 .000
Aﬀective symptoms (%)
       Depression 53 56 43 64 .078
       Anxiety 54 54 50 50 .583
       Apathy 65 68 53 73 .038
       Sleeping problems 50 56 37 27 .008
M = mean, SD = Standard deviation, MMSE = Mini Mental State Examination, AVLT = Auditory Verbal 
Learning Test, HDRS = Hamilton Depression Rating Scale, BDS = Blessed Dementia Rating Scale, GDS = 
Global Deterioration Scale.
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higher for items scored on a 3-point scale, or was 2 or higher for items scored on a 5-point scale. 
Group diﬀerences were analyzed using an independent t-test or Chi square test. Predictive 
accuracy was analyzed using a discrete-time survival analysis model and implemented using 
logistic regression and an appropriately adjusted dataset (Hosmer & Lemeshow, 1999). The 
outcome group included all subjects with AD at follow-up. The reference group included 
subjects without dementia or with non-AD dementia at follow-up. Analyses were performed 
with and without adjustment for age, sex, and education. The diﬀerence in OR for AD between 
subjects diagnosed with AD at the 2-year, 5-year and 10-year follow-up was tested using 
the discrete-time survival analysis model (Hosmer & Lemeshow, 1999). We also investigated 
interactions of aﬀective symptoms with amnestic MCI, and age (younger or older than 70 
years). In order to investigate whether ﬁndings were inﬂuenced by the inclusion of subjects 
with non-AD type dementia in the reference group, we repeated analyses after exclusion of 
subjects with non-AD type dementia. 
Results
At baseline, 263 MCI subjects were included in the study. Their baseline characteristics are 
listed in Table 2. Symptoms of depression, anxiety, and sleeping problems were present in 
about 50% of the subjects, and symptoms of apathy in about 70% (Table 2). 
Outcome at follow-up
At least one follow-up was available for 228 subjects (87%). The number of subjects at each 
follow-up and the reason for the absence of a follow-up are shown in Figure 1. Subjects without 
outcome at a follow-up for which they had been eligible were similar to subjects with outcome 
with regard to: age, sex, education, MMSE score, score on the delayed recall test, HDRS score, 
BDS score, proportion of subjects with amnestic MCI and GDS score.
 Seventy-nine subjects developed AD and 11 subjects other types of dementia 
(vascular dementia (n = 6), frontotemporal dementia (n = 1), Parkinson dementia (n = 3) and 
primary progressive aphasia (n = 1)) at follow-up (see Figure 1). The annualized conversion rate 
to AD was highest for the ﬁrst years of follow-up and decreased with longer follow-up intervals 
(11% for the ﬁrst two years, 4.2% for year 3 to 5, and 3.0% for year 6 to 10). The average follow-
up length was 5.4 years. The baseline characteristics according to outcome are listed in Table 
2. Subjects who converted to AD were at baseline about 5 years older, more often female, had 
lower MMSE and AVLT delayed recall scores, had more often amnestic MCI, and had higher BDS 
and GDS scores compared to the subjects who did not develop AD (Table 2). 
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Figure 1: Flowchart of the follow-up
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Predictors for AD
Univariate analyses showed that the presence of sleeping problems (OR = 0.43, 95% CI = 0.26 
– 0.71, P = 0.001), and symptoms of apathy (OR = 0.58, 95% CI = 0.35 – 0.96, P = 0.034) were 
associated with a decreased risk for AD. Depressive symptoms (OR = 0.62, 95% CI = 0.38 – 1.03, 
P = 0.065) showed a trend in the same direction. 
 After adjustment for age, sex and education, sleeping problems were associated with 
a lower risk for AD (OR = 0.35, 95% CI = 0.20 – 0.62, P < 0.001) (Table 3). Symptoms of depression 
(OR = 0.61, 95% CI = 0.36 – 1.01, P = 0.059) and anxiety (OR = 0.58, 95% CI = 0.34 – 1.0, P = 0.051) 
showed a trend in the same direction (Table 3). After the exclusion of subjects who developed 
a non-AD type dementia, results remained essentially the same. 
Eﬀect of amnestic MCI and age
The presence of amnestic MCI modiﬁed the relation between depressive symptoms and the 
risk for AD (P = 0.017). Depression was associated with a lower risk for AD in subjects without 
amnestic MCI (OR = 0.34, 95% CI = 0.13 – 0.93, P = 0.036), but not in subjects with amnestic MCI 
(OR = 1.1, 95% CI = 0.50 – 2.3, P = 0.85). Age did not modify the risk for AD for any symptom. 
Eﬀect of length of follow-up 
We noted some diﬀerences in predictive accuracy according to time to follow-up (Table 3), but 
these diﬀerences were small. Only the risk of anxiety for the development of AD was statistically 
signiﬁcantly diﬀerent (P = 0.046) for subjects with AD diagnosed at the 5-year follow-up (OR 
= 0.23, 95% CI = 0.08 – 0.66, P = 0.007) and subjects newly diagnosed with AD at the 10-year 
follow-up (OR = 1.7, 95% CI = 0.32 – 9.01, P = 0.539). 
Comment
The major ﬁndings of this clinical, long-term follow-up study are that sleeping problems were 
associated with a decreased risk for AD. In addition, symptoms of depression and anxiety 
showed a trend in this direction. The predictive accuracy of depression was dependent on the 
presence of amnestic MCI and that of anxiety on the length of follow-up. 
 Previous studies on the predictive accuracy of aﬀective symptoms for AD in subjects 
with MCI mainly focused on depressive symptoms. The outcomes of our study are consistent 
with some of these studies (Liu et al., 2007; Rozzini et al., 2005) but in disagreement with others 
(Table 1) (Gabryelewicz et al., 2007; Modrego & Ferrandez, 2004). We found that depressive 
symptoms were only associated with a reduced risk in subjects without amnestic MCI. This 
corroborates our earlier ﬁnding that depression in the absence of moderately severe memory 
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impairment is more likely associated with primary depression than with prodromal AD (Visser, 
Verhey, Ponds, Kester et al., 2000). It is also in line with the observation that depressed subjects 
without a plasma biomarker proﬁle suggestive of AD have better memory performances than 
depressed subjects with such proﬁle (Sun et al., 2008). We did not ﬁnd that the risk of depressive 
symptoms for AD was dependent on follow-up length although population-based studies did 
show that this risk for AD for those with depressive symptoms either increased or decreased 
with follow-up length (Green et al., 2003; Ownby et al., 2006). If data from studies that provided 
dichotomous data in Table 1 were pooled with a random eﬀects model (13 studies with 1362 
subjects), the OR of depression for AD was 1.31 (95% CI = 0.8 – 2.15, P = 0.65) (Deeks et al., 2001). 
The pooled eﬀect-size based on diﬀerences in scores on a depression rating scale expressed as 
Cohen’s delta was 0.0 (95% CI = -0.26 – 0.25, P = 0.98, data from 1781 subjects from 12 studies). 
Thus, our pooled data indicate that depression is not predictive for AD in subjects with MCI, 
unlike a meta-analysis of case-control studies and prospective or retrospective cohort studies 
of subjects who were not selected on the basis of the presence of MCI, which found that 
depression was associated with an increased risk for AD or dementia (OR = 2.03, 95% CI = 
1.81-2.28) (Ownby et al., 2006). Apparently, the relation between depressive symptoms and 
subsequent cognitive decline is less strong in subjects with MCI than in subjects unselected for 
the presence of MCI. One possible explanation for this diﬀerence is that the inclusion criteria 
for MCI may be biased toward inclusion of subjects that have depression-related cognitive 
impairment. Support for this explanation comes from the observation that many depressed 
subjects complain about cognitive impairment and often have cognitive impairment on 
neuropsychological tests and for that reason may meet the criteria of MCI (Kahn et al., 1975; La 
Rue et al., 1986).
 Anxiety was found to be associated with a decreased risk for AD in two other studies 
as well (Liu et al., 2007; Robert et al., 2006). but a population-based study reached the opposite 
conclusion (Palmer et al., 2007). These conﬂicting ﬁndings may be explained by a diﬀerence 
in setting. Our ﬁndings suggested that anxiety is associated with a decreased risk in the short 
time and an increased risk in the long term. This may indicate that the risk of anxiety for AD is 
dependent in the length of follow-up.
 Unlike our study, previous studies reported that apathy was associated with an 
increased risk for AD, although this reached statistical signiﬁcance in only one study (Feldman 
et al., 2007; Robert et al., 2006; Teng et al., 2007). These conﬂicting ﬁndings may have resulted 
from diﬀerent ways of assessing these symptoms, as we used a subscale from the HDRS, while 
other studies used the informant based Neuropsychiatric Inventory (Cummings et al., 1994).
 Sleeping problems have not been investigated as predictors for AD before in subjects 
with MCI. While it is well known that sleep disturbances occur in mild and moderate phases of 
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AD, the present data show that they are not associated with an increased risk for AD in subjects 
with MCI. In contrast to our ﬁndings, a previous study conducted in the general population 
showed that sleep problems were associated with cognitive decline (Jelicic et al., 2002), 
although other studies did not ﬁnd this association (Foley et al., 2001; Tworoger et al., 2006). 
 Age did not modify the relation between aﬀective symptoms and AD, although we 
expected that aﬀective symptoms would be associated with an increased risk for AD in elderly 
subjects. It is possible that the age range in our study was not large enough to detect such an 
interaction.
 There are a number of factors not investigated in the present study that may explain 
the conﬂicting results between studies. First, we already mentioned that predictive accuracy 
may depend on whether the study is conducted in the community or in a clinical setting. In 
addition, the accuracy may depend on how subjects are selected. For example, due to the 
referral process, our sample may have been relatively enriched by subjects with primary 
depression, which would explain the high prevalence of depressive symptoms and the 
decreased risk of aﬀective symptoms for AD. Secondly, predictive accuracy may depend on the 
type of rating scale used. We used a clinician based rating scale for aﬀective symptoms, like most 
of the other studies. Using a self-rating scale for depression and anxiety (Arrindell & Ettema, 
2003; Arrindell & Ettema, 1981) would have yielded similar results (data not shown). Also if we 
used a diagnosis of major depression as predictor, we would obtain similar results (OR = 0.58, 
95% CI 0.29 – 1.2, P = 0.13). Thirdly, the variability between the studies may be explained by 
diﬀerences in the presence of vascular disorders or vascular risk factors, because these factors 
may modify the relation between depression and cognitive impairment (Alexopoulos, 2006). 
Fourthly, the variability may have resulted from an interaction between age, MCI type, length 
of follow-up, setting, vascular risk factors, and diagnostic instruments.  It is also possible that 
the conﬂicting ﬁndings reﬂect random variation given the observation that the pooled OR of 
depressive symptoms for AD was close to 1 and not statistically signiﬁcant. 
 The annual conversion ratio of 11% for the ﬁrst two years is comparable with the 
mean annual conversion rate of 10.2%, found in a meta-analysis (Bruscoli & Lovestone, 2004). 
The annual conversion ratio in our study declined with the length of follow-up as described 
before (Visser et al., 2006).
 Few subjects developed non-AD types of dementia, which is in line with other clinical 
MCI studies (Geslani et al., 2005). After exclusion of subjects with non-AD types of dementia 
results remained similar, indicating that the inclusion of subjects with a non-AD type dementia 
in the reference group did not have eﬀect on the results.
 Strengths of the present study were: the large sample size, the long follow-up period 
of up to 10 years, the high follow-up rate, and the broad inclusion criteria for MCI in which 
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mild depressive symptomatology was not excluded at baseline, in accordance with current 
recommendations (Steﬀens et al., 2006). The limitations of the study were the relatively small 
number of subjects with a 10-year follow-up and the lack of pathological conﬁrmation of the 
clinical diagnosis. 
 There have been several hypotheses regarding the relation between depression, MCI 
and AD (Steﬀens et al., 2006; Wilson et al., 2008). One hypothesis proposes that depressive 
symptoms contribute to the development of AD. A second hypothesis suggests that depressive 
symptoms may be an early manifestation of AD. A third hypothesis is that the cognitive 
impairment results from a primary depressive disorder. Our data supports the last hypothesis 
as we found that aﬀective symptoms were generally associated with a decreased risk for AD. 
 The present study indicates that aﬀective symptoms in subjects with MCI are not 
predictive for prodromal AD. Given the high prevalence of aﬀective symptoms in prodromal 
AD (37-53%), however, the presence of these symptoms does certainly not exclude the 
possibility of prodromal AD. Therefore, mild aﬀective symptoms should not be an exclusion 
criteria for studies that aim to select these subjects, as has been the case in previous MCI trials 
(Visser et al., 2005). It might be possible that in speciﬁc samples aﬀective symptoms are indeed 
associated with an increased risk for AD, but that apart from the type of MCI, other factors that 
characterize such samples remain to be identiﬁed. Because aﬀective symptoms are common in 
subjects with MCI, services for subjects with cognitive complaints, should pay attention to this 
symptomatology, and should have psychiatric expertise available to diagnose and treat these 
symptoms. 
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Abstract
Objectives: To investigate which symptoms are indicative of preclinical dementia in general 
practice and whether subjects with preclinical dementia have an increased contact frequency 
with their GP.
Methods: Individuals with preclinical dementia (n = 75) and non-demented controls (n=125) 
were selected from the Dutch GP registration network (RNH). Number of visits and odds ratio 
for the risk of subsequent dementia (OR) of various symptoms were analysed. Analyses were 
done separately for each 12-month period, in the 5 years prior to the diagnosis of dementia. 
Results: In the 5 years prior to diagnosis, subjects with preclinical dementia visited their GP 
more often than controls. Gait disturbances were the earliest predictor. Cognitive complaints 
were predictive for dementia in the three years before diagnosis. All other symptoms, except 
vascular symptoms, were predictive in the year prior to diagnosis. Sensitivity was highest for 
cognitive symptoms (0.58) and gait disturbances (0.47) in the year before diagnosis.
Conclusion: Preclinical dementia is associated with an increased contact frequency between 
patient and GP at least ﬁve years prior to the diagnosis of dementia. Gait disturbances and 
cognitive complaints are the earliest symptoms of preclinical dementia. 
Keywords:  preclinical, dementia, general practice.
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Introduction
Dementing disorders are often characterized by a preclinical stage in which the individual 
experiences impairments but is not yet demented. It is important to identify subjects with 
preclinical dementia so that early interventions can be applied and psychosocial support can 
be provided.
 The general practitioner (GP) plays an important role in the identiﬁcation of subjects 
with preclinical dementia given that these subjects or their relatives often contact the GP 
ﬁrst with their complaints (Wilkinson et al., 2004). Additionally, GPs are able to detect gradual 
changes in cognition and behaviour, because they often know their patients for a long time. 
However, knowledge with respect to which symptoms are suggestive of preclinical dementia 
in general practice is very limited and this may cause an undesirable delay in time between 
when the ﬁrst symptoms present and the diagnosis (Wilkinson et al., 2004). Additionally, 
early recognition of potential dementing subjects can help GPs to select subjects that may 
beneﬁt from referral to specialized facilities such as memory clinics for further diagnostics and 
prevention of disease progression.  
 The aim of the present study was to investigate how subjects with preclinical dementia 
present in general practice. We investigated these individuals’ contact frequency with their 
GP in the ﬁve years prior to their diagnosis. Additionally, we investigated the symptoms with 
which these subject presented in those ﬁve years. Contact frequency and symptoms of these 
subjects, were compared with those of control subjects. We hypothesized that subjects with 
preclinical dementia would have a higher contact frequency with their GP and would also 
present more complaints that have been previously recognized as early symptoms of dementia 
or risk factors for dementia in the general population. These symptoms include cognitive 
impairment, aﬀective symptoms, behavioural problems, vascular problems, gait disturbances, 
and changes in appetite and weight (Borenstein et al., 2005; Buchman et al., 2005; Copeland et 
al., 2003; Geerlings et al., 2000; Jonker et al., 2000; Verghese et al., 2002). 
Methods
Subjects
Subjects were selected from the Registration Network of Family Practices (RNH). The RNH is a 
computerized and anonymous database that contains patient characteristics and all relevant 
health problems of subjects from 21 rural and urban GPs in the Southern region of the 
Netherlands (Metsemakers et al., 1992). The register oﬀers a unique opportunity as a sample 
frame for research in a general practice setting on which cross-sectional and longitudinal 
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analyses can be performed (Metsemakers et al., 1992). When compared with the Dutch 
population, the RNH population showed a slightly higher mean age. Further, some diﬀerences 
with respect to the marital status were noted (Metsemakers et al., 1992; Van den Akker, 2004). 
 The cases included in this study consisted of subjects who had a diagnosis of dementia 
registered in the RNH database between 1996 and 1999. During the study period, GPs in the 
Netherlands followed the Dutch Guidelines for General Practitioners (NHG) (NHG, 1993) for 
the diagnosis of dementia, which included the DSM-III-R criteria for dementia (APA, 1987). For 
each demented subject, two control subjects were randomly selected from the same practice, 
after matching for age (± ﬁve years) and sex. This resulted in 82 demented subjects and 150 
control subjects. From this sample we excluded 25 subjects, because insuﬃcient data were 
available for the period of at least three years prior to diagnosis. We also excluded eight control 
subjects who had been diagnosed with dementia in the time that passed between the index 
period and the date of analysis. This was done to prevent contamination of the control group. 
The ﬁnal study population consisted of 74 demented patients and 125 non-demented controls 
(Table 1). The study was approved by the Medical Ethical Committee of the university hospital 
of Maastricht. 
Data collection
Data were collected on the contact frequency (including GP consultations, telephone 
consultations and visits) and symptoms presented during each contact. These were collected 
separately for each 12-month period over the course of the ﬁve years prior to the dementia 
diagnosis. For one control subject and two subjects with preclinical dementia, no data were 
Table 1: Baseline characteristics.
Preclinical dementia group 
(n=74)
Control group
 (n=125)
Age, years (SD) 79 (6.2) 79 (7.4)
Sex, % female 62 61
Marital status, % married 53 46
Education Low/Middle/High, % 81/17/2 77/20/3
Hypertension, % 42 36
Coronary heart disease, % 22 24
Stroke, % 18 11
TIA, % 10 8
SD = Standard deviation.
Educational level: Low = lower general and vocational education; Middle: middle general and vocational 
education; and High = higher general and vocational education.
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available for the fourth year prior to diagnosis. For the ﬁfth year prior to diagnosis, data was 
missing for two control subjects and two subjects with preclinical dementia.
 All relevant health complaints presented during a contact (in person or by telephone) 
were entered in the practice ﬁle by the GP. We compiled the presenting symptoms at each 
contact from the anonymous raw data output for the general practice setting and thereby 
derived 136 diﬀerent symptoms. We classiﬁed these symptoms into six categories, namely: 
a) cognitive symptoms (including amnesia, forgetfulness, confusion, cognitive decline, 
orientation problems, language problems, problems with logical thinking, and loss of 
decorum); b) aﬀective symptoms (including fatigue, irritability, anxiety, sleep-related problems, 
depressive mood, being upset, loss of initiative, loss of interest, crying, complaining, sadness, 
hyperventilation, mood changes, and suicidal ideation); c) behavioural symptoms (including 
restlessness, delusions/hallucinations, aggression/agitation, changes in character, and 
suspicion); d) vascular symptoms (including chest pains, loss of speech, temporary paralysis, 
continuous paralysis, loss of strength, decline in vision, and thick tongue); e) gait disturbances 
(including falls and problems with walking); and f ) changes in weight or appetite (including 
loss of appetite and other weight changes. 
Data analyses
Statistical analyses were performed using the SPSS 11 for Macintosh. The diﬀerence in contact 
frequency between subjects with preclinical dementia and controls were analysed using 
independent t-tests. The predictive accuracy of the symptoms for dementia was determined 
using binary logistic regression analyses. The main outcome measure was the odds ratio (OR). 
Secondary outcome measures were the sensitivity (percentage of subjects with preclinical 
dementia who expressed the symptom) and the speciﬁcity (percentage of control subjects 
who did not express the symptom). Analyses were done separately for each 12-month period, 
in the ﬁve years prior to dementia diagnosis. All analyses were performed with a two-tailed 
alpha level of .05.
Results
Frequency of contact
In total, 3837 contacts with the GP were registered during the time period under investigation. 
In each of the ﬁve years, subjects with preclinical dementia showed a signiﬁcantly higher 
contact frequency than subjects without preclinical dementia. A notably more pronounced 
diﬀerence between the two groups in the year prior to diagnosis was also demonstrated 
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(Figure 1) (ﬁve years prior: 3.8 vs. 3.0; four years prior: 4.2 vs. 3.4; three years prior: 4.4 vs. 3.5; 
two years prior: 4.4 vs. 3.5; and one year prior: 6.6 vs. 3.8). 
Predictors of dementia
The earliest predictor was complaints about gait disturbances in the ﬁfth year prior to diagnosis 
((OR=3.5) Table 2). Gait disturbances were also predictive in the third and ﬁnal year before 
diagnosis (OR=3.8 and 6.1 respectively). Cognitive complaints were associated with the highest 
risk for dementia, with ORs ranging from 5.3 ﬁve years before diagnosis to 56 in the year before 
the diagnosis. Aﬀective and behavioural symptoms and symptoms related to weight loss and 
appetite were predictive in the ﬁrst year prior to diagnosis, with ORs ranging from 3 to 14. The 
ORs for all symptoms, except for vascular symptoms, increased progressively over the course 
of the ﬁve years prior to the diagnosis. The ORs of vascular symptoms did not change over time 
(Table 2). Even after adjusting for age and sex, the signiﬁcance of the results remained (data 
not shown).
 Speciﬁcity was above 0.83 for all symptoms indicating that the control subjects did 
not frequently report these symptoms (Table 2). Sensitivity for all symptoms increased over 
the course of the ﬁve years prior to diagnosis. The highest sensitivity noted was related to 
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cognitive symptoms (0.58) and gait disturbances (0.47) in the year before diagnosis was made. 
This suggests that only a subset of subjects with preclinical dementia report these symptoms 
to their GP (table 2).
 As gait disturbances could also result from a stroke, we performed post-hoc analyses 
in which we excluded all subjects who have had a stroke in the past (n = 27). The predicative 
accuracy of gait disturbances in subject without a stroke remained essentially the same (ﬁrst 
Table 2: Predictive values of symptoms for the development of dementia.
Symptoms Fifth year 
prior
Fourth year 
prior
Third year 
prior
Second year 
prior
First year prior
Cognitive symptoms      
  OR (95% CI) 5.3 (0.5-51.8) 2.9 (0.9-9.5) 5.4 (1.1-28)* 13 (3.7-46)*** 56 (16-194)***
  Sensitivity 0.04 0.11 0.08 0.24 0.58
  Speciﬁcity 0.99 0.96 0.98 0.98 0.98
Aﬀective symptoms
  OR (95% CI) 1.5 (0.6-3.7) 0.7 (0.3-1.8) 1.0 (0.4-2.2) 1.1 (0.5-2.3) 3.0 (1.5-6.2)**
  Sensitivity 0.14 0.11 0.15 0.18 0.32
  Speciﬁcity 0.9 0.85 0.85 0.83 0.86
Behavioural symptoms
  OR (95% CI) 1.1 (0.2-7.0) 0.9 (0.2-4.8) 3.5 (0.6-20) 2.4 (0.8-7.2) 14 (3.2-65)**
  Sensitivity 0.03 0.03 0.05 0.11 0.19
  Speciﬁcity 0.98 0.97 0.98 0.95 0.98
Vascular symptoms
  OR (95% CI) 0.7 (0.3-1.9) 0.9 (0.4-2.1) 1.4 (0.6-3.2) 0.96 (0.4-2.4) 1.6 (0.7-3.5)
  Sensitivity 0.08 0.13 0.16 0.11 0.18
  Speciﬁcity 0.89 0.86 0.88 0.89 0.88
Gait disturbances
  OR (95% CI) 3.5 (1.2-10)* 1.5 (0.6-3.6) 3.8 (1.4-11)* 2.2 (0.98-4.9) 6.1 (3.1-12)***
  Sensitivity 0.15 0.14 0.16 0.2 0.47
  Speciﬁcity 0.95 0.9 0.95 0.9 0.87
Changes in weight 
and appetite
  OR (95% CI) 0.6 (0.1-2.8) 0.8 (0.2-3.5) 1.1 (0.4-3.0) 1.8 (0.5-5.6) 5.9 (2.2-16)***
  Sensitivity 0.03 0.04 0.09 0.08 0.23
  Speciﬁcity 0.95 0.95 0.91 0.95 0.95
CI: Conﬁdence interval
***: p < .001, **: p < .01, *: p < .05.
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year prior: OR = 7.3, p < .001; second year prior:  OR = 2.5, p < .05; in the third year prior: OR = 
5.2, p < .01; fourth year prior: OR = 1.3, p > .05; and ﬁfth year prior: OR = 3.3, p < .05).  
Discussion
Preclinical dementia is associated with increased contact frequency to the GP at least ﬁve years 
prior to the diagnosis of dementia. Symptoms that could best predict dementia in the general 
practice setting were cognitive symptoms and gait disturbances. 
 The observation that subjects with preclinical dementia had an increased contact 
frequency up to ﬁve years before the dementia diagnosis supports and extends the ﬁndings 
of a previous study in which an increased contact frequency two years before the diagnosis of 
dementia was found (Albert et al., 2002). It is possible that the increase in contact frequency 
occurred because patients experienced symptoms related to the dementing disorder. 
Alternatively, subjects with preclinical dementia may have had more often control visits for 
conditions that are risk factors for dementia, such as hypertension or diabetes. However, a 
post-hoc analysis indicated that control visits were equally common in both groups (data not 
shown). The increase in contact frequency for subjects with preclinical dementia in the year 
prior to diagnosis may have been the result of the patient entering the diagnostic phase in 
which the dementia was established.
 The earliest predictor of dementia was gait disturbances. This was already predictive 
in the ﬁfth year prior to diagnosis. It is also important to note that cognitive complaints were 
associated with the highest risk for dementia. For most predictors included in this study, the 
OR increased over the course of ﬁve years from to diagnosis. As expected, the predictors were 
most notable in the ﬁnal year before diagnosis. The high ORs for the symptoms in the ﬁnal 
year may be partly explained by circularity since the presence of some of the symptoms likely 
initiated the process by which the diagnosis of dementia could be made. 
 Complaints about everyday memory problems have been associated with cognitive 
impairment and dementia in several clinical and population-based studies (Jonker et al., 2000). 
Although cognitive symptoms are a key feature of dementing disorders, in our study, cognitive 
complaints are indicative of preclinical dementia only in the ﬁnal two years prior to diagnosis. 
In all other years, a low predictive accuracy was found. Further, cognitive symptoms were not 
expressed in the entire sample but only in a subgroup of subjects with preclinical dementia 
and ranged from 4% ﬁve years prior to diagnosis to 58% in the year before diagnosis. A 
possible explanation for this ﬁnding is that the many of the subjects with preclinical dementia 
considered cognitive impairments normal for their age. Alternatively, they may have been 
ashamed of their impairments and thus choose to not reported them. It is also possible that, 
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as a result of the dementing process, subjects were unaware of cognitive changes (Tabert et 
al., 2002). A ﬁnal option was that, especially in the fourth and ﬁfth years prior to diagnosis, 
preclinical subjects simply did not experience any cognitive impairment. Our ﬁndings with 
respect to the low predictive accuracy of cognitive impairments for the group with preclinical 
dementia corresponds with previous studies in which many subjects with preclinical dementia 
did not express cognitive complaints (Ganguli et al., 2006; Palmer et al., 2003; Tabert et al., 
2002). However, because our ﬁndings are based on contact notes of the GP and because it 
is possible that the GPs did not take suﬃciently detailed notes during their contacts with 
patients, we may have underestimated the frequency of cognitive symptoms.
 Our ﬁnding that gait disturbances predict dementia is in agreement with recent 
research that suggests that gait disturbances in aging may be indicative for a cognitive 
impairment that can be objectiﬁed several years later (Scherder et al., 2007; Verghese et al., 
2002). A population-based study demonstrated that subjects with gait abnormalities had an 
increased risk of developing dementia, especially non-Alzheimer’s dementia (Verghese et al., 
2002). In addition, another study noted that fall events occurred in 42% of the participating 
mild to moderate dementia subjects (Horikawa et al., 2005). The present study indicated 
that gait disturbances were reported long before the diagnosis was made and that these 
disturbances were even quite frequent even ﬁve years prior to the diagnosis. In this ﬁfth 
year prior to diagnosis, gait disturbances (15%) were much more frequent than cognitive 
symptoms (4%). This ﬁnding is similar to the study of Ganguli et al. (2006) who, using primary 
care charts, established that falls occurred in 15% of subjects with a CDR total box score of 0.5, 
compared to memory complaints in only 8% of subjects (Ganguli et al., 2006). The speciﬁcity of 
gait disturbances for dementia in our study was high (above .87). Whether this high speciﬁcity 
translates to a high positive predictive value depends on the incidence of dementia, which 
could not be investigated in this study because of the case-control design. 
 The ﬁnding that gait disturbances are a sign of early dementia is in line with 
recent research, summarized by Scherder et al. (2007). They concluded that there is a strong 
relationship between gait and cognition (Scherder et al., 2007), gait and gait-related motor 
disturbances being present in all subtypes of dementia, even in the early and preclinical 
stages. Neural support for this relationship was based on recent studies that found a strong 
involvement of the hippocampus in gait, because of his connections with the prefrontal cortex 
and the striatum (Scherder et al., 2007). 
 A decline in gait and balance is not only associated with vascular white matter lesions 
(Whitman et al., 2001), but also in Alzheimer’s disease, which is consistent with our post-hoc 
analyses, in which we showed that after exclusion of subjects with stroke, gait disturbances were 
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still predictive of dementia. Waite et al. (2005) found that subjects with cognitive impairment 
in combination with impaired motor control were at higher risk for developing dementia than 
subjects with cognitive impairment alone (Waite et al., 2005). 
 Aﬀective symptoms were a marker of preclinical dementia only in the year prior to 
diagnosis. In the other years, aﬀective symptoms were equally common among subjects with 
preclinical dementia and the control subjects. This ﬁnding does not correspond with a recent 
meta-analysis in which the conclusion presented was that a history of depression may be an 
independent risk factor for Alzheimer’s Disease (AD) (Ownby et al., 2006). Our ﬁndings also 
fail to support another conducted study in a general practice setting in which a signiﬁcant 
relationship between old-age depression and subsequent dementia was found (Buntinx et al., 
1996). Had we conducted a depression diagnosis, rather than merely documenting aﬀective 
symptoms we may have possibly been able to demonstrate greater predictive power of 
aﬀective symptoms and, more especially depression. Another possible explanation for this lack 
of predictive power was that the present study included only subjects who visited the GP. It is 
possible that aﬀective symptoms have more discriminative power in the general population. 
 Behavioural symptoms and changes in weight and appetite were only predictive 
in the year preceding diagnosis. This suggests that these symptoms develop later in the 
neurodegenerative process or, alternatively, that these symptoms only became severe enough 
to report to the GP in the ﬁnal year prior to diagnosis.
 In contrast to our expectations, the frequency of contact with the GP as a result of 
vascular symptoms did not diﬀer signiﬁcantly between subjects who developed dementia 
and subjects who did not. The prevalence in both groups was approximately 15%. A possible 
explanation for this is that the vascular complaints that patients presented to their GP in 
this study may not have been speciﬁc for underlying vascular pathology. When we excluded 
symptoms that were thought not to be related to a vascular disorder, results were essentially 
the same.
 In the RNH database dementia is used as diagnostic entity rather than dementia 
subtypes. Still, because the RNH database registered all relevant health care problems 
an indicator for vascular causes of the dementia could be inferred. Of the 74 patients with 
dementia, 13 subjects (18%) had experienced a stroke before the diagnosis of dementia and 
31 subjects (42%) of the subject were known with hypertension. Thus dementia might have 
had resulted from stroke in about 20% of the subjects, while small vessel disease might have 
contributed to the dementia syndrome in about 40%. 
 Dementia was diagnosed according to DSM-IIIR criteria (APA, 1987). The GP, however, 
might have missed the diagnosis at earlier visits, because demented subjects may have been 
unaware of their cognitive impairment, especially when an informant was absent. Therefore, in 
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some subjects symptoms considered to reﬂect preclinical dementia might have been symptoms 
of dementia. Cognitive tests might have been useful to identify subjects with dementia in an 
earlier stage, but such tests were not used for screening purposes on a routine basis, but only 
when cognitive impairment was suspected. 
 One of the strengths of our study was the large size of our study population. A second 
strength was our use of a matched control design in which subjects were included from both 
rural and urban general practices. In doing this, we were able to increase the generalizability 
of our ﬁndings. Our inclusion of ﬁve years worth of data is an additional strength. Lastly, by 
following up on control subjects after the index date, we were able to exclude control subjects 
that had developed dementia in the period between the index date and date of analyses, and 
thereby avoided contamination in so far as was possible.
 Our study also had several limitations. Our reliance on reports written by GPs can be 
considered a limitation. Despite continuous note-taking training (Buntinx, 1994), it is possible 
that some of the reports were incomplete. Additionally, we were not able to obtain data on 
the type of dementia the preclinical subjects developed. An additional limitation worthy of 
attention is the broad CIs of some of the predictors that were noted during the regression 
analyses. It is possible that these broad CIs were caused by the relative infrequency of several 
of the reported complaints. The classiﬁcation of some symptoms might be arbitrary as some 
symptoms could be classiﬁed in more than one category, especially for symptoms classiﬁed 
as cognitive, aﬀective, or behavioural symptoms. When loss of decorum (classiﬁed into the 
cognitive category) and irritability (classiﬁed into the aﬀective category) were classiﬁed as 
behavioural symptoms, however, the results did not change. Finally, our ﬁndings may not 
applicable in diﬀerent settings and in younger subjects.
 The GP plays a crucial role in the timely recognition and early identiﬁcation of subjects 
at risk for dementia (Artero & Ritchie, 2003; Barrett et al., 1996; Wilkinson et al., 2004). The 
present study showed that complaints of cognitive performance and gait should alert the GP 
for incipient dementia. If these symptoms are expressed, the GP may do a formal assessment of 
cognition, refer the patient for further diagnostic evaluation, or keep the patient under clinical 
supervision. Given that almost half of the subjects did not actively report cognitive symptoms 
in the year prior to the diagnosis, we contend that the GP must play an active role in identifying 
subjects at risk for dementia by bringing together all the available information related to the 
medical, cognitive, and daily functioning of their patients. By referring to symptoms that 
present during consultations, GPs are not only in a position whereby they can identify subjects 
at risk for developing dementia, they can also start a process by which additional diagnostic 
testing can be conducted, and follow these subjects over time.
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Abstract
Objective: Memory complaints in the absence of objective test impairments are common. 
Only a subset of these subjects seeks medical attention for these complaints. The aim of the 
present study was to investigate which factors determine why people with subjective memory 
complaints (SMC) seek medical attention.
Methods: Thirty-three cases with SMC from a memory clinic were compared to 85 control 
subjects with SMC from a population-based study who did not seek help for their complaints. 
We investigated whether cases diﬀered from controls with respect to the following: depressive 
and anxiety symptoms (SCL-90), extraversion and neuroticism (EPQ), meta-memory (MIA), 
quality of life (SF-36), changes in memory and daily functioning according to a relative (DECO), 
life-changing events, and a family history of dementia.
Results: Cases with SMC who seek medical attention, scored lower on memory self-eﬃcacy 
and quality of life. They were more often worried due to a positive family history of dementia 
by comparison to the control subjects. Relatives of cases reported more deterioration in daily 
functioning than relatives of controls. Both the cases and control subjects had similar levels of 
depressive and anxiety symptoms, as well as levels of extraversion and neuroticism.
Conclusion: Lower memory self-eﬃcacy and quality of life, deterioration in daily functioning, 
and worries due to a positive family history for dementia are factors that determine why 
subjects with SMC seek medical attention. This information may be useful for the development 
of interventions for these subjects.
Key words: memory complaints without impairment, subjective memory complaints, memory 
self-eﬃcacy, aﬀective symptoms, memory clinic.
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Introduction
Memory complaints are very common in middle-aged and older subjects (Jonker et al., 2000; 
Ponds et al., 1997), and occur in about 40 – 50% of the subjects older than 55 years (Ponds et al., 
1997). Formal cognitive testing reveals that about half of these subjects do not have objective 
memory impairments (Gallassi et al., 2008). Hence, they are considered to have subjective 
memory complaints (SMC). Only a subset of subjects with SMC decides to seek medical 
attention for these complaints, and about 15-20% of the subjects seen at memory clinics 
actually do have SMC (Verhey et al., 2007). The reason why subjects with SMC seek medical 
attention remains largely unknown. One study found that cognitive, psychiatric and health 
related factors played a role in the decision to visit a doctor for cognitive complaints, but this 
study did not focus on SMC only and also included complainers with objective impairments 
(Jorm et al., 2004). Understanding the reasons why subjects with SMC decide to seek medical 
attention is important to determine the needs of these subjects and to provide adequate 
treatment and advice. 
 SMC can reﬂect normal aging or self-awareness of underlying degenerative pathology 
(Barnes et al., 2006; Schmand et al., 1996). However, it may also be related to other factors, such 
as psychiatric symptoms, personality characteristics and poor physical health (Cargin et al., 
2007; Comijs et al., 2002; Derouesne et al., 1999; Jorm et al., 2004; Ponds et al., 1997). 
 The aim of the present study was to investigate which factors determine the decision 
to seek help for SMC. We compared cases with memory complaints, but lacking objective 
memory impairments, who did decide to visit a memory clinic to healthy subjects with memory 
complaints who did not seek medical attention.
 We hypothesized that non-cognitive symptoms such as depression, anxiety, and 
personality factors such as neuroticism and extraversion, would be more frequent in cases with 
SMC who visit a memory clinic than in subjects with SMC who do not seek medical care (Cargin 
et al., 2007; Comijs et al., 2002; Derouesne et al., 1999; Jorm et al., 2004; Ponds et al., 1997). We 
also hypothesized that, compared to subjects who do not visit a memory clinic, the cases who 
visit a memory clinic had a lower quality of life (Mol et al., 2007), had less knowledge about their 
own memory functioning (Ponds & Jolles, 1996a), were more often worried about dementia 
(Commissaris et al., 1994) due to a family history of dementia, had more often experienced a 
life-changing event in the past year, and had experienced more changes in memory and daily 
functioning, as reported by a caregiver (Streams et al., 2003). 
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Methods
Cases from the Maastricht Memory Clinic
Subjects who did seek medical attention for their SMC were selected from an ongoing cohort 
study at the Maastricht Memory Clinic (MMC). The MMC is an outpatient clinic of the university 
hospital Maastricht (Verhey et al., 1993). For the present study, we selected consecutive patients 
(referred to as ‘cases’) at the time of their ﬁrst visit to the MMC if they fulﬁlled the following 
criteria: they were 50 years or older, had SMC but lacked objective memory impairment, which 
was deﬁned as a score below -1.5 SD on the delayed recall test of the Auditory Verbal Learning 
Test (AVLT) (Van der Elst et al., 2005), had a score of 2 or 3 on the Global Deterioration Scale 
(GDS) (Reisberg et al., 1982), were not demented, and at baseline they had no identiﬁed cause 
for their cognitive impairment, such as cerebrovascular disorders, brain trauma, endocrine 
disorders or severe psychiatric disorders (Visser et al., 2000). 
 Eligible cases were mailed information about the study, questionnaires, a written 
informed-consent form, and a self-addressed return envelope in which to return the 
questionnaires and the signed informed consent. Fifty-two cases were eligible for inclusion. 
Subjects who did not return the questionnaires were contacted by telephone. Eighteen cases 
refused to participate and 1 subject returned an incomplete questionnaire. Thus 33 cases 
(63%) were included. Cases who did not participate in the study (n = 19) had a lower level 
of education and were about 8 years older than the cases who did decide to participate. Sex 
distribution and mean MMSE score did not diﬀer between the groups. 
Subjects from the Maastricht Aging Study (MAAS):
The eligible cases selected from the memory clinic were compared to subjects from the 
Maastricht Aging Study (MAAS) (referred to as ‘controls’), a longitudinal population based 
study into the determinants of cognitive aging (Jolles et al., 1995). Participants in the MAAS 
were recruited from the Registration Network Family Practices (RNH) (Metsemakers et al., 1992) 
composed by 42 general practitioners in the province of Limburg, the Netherlands. Subjects 
with medical conditions that could interfere with cognition were identiﬁed using the RNH 
records and excluded from the sample frame. For the present study, we selected subjects 
from this sample if: they were 50 years or older, had memory complaints as measured with 
the question ‘Do you ﬁnd yourself forgetful?’, but lacked objective memory impairment (below 
-1.5 SD) according to the delayed recall test of the AVLT, and had not sought professional help 
for their memory complaints. In total, 83 controls were eligible for comparison with the MMC 
patients. The Medical Ethical Commission of the Academic Hospital Maastricht approved this 
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study. After the study was explained to them, both controls from MAAS and cases from the 
MMC gave their written informed consent. 
Instruments
Memory self-eﬃcacy (MSE). The abridged Dutch Metamemory in Adulthood questionnaire 
(MIA) (Dixon et al., 1988) was used to measure MSE. MSE consists of the MIA subscales capacity, 
change and anxiety, and reﬂects beliefs about the personal competence in various memory 
situations. Subjects rate statements about themselves on a ﬁve point Likert scale, ranging 
from ‘strongly disagree’ to ‘strongly agree’. Higher MIA MSE scores indicate higher self-eﬃcacy 
ratings for memory. Speciﬁcally, the subscale capacity consists of 12 items, and a higher score 
on this subscale indicates greater perceived memory capacity. The change subscale consists 
of 10 items and a higher score indicates less perceived decline (or more stability) in memory 
functioning. The subscale anxiety consists of 12 items, in which a higher score indicates more 
feelings of anxiety and/or distress about one’s memory functioning. 
Mood symptoms. The subscales depression (16 items) and anxiety (10 items) of the Dutch 
Symptom Check List (SCL-90) (Arrindell & Ettema, 2003; Derogatis & Cleary, 1977) were used 
to measure depressive and anxiety symptomatology. The SCL-90 is a multidimensional self-
rating questionnaire (Derogatis & Cleary, 1977), and is a widely used standardized inventory 
of psychiatric symptomatology. Questions are rated on a ﬁve point Likert scale, ranging 
from “strongly disagree” to “strongly agree”. A higher score on these subscales indicate more 
symptoms of depression or anxiety.
Personality symptoms. A shortened version of the Eysenck Personality Questionnaire (EPQ-BV) 
was used to measure symptoms of extraversion and neuroticism. This shortened version of 
the EPQ (Sato, 2005) contained 24 items. It is a self-reporting questionnaire based on a two-
point scale with the response options “yes” and “no”. The EPQ-BV had coeﬃcient alphas for the 
extraversion and neuroticism scales of .92 and .90 respectively (Sato, 2005). Furthermore the 
test-retest reliability values of the two scales turned out to be .92 for both the extraversion and 
neuroticism measures. 
Quality of life. The physical and mental summary scores of the Short Form Health Survey (SF-
36) (Van de Zee et al., 1993) were used to measure quality of life related to physical and mental 
aspects. The SF-36 is composed of 36 items measuring health across eight dimensions: physical 
functioning, social functioning, role limitations due to physical problems, role limitations due 
to emotional problems, pain, mental health, vitality, and general health perception. These 
eight subscales can be summarized into one physical and one mental component summary 
score. Each dimension score ranges from 0 to 100. Higher scores indicate better health-related 
quality of life. 
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Changes in memory functioning. The Détérioration Cognitive Observée (DECO) (Ritchie & 
Fuhrer, 1992) was used to measure changes in memory and daily functioning in the past year. 
The questionnaire is completed by a close relative who had at least monthly contact with the 
patient. The DECO consists of 19 items, scored on a 3-point Likert scale consisting of “the same 
or better”, “less good” and “signiﬁcantly less good”. A higher score on the DECO indicates better 
memory and daily functioning of a subject in experience of the relative. 
Other variables. The Mini Mental State Examination (MMSE) (Folstein et al., 1975) was used to 
measure the general cognitive status. Level of education (LE) was deﬁned by classifying formal 
schooling in a system often used in the Netherlands, which is comparable to the International 
Standard Classiﬁcation of Education (UNESCO, 1976). The participants were grouped as follows: 
those with at most primary education (low), those with junior vocational training (average) and 
those with senior vocational or academic training (high) (Van der Elst et al., 2005). Additionally, 
we asked the subjects (a) about their fear for developing dementia, including the reason, 
and (b) whether they had experienced important life-changing events during the past year. 
Objective memory performance was investigated with the AVLT (Van der Elst et al., 2005).
Statistics
All data were processed with Statistical Package for Social Sciences (SPSS) version 11.0.4 for 
Mac OS X. Group comparisons for variables at interval or ratio level were performed, using 
independent t-tests or Mann-Whitney U tests. Dichotomous variables were analyzed using 
Chi-square tests. All analyses were performed at a two-tailed alpha level of .05. Based on the 
main outcome measure (the MIA-MSE), by 33 cases and 83 control subjects, and a two-tailed 
testing, a power of 0.69 was reached. Based on our hypothesis that cases had lower MIA-MSE 
scores compared to controls, a one-tailed analysis resulted in a power of 0.79.
Table 1: Baseline characteristics. 
Cases
 (n=33)
Controls
(n=83)
p
Age, years (±SD) 62.0 (8.6) 65.1 (10.3) ns
Sex (% male) 61 47 ns
LE (% L/M/H) 27/33/40 49/36/15 .008
MMSE score (±SD) 28.8 (1.5) 28.6 (1.3) ns
Delayed recall, Z-score (± SD) 0.0 (1.0) 0.3 (1.1) ns
Ns = not signiﬁcant at p-value .05, SD = Standard deviation, LE = level of education: L = low, M = medium, 
H = high.
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Results
Subject characteristics
Baseline characteristics of cases and controls are shown in Table 1. There was no diﬀerence in 
age, sex, performance on the immediate recall test, or general cognitive status as measured with 
the MMSE between the two groups. Cases were on average higher educated by comparison 
to control subjects. Because of this diﬀerence we repeated all analyses with correction for 
education. These analyses yielded similar ﬁndings as without correction. Presented data in the 
present study are without correction for education.
 The average scores on the questionnaires by the cases and control subjects are 
presented in Table 2. Cases had signiﬁcantly lower MSE scores on the MIA than the controls. 
More detailed analyses of the MIA-MSE score showed that cases had a signiﬁcantly lower 
score on the subscale capacity, as well as a signiﬁcantly lower score on the subscale change 
indicating less stability in memory performance. Cases scored signiﬁcantly higher on the DECO 
compared to the control subjects. Cases had a signiﬁcant lower mental summary score on the 
SF-36 (Table 2), whereas the physical summary score was equal in both groups.
 The proportion of subjects who reported to be worried about developing dementia 
was similar in both groups. The proportion of subjects who reported to be worried about 
Table 2:  Diﬀerences on rating scales between cases and controls.
 Cases Controls p
 n = 33 n = 83  
SCL-depression 39.5 ± 14.5 35.0 ± 10.6 ns
SCL-anxiety 24.3 ± 8.7 21.2 ± 7.8 ns
EPQ-extraversion 5.2 ± 2.9 5.7 ± 3.0 ns
EPQ-neuroticism 5.3 ± 3.3 4.8 ± 3.5 ns
MIA-MSE 83.6 ± 17.8 91.3 ± 12.4 0.009
DECO-total 31.0 ± 6.4 33.7 ± 4.2 0.037
SF-physical component score 44.8 ± 10.9 45.6 ± 9.5 ns
SF-mental component score 42.2 ± 13.6 49.3 ± 8.8 0.010
Worried to develop dementia (% yes) 70 57 ns
Worried because of family history of dementia (% 
yes)
60 32 0.048
Life-changing event (% yes) 67 66 ns
Data are presented as mean ± standard deviation, ns = not signiﬁcant, SCL = Symptom Check List, EPQ = 
Eysenck Personality Questionnaire, MIA = Metamemory in Adulthood, MSE = Memory Self-Eﬃcacy, DECO 
= Détérioration Cognitive Observée, SF = Short Form Health Survey-36.
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dementia because they had a positive family history of dementia was signiﬁcantly higher in 
cases than in control subjects (Table 2).
 Cases and control subjects had comparable scores on the subscales depression and 
anxiety of the SCL-90. The scores on both subscales were ‘high’ to ‘very high’, compared to the 
SCL-90 standards for the normal population (Arrindell & Ettema, 2003). No signiﬁcant diﬀerence 
was found for the EPQ-BV subscales extraversion and neuroticism between cases and controls. 
The proportion of subjects that had experienced a life-changing event in the past year was also 
comparable in the two groups.
Discussion
The main ﬁnding of this study is that cases who sought help for their SMC at a memory clinic 
were characterized by less personal competence in memory related situations and a lower 
quality of life related to mental health by comparison to controls. In addition, cases showed 
more decline in memory functioning as reported by a relative, they were also more often 
worried about dementia due to a positive family history for dementia, and had more often a 
higher level of education. Symptoms of depression, anxiety, extraversion and neuroticism did 
not diﬀer between cases and controls.
 Cases had more negative beliefs about their personal competence in various memory 
situations, reﬂected by lower MIA-MSE scores. By comparison to control subjects, cases reported 
less memory capacity and more decline (or less stability) in memory functioning despite the 
fact that they had normal cognitive functioning according to the MMSE and a memory test. 
This suggests that the personal (subjective) evaluation of one’s own memory functioning is an 
important factor in determining help-seeking behaviour. 
 Our study showed that cases who had sought medical attention, reported a lower 
quality of life related to mental health by comparison to controls who had not sought help. The 
quality of life related to physical health was equivalent for cases and controls. The existence of 
a relation between memory complaints and a diminished quality of life in the elderly was also 
indicated by a recent review (Mol et al., 2007). However, a study by Jorm et al. (2004) reported 
that both the subjects who did visit a doctor or their memory complaints and subjects who 
did not visit a doctor had comparable mental summary scores. In contrast, this study found a 
signiﬁcant diﬀerence between these groups with regard to the physical summary score. The 
diﬀerences in ﬁndings between the study by Jorm et al. (2004) and the present one can possibly 
be explained by diﬀerences in setting, by the use of another version of the SF for investigating 
quality of life, and by the specialty of the doctor who is visited for the memory complaints.
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 Relatives of cases more frequently reported a decline in memory functioning and 
in functioning during daily activities in the past year than the relatives of control subjects. 
This is in line with the ﬁndings of Streams et al. (2003), who found that changes in cognitive 
or non-cognitive aspects reported by the caregiver accounted for 81% of the trigger events 
to seek help at a memory clinic. Cases also more often reported a positive family history of 
dementia as cause for their worries about their forgetfulness. Therefore, cases with a positive 
family history of dementia may be more prone to interpret their cognitive complaints in a more 
catastrophic way. Such a negative cognition may play an important role in the development 
and maintenance of the memory complaints. 
 Both groups studied here reported high levels of depressive and anxious 
symptomatology compared to normative data of the SCL for the healthy population (Arrindell 
& Ettema, 2003). This is in line with other studies reporting higher depression and anxiety 
scores in subjects with memory complaints (Cargin et al., 2007; Jorm et al., 2004; Jungwirth 
et al., 2004; Lautenschlager et al., 2005; Ponds & Jolles, 1996b). As cases and controls did 
not diﬀer in the levels of depressive and anxiety symptoms, these symptoms appear not to 
be determinants for visiting a memory clinic. The same was true for the personality factors 
extraversion and neuroticism. This is in line with a study of Jorm et al. (2004), which found similar 
levels of extraversion and neuroticism between subjects who visit a doctor for their cognitive 
complaints and subjects who did not. The average levels of extraversion and neuroticism are 
comparable to those in other studies about subjects with memory complaints using the EPQ 
(Jorm et al., 2004). Thus, psychopathological and personality symptoms are present in subjects 
with memory complaints, but they do not appear to be determinants of seeking help at a 
memory clinic.
  Both groups studied here also have comparable MMSE and memory delayed recall 
scores. Moreover, the scores of both groups were also within normal limits, indicating that the 
severity of cognitive impairment, or more especially memory impairment was no explanation 
for deciding to visit a memory clinic in this study. 
 A recent inventory about the organization and functioning of memory clinics in the 
Netherlands showed that about 15% of the memory clinic visitors did not have a cognitive 
impairment (Verhey et al., 2007). The ﬁndings of the present study are important to develop 
interventions with regard to memory-related cognitive mechanisms for this group of memory 
clinic visitors. These interventions should focus on improving the subject’s knowledge about 
their own memory functioning, and changing negative beliefs and expectations about their 
memory. Pharmacological therapy was routine in 97% of the Dutch memory clinics, while 
cognitive therapy was part of the standard treatment options in only 24% of the memory 
clinics (Verhey et al., 2007). Our ﬁndings imply that besides pharmaceutical therapies for 
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improving cognitive functioning and psychopathological symptoms, memory clinics should 
oﬀer cognitive-behavioural therapies to those patients with memory complaints who lack 
objective impairments according to testing. The therapies would include instructions on how 
to cope with the memory complaints and on how to improve subjective memory functioning 
and quality of life related to mental health. 
 However, subjects with memory complaints should be invited for follow-up 
assessments to verify the course of the subjective complaints and the objective test 
performances, because a progressive course of cognitive dysfunctioning caused by underlying 
brain degeneration cannot be excluded in a cross-sectional assessment. Indeed, preliminary 
data showed that of the 27 cases with follow-up data for at least one year, three went on to 
develop dementia compared to none of the subjects from the control group.
 To our knowledge, this is the ﬁrst study in which a comparison is made between clinical 
subjects with memory complaints not classiﬁed as objective impairments who visit a memory 
clinic for their memory complaints on the one hand, and subjects from the general population 
who did not show this help-seeking behaviour on the other. Both groups were recruited from 
the same geographical region and both used for ageing research. Several non-cognitive aspects 
were taken into account. Cases were selected from a memory clinic setting and ﬁndings may 
not be applicable to other settings. The older age and the lower educational level of the cases 
who did not participate in the study (n = 19) could also have biased our results. Another point 
of attention is the way in which memory complaints were assessed in either group. Cases were 
referred to the memory clinic because of memory complaints, whereas control subjects were 
asked if they ﬁnd themselves forgetful. A recent study found, however, that whether a single 
question to identify memory complaints or a more detailed questionnaire is used, did not have 
an inﬂuence on the ability to diﬀerentiate between individuals with memory deﬁcits or normal 
subjects (Cargin et al., 2007). The comparable MMSE and memory scores in both groups also 
imply that the way memory complaints were investigated did not inﬂuence the severity of the 
cognitive impairments in either group. 
Conclusion
Compared to people with SMC who do not seek help, subjects with SMC visiting a memory 
clinic are characterized by less subjective memory self-eﬃcacy, a decreased quality of life 
related to mental health, more deterioration in memory and daily functioning reported by an 
informant, and more worries related to a family history of dementia. These ﬁndings may help 
to develop adequate interventions for subjects without objective memory impairments who 
visit a memory clinic due to memory complaints.
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Abstract
Background. Memory Clinics (MC’s) are multidisciplinary teams involved with early diagnosis 
and treatment of people with dementia. The aim of this study was to investigate whether, 
and how these facilities can play a role in not-demented subjects, such as subjects with Mild 
Cognitive Impairment (MCI). 
Methods. A questionnaire with questions about the organization of the MC, the distribution 
of diagnoses, diagnostics, the aetiology of MCI, used MCI-criteria, and treatment was sent to all 
MC’s in the Netherlands. 
Results. The number of MC’s increased from 12 to 40. The number of referrals per service has also 
increased. The focus is less exclusively on academic centres. Dementia was the most important 
syndromal diagnosis (62%), but also MCI (23%) and no cognitive disorder (15%) were common. 
However, there was a large variability between the settings in the proportion of the diagnoses 
dementia/MCI/no cognitive disorder. 92% of the settings used the concept MCI. The most 
common diagnostic classiﬁcations of subjects with MCI were primary degenerative, vascular 
and not speciﬁed. In 84% of the settings the treatment of MCI subjects was diﬀerent to that of 
demented patients, which mainly implicated a neuropsychological follow-up assessment.
Conclusion. MC’s are part of standard care for people with early dementia, but MC’s play 
also an increasing role in the diagnostic and therapeutic procedures of subjects with milder 
cognitive problems. Because of the large variability between the settings in the proportion 
of the diagnoses dementia/MCI/no cognitive disorder, the treatment possibilities should be 
ﬁtted to the main problems seen at a particular MC.
Key words. Memory clinic, Alzheimer’s disease, Mild Cognitive Impairment, and diagnostics.
MEMORY CLINICS IN THE NETHERLANDS
91
Introduction
Memory Clinics (MC’s) are a relative new phenomenon in health care. The ﬁrst MC’s were set 
up in North America in the mid 1970s, and little later in the UK (Wright & Lindesay, 1995). In 
1986 the ﬁrst MC developed in the Netherlands in Maastricht and Tilburg (Verhey et al., 1987). 
Nowadays, MC’s are an important service in health care. MC’s developed in various ways. They 
had a large variation in their organization, working methods and services, but shared primary 
principles of being multidisciplinary teams, involved with the early diagnosis and treatment 
of people with dementia (Lindesay et al., 2002; Passmore & Craig, 2004). Although MC’s 
aimed the early diagnoses of dementia, the name ‘memory clinic’ suggests that this facility 
also deliver service for non-demented subjects with milder memory problems, such as Mild 
Cognitive Impairment (MCI). MCI is a condition that refers to cognitive impairment in subjects 
without dementia. MCI is a heterogeneous concept and can have many causes. Therefore 
the usefulness of this concept in clinical practice is still under debate (Whitehouse & Moody, 
2006). Nevertheless, there is abundant evidence that subjects with MCI are at increased risk for 
developing dementia (Geslani et al., 2005; Petersen et al., 1999; Visser et al., 2006). However, 
not all subjects with MCI develop dementia in future (Visser et al., 2000), as the cognitive 
functioning of these subjects can also remain stable or improve over time. In these subjects 
cognitive impairments can be caused by other somatic, mood, or psychological factors (Jorm 
et al., 2004; Ponds & Jolles, 1996a). The diﬀerentiation between normal and pathological aging 
is important, because subjects could beneﬁt from other sorts of treatment, and also because 
subjects often worries about their memory complaints and want a decisive answer and a 
prognosis. 
 In 1998, an overview was published about the organization and working methods of 
the MC’s in the Netherlands that were operational at that time (Verhey et al., 1999). The main 
ﬁndings of that study were that MC’s were mainly associated with university hospitals, and were 
involved in scientiﬁc research, mainly clinical trials. Since 1998, several new MC’s has arisen. In 
order to attain more insight into the development and functioning of MC’s we compared the 
data of two inventories, one of 1998 and the other of 2004. Speciﬁcally, we focused on the 
function of MC’s in non-demented subjects such as subjects with MCI and subjects without 
cognitive disorder.
Methods
We sent a questionnaire and a self-addressed return envelope to the coordinators of all MC’s 
in the Netherlands. Settings that did not respond, were attended again by telephone or by 
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mail. Forty-eighty settings were addressed. Forty settings identify themselves as a MC, from 
these 37 settings returned the questionnaire (response 93%). Reasons mentioned for not 
being a MC were not working in a multidisciplinary way, no medical diagnostics, and being 
in the starting phase. A list of identiﬁed MC’s is available at www.alzheimercentrumlimburg.
nl. The questionnaire pertained to the organization of the MC, the distribution of diagnoses 
dementia/MCI/no cognitive disorder, diagnostics, the aetiology of MCI, used MCI-criteria, and 
treatment. MCI was in this case not restricted to the amnestic criteria, but instead we used a 
broad deﬁnition of all subjects who reported an impairment in any cognitive domain. Statistical 
analyses were performed using the Statistical Package for Social Sciences (SPSS), version 11 for 
Mac OS X. Group diﬀerences between the coordinating disciplines were tested using ANOVA’s 
or Chi-square tests.
Results
In 2004, 40 MC’s were identiﬁed. All MC’s were associated with a general or academic hospital. 
Data about the years of starting up was known from 35 settings and is shown in Figure 1. There is 
a large increase in number of MC’s since 1998, before which data only 12 MC’s were operational 
(Figure 2). In 2004, the MC’s were more equally distributed over the country. The disciplines 
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Figure 1: Starting year of memory clinics in the Netherlands, cumulative from 1986 (N=35, 
missing data of 5 settings).
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that were mainly associated with MC’s were clinical geriatry (83 clinicians), (neuro)psychology 
(58 clinicians), neurology (53 clinicians), and psychiatry (35 clinicians). Besides this, also nurses 
played an important role. 
 In 2004, objectives were in more than 90% van the MC’s specialized diagnostics, 
pharmacological treatment and giving advice and information. The majority of the settings 
also oﬀered non-pharmacological treatments or gave advice about future policy (±70%). These 
ﬁndings are similar to that in 1998. Half of the MC’s also was involved in scientiﬁc research, and 
the minority (38%) also had educational aims.
 In the diagnostic phase, neuropsychological assessments were applied in 75% of the 
settings. Laboratory assessments were applied in 97% and all settings used imaging techniques, 
most commonly MRI-scan or CT-scan. All settings used one or more assessments scales. In 97% 
of the settings the Mini Mental State Examination (MMSE) was used. Twenty-six settings  (70%) 
used one or more dementia screenings scales, such as the Alzheimer’s Disease Assessment 
Scale-Cognitive Subscale (ADAS-COG) (8 settings), de Clinical Dementia Rating Scale (CDR) (10 
settings) en de Global Deterioration Scale (GDS) (3 settings). Depression scales were used in 
86% of the settings, mainly the Geriatric Depression Scale (GDS). Other scales used in MC’s 
were the Neuro-Psychiatric Inventory (NPI(-Q)) (8 settings), Interview for Deterioration in Daily 
Living activities in Dementia (IDDD) (7 settings) en Instrumental Activities of Daily Living (IADL) 
(4 settings).
Figure 2: Topographical distribution of MC’s: in 1998 (left) and 2004 (right).
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 The diagnosis MCI was used in 34 of the 37 settings (92%). The criteria MCI were 
deﬁned by 30 settings. Nineteen settings used the amnestic criteria of Petersen et al. (1999). 
A combination of cognitive impairments was used in 8 settings, and 3 settings used other 
criteria. The average percentages of the diagnostic classiﬁcations of MCI-cases are presented 
in Table 1. These data are based on the available data of 23 settings. The diagnoses ‘primary 
degenerative’, ‘vascular’, and ‘not speciﬁed’ were most common. 
 The mean number of patients seen in 2003 per setting was 199 (range 15-615), 
compared to 130 in 1998. Sixty-two percent of the new patients in 2003 were diagnosed 
as demented (range 40-95%) (Figure 3). This implicates that dementia is the most common 
syndromal diagnosis in MC’s in the Netherlands. Besides dementia, a substantial part of the 
subjects (23%, range 5 – 45%) had MCI (i.e. a cognitive impairment in memory and/or other 
cognitive domains). About 15% (range 0-40%) of the subjects had no cognitive disorders. There 
was no signiﬁcant diﬀerence in the proportion of the syndromal diagnoses dementia/MCI/
no cognitive disorders among the coordinating disciplines neurology, psychiatry and clinical 
geriatrics, and also not between academical or not-academical settings. 38% of the settings 
saw for 70% or more subjects with dementia. In about one-fourth (26%) of the MC’s, more than 
half of the subjects did not get the diagnosis of dementia. 
 Pharmacological treatment was used in 97% of the MC’s, not related to a clinical trial. 
All these settings prescribed cholinesterase-inhibitors. The main implication for prescribing 
cholinesterase-inhibitors was Alzheimer’s disease. None of the settings reported MCI as an 
indication for prescribing cholinesterase-inhibitors. Psychosocial treatment was used in 65% of 
the settings. 19 settings (24%) gave some type of cognitive training. Psychosocial interventions 
were more often part of the treatment protocol in settings coordinated by the geriatric (83%) 
or psychiatric (100%) department than in settings coordinated by the neurology department 
(38%, p = .012). In 31 of the 37 (84%) settings was indicated that the treatment of MCI patients 
 Table 1. Diagnostic classiﬁcation of new MCI-patients
Diagnostic classiﬁcation Mean % [min-max]
Primary degenerative 20 [0-80]
Cerebrovascular 20 [0-80]
Not speciﬁed 19 [0-80]
Depression 10 [0-50]
Somatic/internal cause 6   [0-40]
Other neurological cause 9   [0-100] 
Intoxication/Side eﬀects 3   [0-15]
Other psychiatric cause 2   [0-10]
MEMORY CLINICS IN THE NETHERLANDS
95
diﬀered to that of demented patients. Patients with MCI were followed over time in 34 (92%) 
settings. This mainly as a neuropsychological follow-up assessment, either in the kind of a 
scientiﬁc research project or not. A structural collaboration with local service providers for 
mental health increased from 15% of the MC’s in 1998 to 63% in 2004. 
Discussion
MC’s in the Netherlands had a strong development in the past years. Not only the number of 
settings, but also their total capacity showed a substantial increase. Nowadays, the MC’s are 
more equally distributed with respect to the topographical location in the country, and there is 
more balance in the academic or non-academic settings. Besides subjects with dementia, also 
subjects with memory problems who are not demented are a substantial part of the subjects 
who attended MC’s (Figure 3).
 Nowadays, a substantial part of the demented patients are seen in a specialized service 
for the diagnostics of early dementia. The incidence of dementia in the Netherlands is about 
22.500 patients per year (Ruitenberg et al., 2001). In 1998, less than 5% of the new demented 
patients were seen at a MC, compared to 22% in 2004. This indicates that MC’s have outgrown 
the exclusive setting, that was mainly focused on scientiﬁc research, and have get a place in the 
regular care. This development is similar with that in foreign countries (Lindesay et al., 2002). 
The strong increase in the number of settings can be explained by the increasing focus on 
the early diagnosis of dementia and the registration of the ﬁrst pharmaceutical treatments for 
Alzheimer’s disease in the Netherlands, in 1998. 
62%
23%
15%
Dementia
MCI
No Cognitive Disorder
Figure 3: Distribution of diagnoses of new referrals to MC’s.
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 The majority of the settings used neuropsychological assessments and one or more 
screening scales for cognition and dementia, which is in line with the recommendations of an 
evidence-based review about the early detection of dementia (Petersen et al., 2001). However, 
there was a large variability in which speciﬁc scales were used. Harmonization about the 
cognitive domains that should be measured, the used neuropsychological tests or screening 
instruments and the used normative data of these tests would increase the comparability of 
the results between several settings.
 MC’s play an important role in the diagnostic process of dementia, its aetiology, and 
the explanation of this diagnosis to the patient and his family. MC’s also give information 
about the implications of the diagnosis, the course, and advice about coping with the disease. 
However, a MC also has an important function in the diagnostic process of subjects with 
memory complaints who are not demented, as about 40% of the new referrals to a MC had 
MCI or no cognitive disorder. Remarkable is the large variability between the settings in the 
proportion of the diagnoses dementia, MCI and no cognitive disorder. This suggests that 
we can identify two types of MC’s: those that see mainly demented patients, and those that 
see mainly milder types of memory disorders in the absence of dementia. The proportion of 
MC’s that mainly saw demented subjects is decreased from 58% in 1998 (Verhey et al., 1999) 
to 38% in the present study. This implicates that nowadays there is increasing emphasis for 
milder cognitive problems such as MCI and no cognitive disorders. As mentioned before, MCI 
is not always a preclinical phase of dementia, as the cognitive proﬁle of these subjects can also 
remain stable or can even improve over time (Visser et al., 2002). Cognitive impairments that 
remain stable or improve over time will probably not be caused by underlying degenerative 
pathology, but probably by other factors that may cause cognitive complaints such as several 
psychological, behavioural or social factors, which emphasized the importance of an extensive 
neuropsychiatric screening in these subjects.
  About 15% of the visitors of Dutch MC’s did have no cognitive disorder. These subjects 
often experience cognitive complaints because of other factors. Previous research showed 
that memory complaints can be related to psychiatric symptoms, personality characteristics 
and poor physical health (Cargin et al., 2007; Comijs et al., 2002; Derouesne et al., 1999; Jorm 
et al., 2004; Ponds et al., 1997). Subjects with subjective cognitive complaints, but without 
impairments on formal testing are often referred to as ‘worried well’. These subjects often 
worry about their complaints and are feared to become demented. Nevertheless, also these 
subjects seek help at MC’s and should be taken seriously. MC’s should also have treatment 
possibilities for this group of visitors, who are characterized by less memory self-eﬃcacy, a 
decreased quality of life related to mental health, and more worries related to a family history 
of dementia (Ramakers et al., accepted).
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 Pharmacological treatment was available in nearly all MC’s. However, as none of the 
settings prescribed cholinesterase-inhibitors to subjects with MCI, MC’s that are mainly visited 
by subjects with MCI or no cognitive disorder should have other treatment possibilities than 
pharmacological treatment. This implicates that the treatment possibilities of a MC should 
be ﬁtted to the problems of the visitors of that particular MC. The majority of the settings 
performed neuropsychological follow-up assessments in subjects with MCI. Other starting 
points for non-pharmacological treatment in subjects with MCI or subjects with no cognitive 
disorder can be psychosocial treatment, cognitive training, or psycho-education to the patient 
and the family. 65% of the settings reported to have psychosocial treatment available. This is a 
clear increase since 1998 when only 38% of the settings could deliver psychosocial treatment 
(Verhey et al., 1999). This development is in line with nowadays standards (Draskovic et al., 2008), 
in which the availability of non-medication treatments such as psychosocial interventions is 
recommended as part of best MC practice. Psychosocial interventions were more often part of 
the treatment protocol in settings coordinated by the geriatric or psychiatric department than 
settings coordinated by neurologists. This suggests that the composition of the staﬀ of the MC 
has implications for the available treatment possibilities.
 The majority of the settings performed additional diagnostic methods, such as 
extensive neuropsychological assessments, imaging techniques, laboratory ﬁndings, or lumbar 
punctions, to investigate the aetiology of the cognitive impairments. This underlines the shift 
from a syndromal diagnosis to a more aetiological diagnosis at an earlier time point in the 
course of the disease. However, the use of these diagnostic markers should not implicate that 
clinical impressions and observations are less important and should move to the background.
 Half of the MC’s were involved in scientiﬁc research, which is a decrease of 35% since 
1998 (Verhey et al., 1999). This implicates that scientiﬁc research nowadays is less limited to 
academical settings as it was in 1998. The role of scientiﬁc research at a MC is important, as 
MC’s are good settings for the standardized inclusion of subjects along the whole cognitive 
spectrum, ranging from subjective cognitive complaints to dementia. MC’s are also good 
settings for the implementation of new scientiﬁc ﬁndings and for investigating the eﬀects of 
these implementations.
 This inventory shows that MC’s have a large consensus about the objectives, used 
diagnostic criteria for Alzheimer’s disease and vascular dementia, and the used scales. However, 
diﬀerences between the MC’s exist about the number of patients per week, and the partition 
of diagnoses of subjects with dementia and subjects with cognitive impairment without 
dementia. This inventory has reached the majority of the MC’s in the Netherlands. However, 
there will be settings that have comparable objectives and activities, such as monodisciplinary 
settings, which did not participate in this inventory. This leads to an underestimation of some 
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results. Another point of attention is that results are mainly based on estimations. Nevertheless, 
we suppose that this inventory is a representative overview of the current state of MC’s in the 
Netherlands. There is an increasing emphasis on subjects with milder cognitive problems. MC’s 
can and should be adequate settings for referrals along a broad cognitive spectrum, including 
MCI (independent from deﬁnition) and those with ‘only’ subjective memory complaints. There 
is an increasing number of people who want to know about their prognosis and future chance 
to becoming demented. Those who have these questions deserve an honest and evidence 
based answer. MC’s should have diagnostics and expertise available to diﬀerentiate between 
the several underlying causes of cognitive impairments. For subjects who are at increased 
risk for developing dementia, MC’s should have a monitoring function (3rd CCCDTD, 2007). In 
addition, MC’s should be able to give, by itself or in cooperation with other care facilities in the 
region, an integral treatment, that is not only focused on medication and that is ﬁtted to the 
problems of his visitors. 
 In conclusion, these ﬁndings showed that the population of patients that visit a MC’s 
is not limited to demented patients, but also subjects with more mild cognitive problems 
are a substantial part of the visitors to MC’s. Because of the aging population and when new 
treatment possibilities to slow down the disease progression become available, the number 
of subjects with mild cognitive problems that seek help at a MC will increase. The treatment 
arsenal of MC’s should be ﬁtted to this group of subjects, and should not be limited to the 
pharmacological therapy for dementia. 
8 Concluding remarks
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8.1 Introduction
Mild Cognitive Impairment (MCI) is used to describe the transitional phase between normal 
cognitive functioning and dementia. In this phase subjects experience cognitive problems, 
that do not meet the current criteria for dementia. Subjects with MCI are at increased risk for 
developing dementia, especially AD (Geslani et al., 2005; Petersen et al., 1999; Visser et al., 
2006). However, not all subjects with MCI will develop AD (Visser et al., 2002). It is important to 
identify predictors that can diﬀerentiate between subjects who will develop AD and those who 
will not, as both groups can beneﬁt from other types of advice and treatment.
 The aim of the ﬁrst part of the thesis was to investigate predictors for AD or dementia 
in a memory clinic and GP setting. In Chapters 2 and 4, we investigated the predictive accuracy 
of cognitive and non-cognitive variables for AD in subjects with MCI, selected from a memory 
clinic setting. In addition, we studied the predictive value of cognitive, aﬀective, behavioural, 
and vascular symptoms, gait disturbances, and changes in appetite and weight for future 
dementia in subjects from general practice settings (Chapter 5).
 The aim of the second part of the thesis was to investigate the development and 
organization of Memory Clinics, as a relatively new health care facility for subjects with 
cognitive problems. We investigated determinants of help-seeking behaviour for subjective 
memory complaints at a memory clinic (Chapter 6). In addition, we studied the development 
of memory clinics in the Netherlands since 1998, and we focused on the role of this specialized 
health care facility for non-demented subjects with MCI or no cognitive disorder (Chapter 7). In 
this last chapter of the thesis, we will summarize and discuss the general ﬁndings. We will also 
describe the methodological considerations, as well as the scientiﬁc and clinical relevance of 
these ﬁndings. Lastly, recommendations for future research will be made.
8.1  Predictors of Alzheimer’s disease
8.1.1 Memory
It is well known that AD is characterized by impaired memory functioning. Non-demented 
subjects with memory impairments are at increased risk for developing AD (Albert et al., 2007; 
Sarazin et al., 2007; Saxton et al., 2004; Tabert et al., 2006; Twamley et al., 2006; Visser et al., 
2002). Therefore, decreased memory performances may be an early marker of AD. The measure 
generally used for investigating the predictive accuracy of memory for AD, is delayed recall 
performance. However, delayed recall is the result of a variety of processes, such as encoding, 
storage and retrieval. Thus, other aspects of memory functioning may also be indicative of 
early AD. 
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 Findings of the present study showed that the use of an active memory strategy 
during the learning of verbal information correlated with delayed recall performance and 
was also a signiﬁcant predictor for future AD, as lower scores of subjective organization were 
associated with a higher risk for AD up to 10 years after baseline (Chapter 2). The more passive 
learning strategy of serial clustering had no predictive value. In addition, we found that this 
eﬀect was similar in middle-aged subjects (aged 40-59 years) and older subjects (aged 60-
85 years). The ﬁnding that prodromal AD is characterized by impaired learning strategies 
may have implications for the early detection of AD in subjects with MCI. These ﬁndings are 
consistent with the idea that strategies, which are more eﬀortful for the total cognitive brain 
capacity, are more sensitive to degeneration than less eﬀortful, more automatic strategies. 
These ﬁndings give an insight into how the subject has reached the total score. Subjective 
organization depends on the active reorganization of the incoming information, and may 
therefore be related to prefrontal lobe functioning and executive functioning (Fletcher et al., 
1998; Fletcher et al., 1998; Kramer et al., 2005; Savage et al., 2001). We did, however, not ﬁnd 
evidence that learning strategies were dependent on executive functioning, because after 
correction for measures of executive functioning (Stroop III score, TMT B score and ﬂuency), 
results did not change. The ﬁnding that the use of an active learning strategy during the 5 
immediate recall trials is strongly correlated with the performance on the delayed recall can 
be used in the development of cognitive training programs, where subjects with memory 
complaints may learn to use learning strategies to enhance everyday independent memory 
functioning. Recent studies have shown that subjects, also at an older age have the capability 
to learn and that MCI subjects can beneﬁt from memory training programs (Belleville, 2008). 
Nevertheless, the beneﬁts of these training programs will be most eﬀective in early phases of 
the degenerative process. 
 In Chapter 3, we investigated the relation of several aspects of verbal memory and 
learning strategies with the APOE genotype in subjects with MCI. We found that in younger 
subjects impairment in the active memory strategy were related to the APOE e4 genotype, 
a well-known genetic risk factor for AD, whereas in older subjects the APOE e4 allele was 
most strongly related to impaired delayed recall performances. After the exclusion of subjects 
who developed AD at follow-up, the APOE e4 allele remained associated with lower levels 
of subjective organization in the middle-aged subgroup, but was no longer associated with 
any of the memory measures in the older subjects. Thus, the eﬀect of the APOE e4 genotype 
on memory function may be dependent on underlying AD pathology in elderly subjects, but 
not in middle-aged subjects. This suggests that the APOE e4 allele may have an independent 
mechanism on memory functioning in middle-aged subjects with MCI, or that these subjects 
already suﬀer from AD, but that the follow-up period was too short to identify conversion to 
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AD in these middle-aged subjects. In that case, subjective organization could be a very early 
marker of AD. 
8.1.2 Aﬀective symptoms
Besides cognitive problems, subjects with MCI can also experience non-cognitive symptoms, 
such as aﬀective symptoms (Apostolova & Cummings, 2007; Copeland et al., 2003; Gabryelewicz 
et al., 2007; Geda et al., 2004; Liu et al., 2007; Modrego & Ferrandez, 2004; Palmer et al., 2007; 
Panza et al., 2008; Robert et al., 2006; Rozzini et al., 2005; Teng et al., 2007; Tierney et al., 
1999). There are several possible explanations for the relation between aﬀective symptoms, 
cognitive impairment and AD. Aﬀective symptoms and MCI can be caused by an underlying 
depression and in that case aﬀective symptoms would be associated with a decreased risk 
for AD. Aﬀective symptoms and MCI may also be associated with underlying AD pathology 
and then aﬀective symptoms would be associated with an increased risk for AD. It has been 
suggested that aﬀective symptoms are risk factors for AD (Modrego & Ferrandez, 2004; Ownby 
et al., 2006; Palmer et al., 2007). However, there is no consensus about the predictive role of 
these symptoms for AD in subjects with MCI, as other studies found no relation or found a 
decreased risk for AD (see Table 3, Chapter 4 for an over view). These conﬂicting ﬁndings may 
have resulted from several factors. In Chapter 4, we have investigated possible explanations for 
these discrepant ﬁndings such as age, length of follow-up, and deﬁnition of MCI.
 Our ﬁndings showed that indeed aﬀective symptoms are common in subjects with 
MCI, but that these symptoms are not a marker of AD in the predementia stage, as these 
symptoms in general were associated with a decreased risk for AD (Chapter 4). The ﬁnding 
that aﬀective symptoms are common in subjects with MCI is in line with other studies. The 
prevalence of aﬀective symptoms in our study (50-70%) is in line with a recent review that 
reported behavioural symptoms in 35-75% of the MCI-subjects with the most common being 
depression, anxiety, apathy and irritability (Apostolova & Cummings, 2007). The observed 
diﬀerences in the prevalence of aﬀective symptoms between other studies and the present 
one can be explained by diﬀerent sampling methods, diﬀerent settings, diﬀerences in the 
operationalisation of MCI, and the instruments used to measure aﬀective symptomatology.  
 With respect to the predictive value of aﬀective symptoms, we found that sleeping 
problems were signiﬁcantly associated with a lower risk for AD, and that symptoms of 
depression and anxiety showed a trend in this direction. Thus, aﬀective symptoms in subjects 
with MCI seem not to be caused by underlying AD pathology, and therefore cannot be used 
in clinical practice to identify subjects who are at increased risk for AD. As shown in table 
3, Chapter 4, these ﬁndings are in line with several other studies which also found no or a 
negative association between depression and AD (Korf et al., 2004; Panza et al., 2008; Teng 
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et al., 2007; Visser et al., 2000; Wang et al., 2006), however, some other studies did found an 
increased risk (Gabryelewicz et al., 2007; Modrego & Ferrandez, 2004). We could not ﬁnd a 
clear explanation for these inconsistent results among the studies. The type of MCI may have 
an eﬀect on the association between depression and AD, as we found that depression was 
signiﬁcantly associated with a decreased risk for AD in subjects without amnestic MCI, but was 
not associated with AD in subjects with amnestic MCI. We showed that age and the length 
of follow-up did not have a major inﬂuence on these ﬁndings. The predictive value may also 
depend on type of rating scale and setting. We used a clinician based rating scale. However, the 
use of a self-rating scale for depression and anxiety (Arrindell & Ettema, 2003; Arrindell & Ettema, 
1981) would have yielded similar results (data not shown). The setting from which the subjects 
were selected was the Maastricht Memory Clinic, which is embedded in the Department of 
Psychiatry of the hospital. It may be possible that our sample is relatively enriched by subjects 
with primary depression. Despite the lack of usefulness of aﬀective symptoms for identifying 
subjects with preclinical AD in clinical practice, the high prevalence of these symptoms require 
clinical expertise of aﬀective symptomatology in diagnostic and treatment settings for subjects 
with MCI.
8.1.3 Predictors in GP settings
The GP plays an important role in the early identiﬁcation of subjects with preclinical dementia. 
However, knowledge about which symptoms are suspected for preclinical dementia in general 
practice settings is very limited and may cause a delay in time between the presence of the ﬁrst 
symptoms and the diagnosis. In our study (Chapter 5), we found that 5 years prior to diagnosis, 
subjects with preclinical dementia visited their GP more often than controls. Rather unexpected, 
gait disturbances were the earliest predictor of a dementing disorder. Cognitive complaints 
were predictive for dementia in the three years before diagnosis. In the year prior to diagnosis 
cognitive, aﬀective, and behavioural symptoms, gait disturbances and changes in weight and 
appetite were predictive for dementia. Vascular symptoms were not predictive in any of the 
years prior to diagnosis. We found that 58% of the subjects with preclinical dementia reported 
cognitive complaints to their GP in the year prior to diagnosis. These data are of interest for 
identifying subjects at increased risk for dementia, at the same time they imply that 42% of the 
subjects did not report these complaints to the GP in the year before the diagnosis of dementia 
was made. This indicated that the GP should play an active role in the investigation of cognitive 
problems in older subjects, in which the GP should not only wait until the patient contacts him 
with cognitive complaints, but that the GP should inventorise these symptoms in a pro-active 
way to identify those subjects who are at risk for future dementia, and who also could beneﬁt 
form additional diagnostics.
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 The ﬁndings of this chapter seem not to be in line with ﬁndings from Chapter 4, 
in which we investigated the predictive value of aﬀective symptoms in subjects with MCI 
selected from the memory clinic. Findings showed that the presence of aﬀective symptoms 
were associated with a decreased risk for AD in subjects selected from the memory clinic, but 
with an increased risk for dementia in subjects from the GP settings. The diﬀerence may be 
explained by diﬀerences in mean age of the subjects, as subjects from the GP-setting were 
older than subjects from the memory clinic. Also the method of assessment of the aﬀective 
symptoms diﬀered in both studies, which may have resulted in a higher prevalence of aﬀective 
symptoms in the sample selected from the memory clinic compared to the GP-sample. 
8.2 Memory clinics
8.2.1 The development of memory clinics and their role for subjects with MCI
MCs are relatively new facilities in health care. The ﬁrst MC in The Netherlands developed in 1986 
in Maastricht and Tilburg (Verhey et al., 1999). Findings from chapter 7 show that nowadays, 
memory clinics play an important role in the health care system in the Netherlands. They have 
had a strong development in the past years, as there was a strong increase in the number of 
settings, and their total capacity. The most common syndromal diagnosis was dementia. They 
also became important facilities for subjects without dementia, such as subjects with MCI or 
subjects with “only” subjective memory complaints, as these subjects make up about 40% of 
their visitors. Also because of their multidisciplinary way of working, MCs should be able to 
investigate all possible causes which underlie cognitive complaints and to deliver diagnostics 
and treatment possibilities among a broad continuum of cognitive problems.
8.2.2. Seeking help at a memory clinic
Subjective memory complaints (SMC) deﬁned as memory complaints in the absence of 
objective impairments on memory tests, are common in middle-aged and elderly subjects. 
Only a subset of subjects with SMC decides to seek medical attention for these complaints. It 
is important to investigate the characteristics of these help-seeking subjects to determine the 
needs of these subjects and to provide adequate treatment and advice. Compared to subjects 
who do not seek help for their SMC, subjects who seek help at a memory clinic for their SMC 
are characterized by having more negative beliefs about their personal competence in various 
memory situations (low memory self-eﬃcacy), low quality of life related to mental aspects, 
more deterioration as experienced by a close relative, and that these subjects are more often 
worried about dementia because of a family history of dementia (Chapter 6). This information 
is important as these subjects form a substantial part (15%) of the visitors of (Dutch) MCs 
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(Chapter 7). These subjects often worry about their forgetfulness and want a prognosis. MCs 
should also have diagnostics and treatment tools available for this group of MC-visitors. Also, 
in the absence of an objective memory impairment, subjects with SMC who seek help at a 
MC should be taken seriously, as a progressive course of the cognitive complaints caused by 
underlying degenerative pathology cannot be excluded in a cross-sectional assessment. This 
is conﬁrmed by ﬁndings of Chapter 6, which showed that 11% of the subjects with subjective 
memory complaints without impaired memory scores from the MC had developed dementia 
at follow-up.
8.2.3    Methodological considerations
The present thesis showed ﬁndings from several study designs, such as a prospective, 
longitudinal design (Chapter 2 and 4), a retrospective cohort study (Chapter 5), cross-sectional 
studies (Chapters 3 and 6), and an inventory (Chapter 7). 
8.2.3.1 Strengths
Strengths of the Maastricht MCI study (Chapters 2- 4) are its prospective, longitudinal design, 
in which subjects who fulﬁl the inclusion criteria were selected at baseline and were followed 
over time. This prospective design prevents selection biases. Another strength is the long 
follow-up period up to 10 years. To our knowledge, there is only one other study with a 
follow-up period up to ten years, which is however a community study (Ganguli et al., 2004). 
This implies that this follow-up period is unique in clinical research about MCI. A follow-up 
period of 10 years will have identiﬁed the main part of the converters. Another strength of the 
present study was the large sample size, which allows reliable ﬁndings and which enables it to 
apply multivariate statistical analyses. Also the clinical settings, from which the subjects were 
selected, make the ﬁndings of this thesis relevant for clinical practice. In addition, we presented 
ﬁndings from GP-settings (Chapter 5) investigated with a case-control design matched for age, 
sex and GP setting. For this study, we used data from the RNH database (Metsemakers et al., 
1992). This is a large database, which at the time of the data selection contained data from 
21 rural and urban GP practices. The RNH database is a well-documented database, in which 
patient characteristics and all relevant health care problems are stored. The register oﬀers a 
unique opportunity as a sample frame for research in a general practice setting on which cross-
sectional and longitudinal analyses can be performed (Metsemakers et al., 1992). In Chapter 6, 
we compared clinical data from subjects from a memory clinic setting to population-based data 
from the Maastricht Aging Study (MAAS) (Jolles et al., 1995). The MAAS is a large longitudinal 
population-based study into the determinants of cognitive aging and was performed in the 
same geographical region as the Maastricht Memory Clinic.
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8.2.3.2 Loss to follow-up
On the other side, the study described in this thesis also had several methodological problems. 
Firstly, as in any longitudinal study loss to follow-up is a problem as loss to follow-up may not 
be random. In our study the loss to follow-up was 15 to 18% (Chapters 2 and 4). In order to 
analyze whether the loss to follow-up had biased our results, we compared subjects with and 
without missing data (outcome) at follow-up. The ﬁndings of Chapter 4 showed that in the study 
population of subjects older than 55 years, there were no diﬀerences in baseline characteristics 
between subjects with and without outcome at follow-up. The ﬁndings of Chapter 2 showed 
that in the total study sample (40 years or older), subjects without outcome at follow-up were 
about three years older, and had signiﬁcantly lower scores on the GDS and BDS. This implied 
that the ﬁndings of the study were based on somewhat younger subjects who had a higher 
level of functioning than the total MCI population from the memory clinic. As subjects who are 
older and have a greater decline in functioning are at higher risk for developing AD, ﬁndings 
with respect to conversion rates will be slightly underestimated. However, our conversion 
rates to AD in subjects with MCI was 11% in the ﬁrst two years (Chapters 2 and 4), which is in 
agreement with the mean conversion rate reported in a recent review about conversion rates 
to AD in MCI subjects of 10.2% per year (Bruscoli & Lovestone, 2004). 
8.2.3.3 Follow-up study design
The Maastricht MCI study was an ongoing study. This implied that not all subjects could have 
had a follow-up assessment after 5 or 10 years, because they did not participate for long enough 
in the study. This resulted in smaller sample sizes at the 5-years follow-up and at the 10-years 
follow-up, and may have inﬂuenced the statistical power. We had follow-up assessments after 
2, 5 and 10 years. This implicates that AD is diagnosed at one of these time-points, but that 
the subjects may have suﬀered from it earlier. Thus, the precise date of the diagnosis is not 
available. Therefore, we used a discrete-time survival analysis model (Hosmer & Lemeshow, 
1999), which was implemented using logistic regression and an appropriately adjusted dataset 
(Hosmer & Lemeshow, 1999) to investigate the predictive accuracy of the cognitive (Chapter 2) 
and aﬀective symptoms (Chapter 4) after 2-years, 5-years and 10-years. This technique analyzes 
time in discrete chunks during which AD could occur.
8.3.4 Generalizibility
Another point of attention is the generalizibility of our results. Our studies with subjects 
with MCI were conducted in a memory clinic of a university hospital. The university hospital 
of Maastricht combines an academic and a regional setting, which makes the study sample 
representative for clinical settings. However, the ﬁndings based on this sample may not be 
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applicable to community-based samples. The Maastricht memory clinic is embedded in the 
psychiatry department of the hospital. Therefore, the ﬁndings based on this sample may not 
be totally applicable to settings that are based on neurological or geriatric departments, 
as these may diﬀer in mean age of the subjects, severity of the cognitive impairments, and 
comorbidities, such as aﬀective or vascular problems. 
 We also performed a study in settings of GP-practices, including subjects selected from 
the Registration Network of Family Practices (RNH). The RNH is computerized and anonymous 
database that contains all relevant health care problems of rural and urban GPs in the Southern 
of The Netherlands (Metsemakers et al., 1992). As it can be assumed that every inhabitant of 
The Netherlands has a GP, this database is an adequate reﬂection of the Dutch population.
5.5.5 MCI deﬁnition and concept
In the literature many deﬁnitions can be found to describe the transitional phase between 
normal cognitive functioning and dementia. The use of diﬀerent deﬁnitions has an impact on 
prevalence and incidence rates, and on conversion rates for AD. In addition, the used deﬁnition 
has to be taken into account in the generalizibility of the results.
 On the one hand, there is variation in the cognitive domains involved. Some of 
these deﬁnitions focus only on memory impairments, such as Petersen’s MCI (Petersen et al., 
1999), while others include also impairments in other cognitive domains, such as attention, 
concentration, language or executive functioning for example Cognitive Impairment No 
Dementia (Graham et al., 1997)). 
 On the other hand, there is variation in the deﬁnition of an ‘impairment’. Some 
researchers mention that these impairments can be reported subjectively by the subject and/
or a relative (GDS; (Reisberg et al., 1982)), or can be a clinical judgement, while others require 
that these impairments are objectiﬁed by impaired test performances, of which again there is 
no consensus about the cut oﬀ scores.
 In addition, the usefulness of MCI in clinical practice is still under debate. Some 
researchers state that MCI represent a useful clinical entity (Petersen et al., 2004). However, 
criticisms of the MCI concept call MCI a heterogeneous concept and an unreliable term, and 
are sceptic about using MCI as a clinical entity. They challenge the use of criteria originally 
developed for research purposes as a diagnosis in clinical practice (Whitehouse & Moody, 
2006). However, nowadays more and more subjects with MCI ask for clarity about the nature of 
their complaints and want to get a prognosis. These subjects deserve an honest, reliable, and 
valid answer to their questions. The deﬁnition, nature and clinical usefulness of MCI will remain 
an area of interest in aging research. However, whatever the preferred deﬁnition may be, the 
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presence of having mild cognitive problems, makes subjects at increased risk for developing 
AD in future. 
 In this thesis, we used MCI to refer to subjects, who had subjective memory complaints 
in the absence of dementia, and had a GDS score of 2 or 3, and no signiﬁcant impairment 
in general cognitive functioning or daily functioning. This deﬁnition is broader than the 
original MCI-criteria of Petersen and colleges (Petersen et al., 1999), which require a cognitive 
impairment objectiﬁed on formal testing. However, we chose to use this broad deﬁnition 
to investigate the whole cognitive spectrum between subjective cognitive complaints and 
dementia. Also other studies have used these criteria (Feldman & Jacova, 2005; Tabert et al., 
2006; Tierney et al., 1996). The use of a broad deﬁnition of MCI leads to higher sensitivity for 
AD, but speciﬁcity will be lower, as more subjects included in our study that had cognitive 
problems due to reasons other than brain degeneration caused by AD compared to studies 
that used the more restricted amnestic MCI criteria. However, in research about early markers 
for AD it is important to include a broader cognitive range, as previous studies found that even 
very mildly impaired individuals are at increased risk for AD within about 5 years (Dickerson et 
al., 2007). Post-hoc analyses in the memory clinic sample showed that the exclusion of subjects 
without an objectiﬁed memory impairment at baseline would in the present study result in the 
lack of detection of 26% of the subjects who convert to AD. 
 
8.4 Recommendations
8.4.1 Scientiﬁc implications
Based on our ﬁndings, we have some recommendations for future scientiﬁc research. The use 
of eﬀortful memory strategies has shown to be a signiﬁcant predictor for AD. Further research 
should investigate the relation between memory strategies and other cognitive measures and 
between memory strategies and other biological aspects, such as imaging and cerebrospinal 
ﬂuid markers. Studies into the preclinical phase of dementia should not be restricted to subjects 
with impairments on formal memory tests as the present study showed that this would have 
lead to the lack of detection of a substantial number of the subjects with future dementia. 
Also, other studies have shown that even subjects with only cognitive complaints (Dik et al., 
2001; Jonker et al., 2000; Saykin et al., 2006) or very mildly impaired subjects (Dickerson et al., 
2007) are at increased risk for developing AD. Another ﬁnding, which should be recommended 
for future research is the inclusion of subjects with aﬀective symptomatology at baseline. 
Aﬀective symptomatology is common is subjects with MCI. We reported prevalence ranging 
from 50 to 70% in our population (Chapter 4). Because this prevalence is also high in subjects 
who converted to AD over time, the exclusion of these symptoms on forehand would also lead 
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to the lack of detection of a substantial number of the subjects at risk. We also recommend 
a follow-up period of 5 to 10 years, depending on the severity of the cognitive impairments 
at baseline. Studies that include subjects with milder cognitive problems should have longer 
follow-up periods, because the time to conversion will take longer in these subjects compared 
to subjects with more prominent cognitive impairments. In the present study a substantial 
number (12%) of the subjects with AD had converted at the 10-years follow-up (Chapter 4), 
and this percentage will be an underestimation because of the ongoing study design. 
8.4.2 Clinical implications
The clinical relevance of the main ﬁndings are that the risk factors investigated in the ﬁrst part 
of this thesis are helpful in the identiﬁcation of MCI subjects who are at risk for developing AD. 
In a general practice setting gait disturbances are the earliest prodromal signs of dementia 
and cognitive symptoms were the strongest predictor for dementia. The presence of these 
symptoms should make the GP aware of a possible underlying dementia process and the GP 
should consider whether additional diagnostics or a referral to specialized facilities would give 
more clarity. Remarkably 42% of the subjects did not report cognitive symptoms in the year 
prior to the diagnosis of dementia. This highlights the importance of an active participation of 
the GP in clarifying complaints and problems, to identify subjects at risk. Identiﬁed risk factors 
in subjects from a memory clinic setting were impairments in quantitative memory scores, 
but also impairments in qualitative memory performances such as decreased use of eﬀortful 
memory strategies during learning. Also, the ﬁnding that the use of memory strategies during 
learning improved long-term recall performances could be used in memory training programs 
to enhance memory functioning in daily life. Aﬀective symptoms, on the other hand, seem not 
to be useful in the identiﬁcation of MCI subjects at risk for AD. Nevertheless, the prevalence 
of aﬀective symptoms in subjects with MCI was high. This implies that subjects with MCI are 
not only characterized by cognitive impairments, but also by non-cognitive aspects, such as 
aﬀective symptomatology. This highlights the importance of a multidisciplinary approach in 
the diagnostics and treatment possibilities for subjects with MCI.
 This multidisciplinary approach should be present in memory clinic settings as 
described in Chapter 7. This study showed that about one quarter of the visitors to a memory 
clinic had MCI. Another 15% of the memory clinic visitors had no cognitive disorder. Taken 
together these ﬁndings imply that a substantial number of MC-visitors turned out not to be 
demented. Because of the multi-causality of memory complaints in subjects with MCI or no 
cognitive disorders, MC’s should also have diagnostics and treatment possibilities available 
for this group of subjects. With no current pharmacological therapy available, the treatment 
possibilities for these non-demented subjects should have other starting points such as 
CHAPTER 8
110
psychosocial treatment, cognitive training or psycho-education. These non-pharmacological 
treatments can be further speciﬁed to ﬁndings of Chapter 6, which showed that subjects with 
no cognitive disorders who visit the memory clinic for subjective memory complaints are 
characterized by lower memory self-eﬃcacy, lower quality of life related to mental aspects, 
and more often worries about their forgetfulness because of a family history of dementia. This 
knowledge should be used in the development of interventions for memory clinic visitors who 
have subjective memory complaints. 
8.5 Conclusion
In the present thesis, we increased the knowledge about predictive and diagnostic aspects for 
prodromal AD in memory clinic and GP practice settings. It is important to diﬀerentiate early 
between progressive and non-progressive MCI, as both groups can beneﬁt from other types 
of advice and treatment. Early recognition of a neurodegenerative disorder starts in the GP 
practice and the diagnosis may be clariﬁed by specialized services, such as multidisciplinary 
memory clinics. We found that cognitive, aﬀective, and biological predictors are important 
to consider in the early identiﬁcation of subjects at risk. However, we are aware that not all 
possible predictors for AD in subjects with MCI were investigated in this thesis. It seems likely 
that a multi-factorial model including cognitive, non-cognitive, and biological predictors will 
optimize the early recognition of subjects with prodromal AD. 
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Problems in cognitive functioning are common in middle-aged and older subjects. Whether 
these cognitive problems are early symptoms of AD or not remains an important question. The 
transitional phase between normal cognitive functioning and dementia is often called Mild 
Cognitive Impairment (MCI). In the last 20 years, there has been a lot of interest in subjects with 
MCI, because these subjects are at increased risk for developing AD. However, not all subjects 
with MCI will develop AD in the future. To be able to diﬀerentiate between subjects who will 
develop AD and those who will not, it is important to identify predictors for future AD in 
subjects with cognitive problems. In the ﬁrst part of this thesis, the predictive value of several 
cognitive and non-cognitive factors for AD was investigated. In the second part, we focused 
on the development of memory clinic settings in the Netherlands and on the characteristics of 
subjects who seek help at a memory clinic for subjective memory complaints.
 In Chapter 2, the predictive accuracy of learning strategies for AD was investigated in 
subjects with MCI from the Maastricht memory clinic. Subjects were reassessed over a period 
of 10 years. We found that eﬀortful strategies, such as subjective organization, which requires 
an active reorganization of the presented information, was a signiﬁcant predictor for future AD 
in subjects with MCI. The more passive serial clustering, on the other hand, was no predictor 
for AD. These eﬀects were similar in middle-aged and older subjects. This ﬁnding may help 
to identify subjects with prodromal AD in subjects with MCI. We also found an association 
between the use of subjective organization during the immediate recall trials and the delayed 
recall performance. This information can be used in the development of cognitive training 
programs. 
 In Chapter 3, we investigated the relation between the Apolipoprotein (APOE) 
e4 allele and memory dysfunction in middle-aged and older subjects with MCI from the 
Maastricht memory clinic. In middle-aged subjects, the APOE e4 allele was most strongly 
related to decreased subjective organization and in the older subgroup to a decreased delayed 
recall performance. After excluding subjects with incipient AD, results remained similar in the 
middle-aged subgroup, but there was no longer an association between the APOE genotype 
and any of the memory measures in the old subgroup. We concluded that the APOE e4 allele is 
associated with impaired memory functioning, but that the memory measure aﬀected varies 
with age. We also concluded that the eﬀect of the APOE e4 allele on memory function may be 
dependent on underlying AD pathology in elderly subjects, but not in middle-aged subjects. 
This could mean that the APOE e4 allele directly aﬀects memory functioning, independent 
of underlying AD pathology, or that the follow-up period was not long enough for middle-
aged subjects to identify everyone who would progress to clinical AD. In that case subjective 
organization could be a very early marker of AD. 
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 In Chapter 4, the predictive value of aﬀective symptoms for AD was investigated 
in subjects with MCI selected from the Maastricht memory clinic. We focused on symptoms 
of depression, anxiety, apathy, sleep problems, and somatic problems as measured with the 
HDRS. The follow-up period was up to 10 years. At least one follow-up was available for 228 
subjects. Seventy-nine subjects developed AD. At baseline, aﬀective symptoms were present in 
50-70% of the MCI subjects. Sleeping problems were associated with signiﬁcantly lower risk for 
AD. Symptoms of depression and anxiety showed a trend in the same direction. The presence 
of amnestic MCI modiﬁed the relation between depressive symptoms and the risk for AD, as 
depression was associated with a decreased risk in subjects without amnestic MCI, but not in 
subjects with amnestic MCI. Age and length of follow-up did not modify the risk of aﬀective 
symptoms for AD. We concluded that aﬀective symptoms are not diagnostic for prodromal 
AD as these symptoms are associated with decreased risk for AD. In table 3 of this chapter, 
an overview is given of previous studies that established the predictive value of depressive 
symptoms for AD in subjects with MCI. The pooled OR of these studies indicates that depression 
is not predictive for AD in subjects with MCI. However, given the high prevalence of these 
symptoms in prodromal AD, the presence of these symptoms does certainly not exclude the 
possibility of prodromal AD. Because aﬀective symptoms are common in subjects with MCI, 
services for subjects with cognitive complaints should pay attention to this symptomatology, 
and should have psychiatric expertise available to diagnose and treat these symptoms. 
 In Chapter 5, we investigated the predictive value of cognitive impairments, aﬀective 
symptoms, behavioural problems, vascular problems, gait disturbances and changes in weight 
and appetite for dementia in subjects from the GP registration network (RNH). We compared 74 
subjects with dementia to 125 age and sex matched control subjects from the same GP setting. 
In this study, we investigated a period of ﬁve years prior to the diagnosis of dementia. In the 
ﬁve years prior to the diagnosis of dementia, subjects with preclinical dementia visited their GP 
more often than control subjects. Gait disturbances were the earliest predictor for dementia. 
Cognitive complaints were predictive in the three years before the diagnosis of dementia, with 
the strongest predictive value in the year before the diagnosis. In the year before the diagnosis 
58% of the subjects with preclinical dementia reported these symptoms to their GP compared 
to only 2% of the control subjects. All other symptoms, except vascular symptoms, were 
predictive in the year prior to diagnosis. We concluded that preclinical dementia is associated 
with an increased contact frequency between patient and GP at least ﬁve years prior to the 
diagnosis of dementia. Gait disturbances and cognitive complaints are the earliest symptoms 
of preclinical dementia in GP practice. Given that almost half of the subjects with preclinical 
dementia did not report cognitive symptoms in the year prior to the diagnosis, we contend 
that the GP must play an active role in identifying subjects at risk for dementia.
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 In Chapter 6, we investigated which factors determine why people with subjective 
memory complaints (SMC) seek medical attention. We compared 33 cases with SMC who 
sought help at a memory clinic to 85 control subjects with SMC from a population-based study 
who did not seek help for their memory complaints. All cases and control subjects did not 
have an objectiﬁed impairment on formal memory tests and both groups had comparable 
MMSE scores. We investigated symptoms of depression, anxiety, extraversion and neuroticism, 
memory self-eﬃcacy, quality of life, changes in memory and daily functioning according to a 
relative, life-changing events, and a family history of dementia. Cases who sought help for SMC 
had lower memory self-eﬃcacy and lower quality of life related to mental aspects. Relatives 
of cases reported more deterioration in daily functioning than relatives of control subjects 
and cases were more often worried due to a positive family history of dementia. Levels of 
depression, anxiety, extraversion and neuroticism were comparable in cases and control 
subjects. We concluded that subjects who seek medical attention for SMC are characterized 
by lower memory self-eﬃcacy and quality of life, more deterioration in daily functioning and 
worries due to a family history of dementia, compared to subjects who did not seek help for 
SMC. These ﬁndings are important for the development of adequate interventions for subjects 
without objective memory impairment who visit a memory clinic for memory complaints.
 In Chapter 7, we investigated the development of memory clinics (MCs) in the 
Netherlands. In addition, we studied whether, and how these facilities can play a role in non-
demented subjects, such as subjects with MCI. We found that since 1998, the number of 
MC’s increased from 12 to 40 and that the number of referrals per service has also increased. 
Nowadays, the focus is less exclusively on academic centres. Dementia was the most important 
syndromal diagnosis (62%), but also milder cognitive problems, such as MCI (23%) and 
no cognitive disorder (15%) were common. Compared to 1998, current there is increasing 
emphasis for milder cognitive problems. There was a large variability between the settings in 
the proportion of the diagnoses dementia/MCI/no cognitive disorder. The concept MCI was 
used in 92% of the settings. The most common diagnostic classiﬁcation of subjects with MCI 
were primary degenerative, vascular and not speciﬁed. The treatment of subjects with MCI 
was in 84% of the settings diﬀerent to the treatment of demented subjects. The conclusion 
was that MCs are nowadays part of the standard care for subjects with dementia. Besides this, 
MCs play also an increasing role in the diagnostic and therapeutic procedures of subjects with 
milder cognitive problems. The treatment possibilities of MCs should be ﬁtted to the problems 
of their visitors, and should not be limited to the pharmacological treatment for dementia.
 In the last chapter of this thesis (Chapter 8), a general discussion of the main ﬁndings 
is provided. Methodological considerations with respect to study designs, selected subjects, 
SUMMARY
115
used MCI criteria and statistical methods were made. We discussed the scientiﬁc and clinical 
relevance of the ﬁndings and made some recommendations for future research.
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Problemen in het cognitief functioneren komen vaak voor bij mensen van middelbare 
en oudere leeftijd. Het blijft een belangrijke vraag of deze cognitieve problemen vroege 
symptomen zijn van de ziekte van Alzheimer (AD) of niet. De overgangsfase tussen normaal 
cognitief functioneren en dementie wordt vaak Mild Cognitive Impairment (MCI) genoemd. In 
de laatste 20 jaar is er grote interesse ontstaan in mensen met MCI, omdat deze mensen een 
verhoogd risico hebben om AD te ontwikkelen. Echter niet alle mensen met MCI zullen in de 
toekomst AD ontwikkelen. Om te kunnen diﬀerentiëren tusssen mensen die wel of geen AD 
zullen ontwikkelen, is het belangrijk om voorspellers te identiﬁceren voor toekomstige AD in 
mensen met cognitive problemen. In het eerste deel van dit proefschrift wordt de voorspellende 
waarde van verschillende cognitieve en niet-cognitieve factoren voor AD onderzocht. In 
het tweede deel hebben we ons gericht op de ontwikkeling van de geheugenpolikliniek in 
Nederland en hebben we de kenmerken onderzocht van mensen die hulp zoeken bij een 
geheugenpolikliniek voor subjectieve geheugenklachten. 
 In hoofdstuk 2 is de voorspellende waarde van leerstrategieën voor AD onderzocht in 
mensen met MCI van de Maastrichtse geheugenpolikliniek. Mensen krijgen herhalingsonder-
zoeken gedurende 10 jaar. We vonden dat eﬀortful strategieën, zoals subjectieve organisatie, 
die een actieve reorganisatie van de aangeboden informatie vereist, een signiﬁcante voorspel-
ler is van toekomstige AD in mensen met MCI. De meer passieve strategie, seriële clustering, 
was daarentegen geen voorspeller voor AD. Deze eﬀecten zijn gelijk in mensen van middel-
bare en oudere leeftijd. Deze bevinding kan bijdragen bij het identiﬁceren van mensen met 
prodromale AD in mensen met MCI. Ook was er een associatie tussen het gebruik van subjec-
tieve organisatie tijdens de leerfase en de uitgestelde geheugen prestatie. Deze informatie kan 
gebruikt worden bij de ontwikkeling van cognitieve training programma’s.
 In hoofdstuk 3 hebben we de relatie tussen het APOE e4 allel en geheugen disfunc-
tioneren onderzocht in mensen met MCI van middelbare en oudere leeftijd van de Maastricht-
se geheugenpolikliniek. In mensen van middelbare leeftijd was het APOE e4 allel het sterkst 
gerelateerd aan een verminderde subjectieve organisatie en in de oudere groep aan een ver-
laagde uitgestelde recall prestatie. Na de exclusie van mensen met onderliggende AD blijven 
de resultaten  gelijk voor mensen van middlebare leeftijd, maar er was geen relatie meer tus-
sen het APOE genotype en de geheugenmaten in de oudere subgroep. Wij hebben geconclu-
deerd dat het APOE e4 allel geassocieerd is met beperkingen in het geheugenfunctioneren, 
maar dat de geheugenmaat die betroﬀen is, varieert met de leeftijd. Wij concludeerden ook 
dat het eﬀect van het APOE e4 allel op geheugenfunctioneren afhankelijk kan zijn van onder-
liggende AD pathologie in oudere mensen, maar niet in mensen van middelbare leeftijd. Dit 
kan betekenen dat het APOE e4 allel een directe invloed heeft op het geheugenfunctioneren, 
onafhankelijk van AD pathologie, of dat de follow-up periode voor mensen van middelbare 
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leeftijd niet lang genoeg was om iedereen die klinische AD zal ontwikkelen, te identiﬁceren. In 
dit geval zou subjectieve organisatie een hele vroege voorspeller van AD kunnen zijn. 
 In hoofdstuk 4 is de voorspellende waarde van aﬀectieve symptomen voor AD 
onderzocht in mensen met MCI van de Maastrichtse geheugenpolikliniek. We hebben 
symptomen van depressie, angst, apathie, slaapproblemen en somatische problemen zoals 
gemeten met de HDRS onderzocht. De follow-up periode was 10 jaar. 228 mensen hadden 
tenminste een follow-up meting beschikbaar. 79 mensen ontwikkelden AD. Op baseline 
waren aﬀectieve syptomen aanwezig in 50-70% van de mensen met MCI. Slaapproblemen 
waren geassocieerd met een signiﬁcant lager risico op AD. Depressieve en angst symptomen 
lieten een trend in dezelfde richting zien. De aanwezigheid van amnestische MCI had invloed 
op de relatie tussen depressieve symptomen en het risico op AD. Depressie was namelijk 
geassocieerd met een signiﬁcant lager risico bij mensen zonder amnestische MCI, maar niet in 
mensen met amnestische MCI. Leeftijd en lengte van de follow-up periode had geen invloed 
op het risico van aﬀectieve symptomen op AD. Wij concludeerden dat aﬀectieve symptomen 
geen diagnosticum zijn voor prodromale AD, omdat deze symptomen geassocieerd waren 
met een verlaagd risico op AD. In tabel 3 van dit hoofdstuk wordt een overzicht gegeven van 
eerdere studies die de voorspellende waarde van depressieve symptomen op AD hebben 
onderzocht in mensen met MCI. De gepoolde OR van deze studies laat zien dat depressie 
niet voorspellend is voor AD in mensen met MCI. Maar gezien de hoge prevalentie van deze 
symptomen in prodromale AD, sluit de aanwezigheid van deze symptomen de mogelijkheid 
van prodromale AD zeker niet uit. Omdat aﬀectieve symptomen vaak voorkomen in mensen 
met MCI, zouden zorginstellingen voor mensen met cognitieve klachten aandacht moeten 
besteden aan deze symptomatologie en psychiatrische expertise beschikbaar moeten hebben 
om deze symptomen te diagnosticeren en behandelen. 
 In hoofdstuk 5 wordt de predictieve waarde van cognitieve beperkingen, aﬀectieve 
symptomen, gedragsmatige problemen, vasculaire problemen, loopstoornissen en verande-
ringen in gewicht en eetlust voor dementie onderzocht in mensen van het RegistratieNet Huis-
artsenpraktijken (RNH). We hebben 74 mensen met dementie vergeleken met 125 controles, 
gematched voor leeftijd, geslacht en huisartsenpraktijk. In deze studie hebben we een periode 
van vijf jaar voorafgaande aan de diagnose dementie onderzocht. In de vijf jaar voorafgaande 
aan de diagnose dementie bezochten mensen met preklinische dementie hun huisarts vaker 
dan controle personen. Loopstoornissen waren de vroegste voorspeller voor dementie. Cogni-
tieve klachten waren voorspellend vanaf drie jaar voor de diagnose, waarbij de voorspellende 
waarde het sterkste was in het eerste jaar voorafgaande aan de diagnose. In het eerste jaar 
voorafgaande aan de diagnose rapporteerden 58% van de mensen met preklinische dementie 
cognitieve klachten bij hun huisarts vergeleken met 2% van de controle personen. Alle an-
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dere symptomen, met uitzondering van vasculaire symptomen waren voorspellend in het jaar 
voorafgaande aan de diagnose. Wij hebben geconcludeerd dat preklinische dementie geas-
socieerd is met een toename van het aantal huisartsbezoeken vanaf tenminste vijf jaar vooraf-
gaande aan de diagnose dementie. Loopstoornissen en cognitieve klachten zijn de vroegste 
symptomen van preklinische dementie in de huisartsenpraktijk. Gegeven het feit dat bijna de 
helft van de mensen met preklinische dementie geen cognitieve klachten rapporteert in het 
jaar voorafgaande aan de diagnose, vinden we dat de huisarts een actieve rol moet spelen bij 
het identiﬁceren van mensen met een verhoogd risico op dementie. 
 In hoofdstuk 6 hebben we onderzocht welke factoren bepalen of mensen met 
subjectieve geheugenklachten (SMC) medische hulp zoeken. We hebben 33 mensen met SMC 
die hulp gezocht hebben bij een geheugenpolikliniek vergeleken met 85 controle personen 
met SMC van een populatiestudie die geen hulp hebben gezocht voor hun geheugenklachten. 
Zowel de mensen van de geheugenpolikliniek als ook de controlepersonen hadden geen 
objectieve stoornis op geheugentests en beide groepen hadden een vergelijkbare MMSE 
score. We onderzochten symptomen van depressie, angst, extraversie en neuroticisme, 
memory self-eﬃcacy, kwaliteit van leven, veranderingen in geheugen en dagelijks functioneren 
beoordeeld door een naaste, life-events en een familie anamnese voor dementie. Mensen die 
hulp zochten voor hun SMC hadden een lagere memory self-eﬃcacy en een lagere mentale 
kwaliteit van leven. Naasten van mensen die hulp zochten rapporteerden een grotere afname 
in dagelijks functioneren dan naasten van controle personen en mensen die hulp zochten 
waren vaker bezorgd omdat ze een positieve familie anamnese hadden voor dementie. Mate 
van depressie, angst, extraversie en neuroticisme waren vergelijkbaar in beide groepen. 
Wij concludeerden dat mensen die medische hulp zochten voor hun SMC gekenmerkt 
werden door een lagere memory self-eﬃcacy en kwaliteit van leven, meer achteruitgang in 
dagelijks functioneren en bezorgdheid door een positieve familie anamnese voor dementie 
vergeleken met mensen die geen hulp zochten voor SMC. Deze bevindingen zijn belangrijk 
bij de ontwikkeling van adequate interventies voor mensen zonder objectiveerbare 
geheugenstoornis die een geheugenpolikliniek bezoeken voor geheugenklachten. 
 In hoofdstuk 7 is de ontwikkeling van geheugenpoliklinieken in Nederland onder-
zocht. Daarnaast hebben we onderzocht of en hoe deze voorzieningen een rol kunnen 
spelen in niet-demente mensen, zoals mensen met MCI. We vonden dat sinds 1998 het aantal 
geheugenpoliklinieken is toegenomen van 12 naar 40 en dat het aantal verwijzingen per 
instelling ook is toegenomen. Tegenwoordig ligt de nadruk minder op academische centra. 
Dementie was de belangrijkste syndroom diagnose (62%), maar ook lichtere cognitieve 
problemen, zoals MCI (23%) en geen cognitieve stoornis (15%) waren gebruikelijk. In vergelij-
king met 1998 is er tegenwoordig toenemende aandacht voor lichtere cognitieve problema-
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tiek. Er was een grote variabiliteit tussen de instellingen in de verdeling van de diagnoses 
dementie/MCI/geen cognitieve stoornis. Het concept MCI werd gebruikt in 92% van de 
instellingen. De meest voorkomende  diagnostische classiﬁcatie van mensen met MCI was 
primair degeneratief, vasculair en niet gespeciﬁceerd. De behandeling van mensen met MCI 
was in 84% van de instellingen anders dan de behandeling van mensen met dementie. De 
conclusie was dat geheugenpoliklinieken tegenwoordig deel uitmaken van het reguliere 
zorgsysteem voor patienten met dementie. Daarnaast spelen geheugenpoliklinieken ook 
een steeds grotere rol in de diagnostiek en therapeutische procedures van mensen met 
lichtere problematiek. De behandelmogelijkheden van geheugenpoliklinieken zouden 
afgestemd moeten zijn op de problematiek van de bezoekers en moet niet beperkt zijn tot de 
farmacologische behandeling van dementie. 
 In het laatste hoofdstuk van dit proefschrift (hoofdstuk 8) wordt een algemene 
discussie van de hoofdbevindingen gegeven. Methodologische overwegingen met betrekking 
tot designs van de studies, geselecteerde patiënten, gebruikte criteria voor MCI en statistische 
methoden worden beschreven. We discussieerden de wetenschappelijke en klinische 
relevantie van de bevindingen en beschreven aanbevelingen voor toekomstig onderzoek.
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